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SUMMARY 
 
 
Strain ST4SA, isolated from soya beans, was identified as Enterococcus mundtii. 
BacST4SA, a bacteriocin produced by strain ST4SA inhibited the growth of Acinetobacter 
baumannii, Bacillus cereus, Clostridium tyrobutyricum, Enterococcus faecalis, Enterococcus 
faecium, Lactobacillus sakei, Propionibacterium spp., Streptococcus caprinus, Pediococcus 
sp., Listeria monocytogenes, Staphylococcus aureus, Streptococcus pneumoniae, and 
unidentified middle ear isolates A, BW, DW, F, G, and H. BacST4SA was active against 
Pseudomonas aeruginosa G, BG, I, J, B and E, although variable degrees of resistance were 
observed for some strains. 
 
BacST4SA is positively charged, hydrophobic, contains the YGNGV sequence in the 
N-terminal, a double-glycine processing site and a disulphide bridge, all of which is typical of 
a class IIa bacteriocin. The operon, which contains a structural-, ATP-dependent transporter- 
and immunity gene, is located on a 50-kb plasmid. The 58-amino acid prepeptide is 
homologous to mundticin KS, mundticin AT06 and bacteriocin QU 2, and differs from 
enterocin CRL35 by only two amino acids. The 674-amino acid ATP-dependent transporter, 
consisting of a peptidase C39B domain, an ABC-transporter and an ABC-DLP family domain, 
displayed 98.9% homology to mundticin KS and 99.25% to enterocin CRL35. The 98-amino 
acid immunity gene of bacST4SA is completely homologous to enterocin CRL35 and 96.9% 
to mundticin KS. 
 
BacST4SA is 3.950 kDa in size, based on electron spray mass spectrometry. The 
peptide was isolated from the cell-free supernatant, precipitated with 80% saturated 
ammonium sulphate, dialysed and freeze-dried to 1 638 400 AU (arbitrary units) per ml. No 
change in antimicrobial activity was recorded when bacST4SA was incubated in buffer 
ranging from pH 2 to 12, heated to 100 °C for 90 min and 121 °C for 20 min, and when 
incubated in the presence of Tween 20, Tween 80, Triton X-100, SDS, urea, EDTA, middle 
ear fluid and blood.  
 
Optimal levels of bacST4SA production (51 200 AU/ml) was recorded after 14 h of 
growth in MRS broth at 30°C. Maximum production (102 400 AU/ml) was recorded in 
modified MRS media supplemented with tryptone, yeast extract, a combination of tryptone 
and yeast extract, K2HPO4 (10.0 or 20.0 g/l), or with the addition of DL-6,8-thoictic acid, L-
ascorbic acid, and thiamine, respectively. 
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BacST4SA is bactericidal towards E. faecium HKLHS and bacteriostatic towards S. 
pneumoniae 40 and middle ear isolates F, BW and H. The peptide adsorbed maximal (94%) 
to S. pneumoniae 40, P. aeruginosa 25 and E. faecium HKLHS. BacST4SA forms pores in 
the cytoplasmic membrane of sensitive cells, leading to dissipation of the cell membrane and 
leakage of cytoplasmic material.  
 
BacST4SA was compared with various other antimicrobial treatment agents, and 
revealed similar to a higher activity towards a number of these agents. BacST4SA revealed a 
similar level of activity against E. faecium HKLHS and middle ear pathogens P. aeruginosa J 
and S. pneumoniae 27 when compared with tetracycline (30µg). However, bacST4SA 
revealed much higher activity when compared to nasal sprays, aminoglycosides, 
cephalosporins, fluoroquinolones, lincosamides, macrolides, nitroimidazole, penicillin, 
quinolones, sulfonamides, chloramphenicol, furanzolidone, fusidic acid, rifampicin, 
trimethoprim, trimethoprim-sulfamethoxazole and vancomycin when tested in vitro.  
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OPSOMMING 
 
 
Stam ST4SA, geïsoleer uit sojabone, is as Enterococcus mundtii geidentifiseer. 
BacST4SA, ‘n bakteriosien geproduseer deur stam ST4SA het die groei van Acinetobacter 
baumannii, Bacillus cereus, Clostridium tyrobutyricum, Enterococcus faecalis, Enterococcus 
faecium, Lactobacillus sakei, Propionibacterium spp., Streptococcus caprinus, Pediococcus 
sp., Listeria monocytogenes, Staphylococcus aureus, Streptococcus pneumoniae en 
ongeïdentifiseerde middeloor isolate A, BW, DW, F, G, en H geinhibeer. BacST4SA is aktief 
teen Pseudomonas aeruginosa stamme G, BG, I, J, B en E, alhoewel effense weerstand 
soms waargeneem is. 
 
BacST4SA het ‘n netto positiewe lading, is hidrofobies, bevat die YGNGV-volgorde in 
die N-terminaal, ‘n dubbel-glisien prosesserings setel en ‘n disulfied brug, kenmerkend van 
klas IIa bakteriosiene. Die operon, wat bestaan uit ‘n strukturele geen, ‘n ATP-afhanklike 
transport sisteem geen en ‘n immuniteits-geen, is op ‘n 50 kb plasmied gelokaliseer. Die 
voorloper peptied (58 aminosure lank), is homoloog aan mundticin KS, mundticin AT06 en 
bakteriosien QU 2 en verskil van enterocin CRL35 met slegs twee aminosure. Die ATP-
afhanklike transporter (674 aminosure lank) bestaan uit ‘n peptidase C39B domein, ‘n ABC-
transporter en ‘n ABC-DLP tipe domein en is 98.9% homoloog aan mundticin KS and 
99.25% aan enterocin CRL35. Die immuniteits-geen (98 aminosure lank) van bacST4SA is 
ten volle homoloog aan enterocin CRL35 en 96.9% homoloog aan mundticin KS. 
 
BacST4SA is 3.950 kDa groot, gebaseer op elektrosproei-massa spektrometrie. Die 
peptied is uit selvrye supernatant geïsoleer, met 80% versadigde ammonium sulfaat 
gepresipiteer, gedialiseer en gevriesdroog tot ’n finale konsentrasie van 1 638 400 AE 
(arbitrêre eenhede) per ml. Geen verandering in antimikrobiese aktiwiteit is waargeneem 
tydens inkubasie van bacST4SA in buffer van pH 2 tot 12, tydens verhitting (100 °C vir 90 
min en 121 °C vir 20 min) en tydens inkubasie in die teenwoordigheid van Tween 20, Tween 
80, Triton X-100, SDS, ureum, EDTA, middeloor vloeistof en bloed. 
 
Optimale vlakke van bacST4SA produksie (51 200 AE/ml) is na 14 h groei in MRS 
media by 30°C waargeneem. Maksimale vlakke van die peptied (102 400 AE/ml) is 
geproduseer in gemodifiseerde MRS medium, aangevul met triptoon, gisekstrak, ‘n 
kombinasie van triptoon en gisekstrak, K2HPO4 (10.0 of 20.0 g/l), of met byvoeging van DL-
6,8-thioktiensuur, L-askorbiensuur, en tiamien onderskeidelik. 
 
 v
BacST4SA is bakteriosidies teenoor E. faecium HKLHS en bakteristaties teenoor S. 
pneumoniae 40 en middeloor isolate F, BW en H. Die peptied adsorbeer optimaal (94%) aan 
S. pneumoniae 40, P. aeruginosa 25 en E. faecium HKLHS. BacST4SA vorm porieë in die 
selmembraan van sensitiewe selle en lei tot vernietiging van die selmembraan en lekkasie 
van die sitoplasma inhoud. 
 
In vergelykende studies het bacST4SA ‘n soortgelyke en selfs hoër antimikrobiese 
aktiwiteit teenoor ‘n aantal bekende antimikrobiese middels getoon. Die aktiwiteit van 
bacST4SA is soortgelyk aan dié van tetrasiklien (30µg) in toetse teen E. faecium HKLHS en 
middeloor patogene P. aeruginosa J en S. pneumoniae 27. BacST4SA het egter in ’n in vitro 
vergelyking met neussproeie, aminoglisiedes, cephalosporiene, fluoroquinolone, 
lincosamides, makroliede, nitroimidazole, penisilien, quinolone, sulfonamide, 
chloramphenicol, furanzolidone, fusiensuur, rifampisien, trimethoprim, trimethoprim-
sulfamethoxazool en vankomisien ‘n baie hoër aktiwiteit teen patogene getoon. 
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PREFACE 
 
The literature review includes an update on otitis media, the genus Enterococcus, 
and class II bacteriocins they produce. 
 
The papers, “Characterization of bacteriocin ST4SA, produced by Enterococcus 
mundtii ST4SA isolated from soya beans”, and “Bacteriocin ST4SA, a class IIa peptide from 
Enterococcus mundtii, inhibits bacteria associated with otitis media”, has been written 
according to the style of Applied and Environmental Microbiology. 
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INTRODUCTION 
 
Otitis media (OM), an infection of the middle ear, affects more than 60% of children 
under the age of two (Rosenfeld et al., 2004; Kouwen et al., 2005). Most of the severe 
infections are caused by β-lactamase–producing pathogens, Haemophilus influenzae and 
Moraxella catarrhalis, and multi-drug resistant Streptococcus pneumoniae (McCracken, 
2002; Klein, 1999; Segal et al., 2005). Antibiotics used to treat these pathogens include high-
dose amoxicillin, amoxicillin-clavulanate (augmentin), cefuroxime axetil and intramuscular 
ceftriaxone (Klein, 1999; McCracken, 2002; Segal et al., 2005). The major problem 
encountered with antibiotic treatment of acute otitis media is the tremendous increase in the 
resistance to antibiotics (Klein, 1999; Rovers et al., 2004; Segal et al., 2005). If not treated, 
the disease may lead to complications in the aural cavity, intratemporal and intracranium 
areas, and may manifest in mastoiditis, meningitis and brain abscess (Eneli, 1998; Penido et 
al., 2005). 
 
In recent papers, ribosomal synthesized cationic peptides, known as bacteriocins, 
have been considered as an alternative to antibiotics (Delves-Broughton et al., 1996; Ryan et 
al., 1999; Cleveland et al., 2001; Hancock and Patrzykat, 2002; Riley and Wertz, 2002). 
Class IIa bacteriocins have received particular interest in the food industry (Chen and 
Hoover, 2003; Moreno et al., 2005) and as antiviral agent (Wachsman et al., 1999; 
Wachsman et al., 2003; Todorov et al., 2005). Attempts to use bacteriocins in medicine have 
only been studied in a few cases, with some cationic peptides used with success in clinical 
trails (Giacometti et al., 2000; Ingham et al., 2003). An indolicin-like peptide, MBR-226 has 
successfully prevented catheter-related bloodstream infections in phase III clinical trails 
(Hancock and Patrzykat, 2002). Indolicin-like peptides have also been used for therapy of 
acute acne (in phase II clinical trails) and the eradication of methicillin-resistant 
Staphylococcus aureus in nares (Hancock and Patrzykat, 2002). Piscicolin 126, a bacteriocin 
produced by Carnobacterium piscicola, is the first reported class IIa bacteriocin displaying in 
vivo antimicrobial activity against Listeria monocytogenes. However, piscicolin 126 could not 
eradicate intracellular bacteria (Ingham et al., 2003). The lantibiotic nisin has shown to be 
active against Staphylococcus aureus, and vancomycin-resistant enterococci when tested in 
vitro (Brumfit et al., 2002), and has been used to prevent colonization of chicken skins by 
Salmonella typhimurium (Natrajan and Sheldon, 2000). A two component bacteriocin, lacticin 
3147, produced by Lactococcus lactis, and nisin have also shown to be effective in the 
control of surface-related infections, such as mastitis (Sears et al., 1992; Ryan et al., 1999).  
The use of cationic peptides as an antibiotic complement has also been observed.  A study 
by Giacometti et al. (1999) reported increased in vitro activity of peptides cecropin P1, 
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indolicin, magainin II, nisin and renalexin combined with polymyxin E and clarithromycin, 
respectively, against Pseudomonas aeruginosa. In another combinational study, polycationic 
peptides ranalexin and polymycin E, doxycycline and clarytromycin showed synergism 
against clinical isolates of Gram-positive and Gram-negative aerobic bacteria (Giacometti et 
al., 2000). Magainin II has shown to be synergistic with beta-lactam antibiotics (Giacometti et 
al., 2000). 
 
 Enterococci have the ability to produce small peptides, known as enterocins (De 
Vuyst and Vandamme, 1994; Franz et al., 1999). Enterocins are grouped into class I, class 
IIa, class IIb, class IIc and class III, with classes IIa and IIc the most abundant groups 
(Moreno et al., 2005).  These peptides are generally active towards closely related Gram-
positive bacteria, including food-borne pathogens Listeria, with only a few enterocins active 
against Gram-negative species (Chen and Hoover, 2003; Franz and Holzapfel, 2004). 
Enterocin AS-48, a class IIc bacteriocin produced by E. faecalis S-48, is active towards a 
variety of Gram-negative bacteria (Ananou et al., 2005). Enterocin 012, produced by 
Enterococcus gallinarum, inhibits the growth P. aeruginosa and Escherichia coli (Jennes et 
al., 2000), whilst enterocin MR99 of E. faecalis inhibits E. coli (Sparo et al., 2006). Enterocins 
have developed a great deal of interest as an approach to control food-borne diseases, to be 
used as starter cultures and biopreservative in various food products (De Vuyst and 
Vandamme, 1994; Franz et al., 1999; Franz and Holzapfel, 2004; Moreno et al., 2005). The 
use of enterocins in medicine is a completely new research field. However, the use of 
enterocin CRL35 as an antibiotic compliment on Listeria (Minahk et al., 2004) and as an 
antiviral agent has been observed (Wachsman et al., 1999; Wachsman et al., 2003).  
 
In this study, a lactic acid bacterium isolated from soya beans, was screened for the 
production of a bacteriocin inhibitory towards various lactic acid bacteria, food-borne- and 
middle ear pathogens. The strain was identified to species level and the genes encoding the 
peptide have been sequenced. The mode of activity was determined and the antimicrobial 
action compared with that of antibiotics currently used to treat otitis media.  
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1. Middle ear infection, otitis media 
 
1.1. Introduction 
 
Otitis media (OM) is the accumulation of fluids in the middle ear, with or without 
symptoms of inflammation. The infection is caused by dysfunction or obstruction of the 
eustachian tube (Kouwen et al., 2005). It is the most commonly diagnosed upper respiratory 
tract infection (URTI) in children under the age of 2, for which antibiotics are prescribed, and 
has a high morbidity and low mortality rate (McCaig and Hughes, 1995; Segal et al., 2005). 
 
The microbiology of OM differs, with Streptococcus pneumoniae, non-typeable 
Haemophilus influenzae (NTHI), and Moraxella catarrhalis the most commonly isolated 
pathogens (Block, 1997; McCracken, 2002). The increasing emergence of penicillin-resistant 
S. pneumoniae and β-lactamase-producing strains, NTHI and M. catarrhalis, has become a 
major health issue, making the diagnosis and treatment of OM a priority (Segal et al., 2005). 
Health care costs associated with treatment are substantial, especially in cases of 
unresponsive treatment as a result of incorrect diagnosis (McCracken, 2002). Otitis media is 
classified into three main types: (1) otitis media with effusion (OME), i.e. middle ear effusion 
without symptoms of inflammation; (2) acute otitis media (AOM), i.e. middle ear effusion with 
symptoms of acute inflammation; and (3) chronic suppurative otitis media (CSOM), i.e. 
chronic inflammation of the middle ear, as a result of untreated or prolonged AOM, 
associated with perforation or poor response to treatment (Cripps et al., 2005). Some cases 
of OM may resolve spontaneously, while most cases require antibiotic treatment. 
Recognition of risk factors is crucial for clinical management (Tong et al., 2006). 
 
In the United States approximately 3.5 billion US dollars are spent annually on antibiotic 
treatment of AOM. Prevention of a small percentage of cases will have a major impact on 
health and economical resources (Segal et al., 2005). To combat the persistent spread of 
OM, research on alternative treatment has developed considerably, especially on 
pneumococcal vaccines (Cripps et al., 2005). Another extensive focus is the bacterial 
interference (BI) of natural nasopharyngeal flora and their production of antibacterial 
compounds against pathogens (Brook, 2005). 
 
To prevent the increasing occurrence of antibiotic resistance, the American Academy of 
Pediatrics (AAP) and the American Academy of Family Physicians (AAFP) have developed 
guidelines for the diagnosis and management of OM (AAP and AAFP, Clinical Practice 
Guidelines; Subcommittee on Management of Acute Otitis Media, 2004).  
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1.2. The human ear 
 
1.2.1. Anatomy of the ear 
The human ear is part of the peripheral nervous system (Vander et al., 2001). It is divided 
into three main sections: the outer/external, the middle-, and the inner-ear (Fig. 1). The 
middle ear is a small, air-filled chamber consisting of a tympanic membrane (TM) and 
ossicles (malleus, incus, and stapes) joined together, serving as a mechanical sound 
transformer. The TM seals off the outer auditory canal from the middle ear chamber and 
prevents micro-organisms from entering the middle ear and causing infection. The middle ear 
is connected to the nasopharynx via the eustachian tube. The inner-ear is a helically-shaped 
bony structure and is the most complex part of the auditory system. It consists of the 
cochlea, the vestibule and semicircular canals. The cochlea is a small bony structure with 
sensory nerves that convert sound waves to impulses. The vestibule and semicircular canals 
play a role in balance (Vander et al., 2001). 
 
Outer ear Middle 
ear
Inner 
ear
Pinna
Concha
External
Auditory
meatus
Incus
Stapes
Bone
Malleus
Semicircular
canals
Oval 
window
Facial 
nerve
Vestibula
nerve
Cochlea 
nerve
Tympanic 
membrane
Round window
Vestibule
Cochlea
Eustachian tube  
 
Fig. 1. Anatomy of the human ear (http://www.utdallas.edu/~tres/integ/sen5/sense_5.html). 
 
1.2.2.  The Eustachian tube and mucociliary system of the middle ear 
The eustachian tube is a bony structure that starts at the anterior wall of the tympanic 
cavity and ends in the nasopharynx (Eneli, 1998). The nasopharyngeal passage remains 
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closed at rest and opens with swallowing, yawning, or forced inflation (de Ru and Grote, 
2004). 
 
The nasopharyngeal opening of the eustachian tube and anterior section of the middle 
ear are covered with ciliated columnar epithelial cells. The ciliary activity is sensitive to 
bacteria, allowing pathogens to attach and protect against infection. The eustachian tube 
consists of goblet cells, and two subepithelial mucous gland layers (the large dorso-caudal 
layer and a smaller ventro-cranial gland layer). Large mucus glands are situated in the 
lamina popria and adjacent wall of the nasopharynx orificium (Cayé-Thomasen and Tos, 
2004). Mucus is normally transported across the middle ear mucosa, down the eustachian 
tube, enters the nasopharynx and is swallowed. The mucus consists of water, cells, cell 
debris, immunoglobins, lysozyme, lactoferrin, antimicrobial peptides, leukotrienes and 
cytokines, which protect the middle ear against invading pathogens (de Ru and Grote, 2004). 
The eustachian tube and mucosal system share several physiological functions (see Table 
1). 
 
Table 1: Physiological functions of the eustachian tube and mucociliary system with 
respect to the middle ear 
Eustachian tube functiona, b Mucociliary system function c
1. Ventilation of middle ear, equalising air 
pressure with atmospheric pressure caused 
by gas exchange between cavity and 
surrounding mucosa  
1. Physical removal of bacteria, dust, viruses 
and allergens by ciliary clearance 
2. Drainage of nasopharyngeal secretions 
and debris from the middle ear towards the 
nasopharynx with its mucociliary epithelium 
2. Presence of a broad-spectrum of 
antimicrobial agents in the mucus  
3. Protection from excessive 
nasopharyngeal secretions and fluctuations 
in the nasopharynx 
3. Recruitment of phagocytotic cells and an 
inflammatory response 
a Eneli, 1998; b Kouwen et al., 2005; c de Ru and Grote, 2004 
 
Normal functioning of the eustachian tube and mucociliary system are important for 
maintaining a healthy middle ear cavity (de Ru and Grote, 2004). 
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1.3. Epidemiology 
 
Otitis media continues to be one of the most commonly diagnosed childhood infections 
(Rosenfeld and Bluestone, 1999). An estimated 2.2 million episodes per annum, at a total 
cost of 4.0 billion US dollars, affects more than 90% children in preschool and 60% in the first 
two years after birth (Rosenfeld et al., 2004). Otitis media is the most common condition in 
children under two years of age and is most prevalent between six months and eighteen 
months of age (Eneli, 1998; Klein, 1989; Bamberger and Jackson, 2001).  At least 60-65% of 
children will experience at least one episode of AOM within their first year, and approximately 
17-30% will have suffered more than three episodes (Eneli, 1998; Fendrick et al., 2001; 
McCracken, 2002; Segal et al., 2005). Population-based studies in Finland and the USA 
have revealed an increase in AOM over the past 10 to 20 years. This is directly linked to an 
increase in the number of children attending day-care centers (Barden et al., 1998; Gould, 
1998). Children younger than three years of age are more prone to OM because of a narrow, 
shorter, less cartilaginous, and horizontal eustachian tube, making the functions less 
effective (Eneli, 1998; Kouwen et al., 2005). Otitis media with effusion (OME) has been 
reported in 5-13%, 11-20% and 13-18% of children of ages one, three and five years, 
respectively, with the greatest risk at age 2, affecting 80% of pre-school children, and being 
the most common reason for surgery (de Ru and Grote, 2004; Kouwen et al., 2005). It is 
estimated that nearly every child will have at least one episode of OME before 4 years of age 
(Zielhuis et al., 1990).  
 
Host-, extrinsic- and protective factors increase the risk of OM, and may play a role in 
persistent effusion and chronic disease. Host factors include age, craniofacial abnormalities 
(cleft palate), large adenoids, atopic history, recent viral URTI, recent sinusitis, eustachian 
tube dysfunction, immune deficiency or suppression disorders, and a family history of OM. 
Exposure to tobacco smoke and attendance of day-care programmes are considered 
extrinsic factors. Breast feeding for at least three months confers protection in the first year 
(Bamberger and Jackson, 2001; Eneli, 1998; Fendrick et al., 2001; Segal et al., 2005). The 
season of birth does not predict an episode of AOM or an early onset of AOM. However, 
children born during summer and autumn tend to attract AOM more easily and are at higher 
risk. The highest incidence of OM is usually during spring, autumn and winter, and lowest in 
summer (Homoe et al., 2005). Winter months are always peak season for respiratory viruses 
(Bamberger and Jackson, 2001). A higher incidence of AOM has been recorded amongst 
males (Eneli, 1998). The reason for this is unknown. 
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The geographic distribution of OM pathogens, especially antibiotic-resistant 
pneumococci, follows a certain pattern. This is not fully understood, however it may be a 
result of social differences or prescription practices in different parts of the world (Reinert, 
2004). In the 1940s penicillin was introduced as an alternative for the treatment of infectious 
diseases (Jacobs, 2004). Antibiotic resistance, first observed in 1967, has increased rapidly 
(Hansman and Bullen, 1967; Jacobs, 2004). The first report of multi-drug-resistant 
pneumococci (MDRP), S. pneumoniae, was published in the 1980s (Klein, 1999). This, and 
β-lactamase-producing strains of H. influenzae and M. catarrhalis, are considered major 
health threats. 
 
In South Africa, MDRP was first recognised in 1977 and has increased since then. 
National surveys covering 1979-1986, 1979-1990 and 1991-1998, support the increase in 
multi-drug resistance (Klugman and Koornhof, 1988; Koornhof et al., 1992; Witte, 1999; 
Huebner et al., 2000). Although an increase in the number of resistant strains has been 
reported, the proportion of strains with high-level resistance has remained the same. A 
survey conducted from 1999 to 2002 revealed a slight decrease (1.8%) in the number of 
penicillin-resistant strains. Multi-drug-resistant phenotypes accounted for less than 10% of all 
isolates in South Africa, Brazil and Europe (Jones et al., 2003). Penicillin resistance has 
increased markedly for β-lactamase-producing strains over the past decade. In a 1997 AOM 
case study, approximately 30% of the isolated penicillin-resistant strains H. influenzae and all 
strains of M. catarrhalis were β-lactamase positive (Segal et al., 2005).  
 
Resistance of S. pneumoniae to penicillin, other β-lactam antibiotics, macrolides and 
trimethoprim-sulfamethoxazole is of concern throughout the USA (McCracken, 2002). 
Currently, 14% of S. pneumoniae strains are resistant to three or more classes of antibiotics 
(Whitney et al., 2000). Forty percent of penicillin-resistant S. pneumonia are resistant to 
trimethoprim-sulfamethoxazole and 30% to macrolides (Dowell et al., 1999; Jacobs et al. 
1999). Increased resistance to tetracycline, chloramphenicol and co-trimoxazole is an 
additional point of concern (Appelbaum, 1992; Appelbaum, 1995).  
 
Sporadic cases of penicillin-resistant pneumococci have been reported from various parts 
of the world since about 1964. During the 1990s, penicillin-resistant S. pneumoniae (PRSP) 
increased in the USA, with incidences of 40% among children in day-care centres and 17% 
among children diagnosed with AOM (Segal et al., 2005). Serotypes 19A, 14 and 23F 
developed high-level penicillin resistance and multiple resistances to other antimicrobials. 
The original strain representing serotype 23F originated in Spain, but clones thereof were 
subsequently isolated in Portugal, France, Croatia, USA, Mexico, and recently also in South 
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Korea and South Africa (Munoz et al., 1991; Sibold et al., 1992). Resistance to antibiotics 
amongst clones of serotype 23F differs (Stein et al., 2003). One explanation for the latter is 
mutational changes in penicillin-binding proteins (PBPs) (Segal et al., 2005). In an Israeli 
study, 50-70% of strains recovered from children with AOM were PRSP, with 10-30% of 
these strains resistant to macrolides, 50% to trimethoprim/sulphamethoxazole and 17% to a 
combination of antibiotics (Leibovitz and Dagan, 2000; Leibovitz and Dagan, 2001a; 
Leibovitz and Dagan, 2001b). 
 
 
1.4. Pathogenesis and microbial etiology 
 
Otitis media is caused by bacteria and viruses in other upper respiratory tract infections, 
normally the nasopharynx. Entrance to the middle ear is facilitated by dysfunctional 
mucociliary and an abnormal, poorly ventilated eustachian tube (Kouwen et al., 2005). The 
nasopharynx acts as a bacterial reservoir for AOM (Kaieda et al., 2005). Obstruction of the 
eustachian tube causes accumulation of fluids by surrounding epithelial cells and 
inflammation of the mucoperiosteal lining of the middle ear, resulting in OME and AOM, 
respectively (Bamberger and Jackson, 2001; de Ru and Grote, 2004). Infection is aggravated 
by viral URTI, allergies, smoke, anatomical abnormalities and swollen adenoids (Eneli, 1998; 
Kouwen et al., 2005; Tong et al., 2006). Smoke decreases ciliary beat frequency, which 
leads to clogging of the respiratory tract with mucous and adherence of pathogens to 
pharyngeal cells (Fainstein and Musher, 1979; Vastag et al., 1986). Allergies cause 
dysfunction of the eustachian tube as a result of upper respiratory swelling, resulting in 
impaired mucociliary activity and increased colonisation of microbial cells (Kvaerner et al., 
1996; Fireman, 1997; Hastie et al., 1997; Tanaka et al., 1998).  
 
S. pneumoniae consists of various virulent determinants, rendering the organism more 
pathogenic. The virulent determinants include surface protein adhesion and secretory IgA 
protease involved in colonisation to epithelial cells and capsules (Alonsodevelasco et al., 
1995). Based on the antigenic properties of the capsules, more than 90 serotypes have been 
classified. In AOM a number of serotypes may be present. However, strains of serological 
groups 1, 3, 4, 6, 7, 9, 14, 15, 18, 19 and 23 account for up to 85% of infections in children 
(Bamberger and Jackson, 2001; Sokos, 2005). S. pneumoniae causes severe AOM infection 
for up to 10 days, followed by an increase in the eustachian tube gland volume and goblet 
cell density 6 and 3 months after AOM. S. pneumoniae is known for its ability to induce 
change in bone tissue structures (osteoresorption and osteoneogenesis). This may be due to 
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a decrease in the ventilation spaces, causing predisposing morbidity (Cayé-Thomasen and 
Tos, 2004).  
 
Non-typeable H. influenzae is responsible for 23-40% of bacterial cases of AOM, causing 
a milder but more prolonged course.  H. influenzae biotypes 2 and 3 are predominant in OM, 
with only 10% type b (Eneli, 1998; Bamberger and Jackson, 2001; McCracken, 2002).  Type 
b H. influenzae causes a short but severe AOM, while M. catarrhalis is responsible for 10-
15% of cases, and induces only a mild but purulent course of infection. Non-typeable H. 
influenzae increases more severe or protracted histopathological changes in the middle ear, 
causing a dramatic increase in the eustachian tube gland volume and goblet cell density, 
with the formation of polyp and fibrous adhesion, leading to mucosal scarring. The increase 
usually persists for 6 months after AOM, whereas the increase in eustachian tube gland 
volume occurs after 3 months (Cayé-Thomasen and Tos, 2004). M. catarrhalis induces the 
mildest and slightest change, with an increase in goblet cell density for only a short period of 
infection, and with no increase in the eustachian tube gland volume. Differences in response 
are due to different effects of bacterial capsules or exotoxins on the immune system, causing 
different patterns of host response (Cayé-Thomasen and Tos, 2004). 
 
Other pathogens less frequently isolated include Staphylococcus aureus (3%), group A 
streptococci (1%), Streptococcus pyogenes (1-5%) and Gram-negative bacilli (Eneli, 1998; 
McCracken, 2002; Segal et al., 2005). Gram-negative enteric pathogens, S. aureus and 
group B beta-hemolytic streptococci are found in neonates but rarely encountered in older 
infants, children and adults (Turner et al., 2002). Pseudomonas aeruginosa has been found 
in 67% of cases, with less than 1% of cases caused by Mycobacterium tuberculosis 
(Bamberger and Jackson, 2001). 
 
Respiratory viruses are important co-pathogens and may contribute to the etiology and 
pathogenesis of AOM by causing inflammation of the mucosa and blockage of the 
eustachian tube.  This impairs the host’s immunity and increases the risk of attracting 
pathogens (Buchman and Brinson, 2003; Heikkinen and Chonmaitree, 2003; Kleemola et al., 
2006). Viral URTI causes eustachian tube failure and leads to build-up of pressure in the 
middle ear (de Ru and Grote, 2004). Kleemola et al. (2006) reported no distinct species-
specific association between viral and bacterial infections. Viruses may precede clinical ear 
symptoms with or without bacteria (Kleemola et al., 2006). Depending on the methods of 
detection, viruses account for up to 20-41% of infections, while 65% are caused by bacteria 
(Eneli, 1998; Heikkinen et al., 1999; Nokso-Koivisto et al., 2004; Segal et al., 2005). 
Respiratory syncytial virus (RSV) is the most commonly isolated. Others include rhinovirus, 
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parainfluenzae, influenza A, enterovirus and adenovirus (Eneli, 1998; Bamberger and 
Jackson, 2001; Segal et al., 2005). 
 
 
1.5. Diagnosis 
 
Upper respiratory tract infections have an enormous impact on the economy of 
communities and health care systems worldwide. Thirty to fifty percent of infants and children 
are diagnosed incorrectly and contributes to the misuse of medication and increase in 
antibiotic resistance (Lyon et al., 1998; McCracken, 2002; Blomgren and Pitkäranta, 2005). 
Diagnostic procedures have to be cost-effective, quick and easy, with high sensitivity, 
specificity and accuracy for the detection of fluids in the middle ear (Blomgren and 
Pitkäranta, 2003; Blomgren and Pitkäranta, 2005; Segal et al., 2005).  
 
Accurate diagnosis of various types of OM are based on several symptoms of 
inflammation, including the colour, position, movement and bulging of the tympanic 
membrane, the presence or absence of effusions in the middle ear cavity, and the abrupt 
onset of OM (Blomgren and Pitkäranta, 2003; Blomgren and Pitkäranta, 2005; Segal et al., 
2005). Pneumatic otoscopy is based on direct visualisation of TM anatomy and colour, 
degree of mobility and the presence of effusions with over 90% sensitivity, and nearly 80% 
specificity (Eneli, 1998; Bamberger and Jackson, 2001; McCracken, 2002; Blomgren and 
Pitkäranta, 2003; Blomgren and Pitkäranta, 2005). If the pneumoscope is inconclusive, 
tympanometry and acoustic reflextometry are used, providing more evidence about the 
presence of middle ear effusion (McCracken, 2002). Tympanometry is the indirect 
measurement of the TM compliances and an estimation of middle ear pressure, with 90% 
efficacy. Sound waves are introduced to the TM and measurements are traced out 
graphically, indicating normal or poor compliance, flaccid or stiff TM, and eustachian tube 
dysfunction without middle ear effusion (Eneli, 1998). Prior to the use of tympanometry, 
symptoms have to be present, and results have to be interpreted in conjunction with the 
patient’s history and clinical examination (Blomgren and Pitkäranta, 2003; Blomgren and 
Pitkäranta, 2005). 
 
Diagnosis of AOM is based on the history of acute onset and the presence of 
inflammation (Segal et al., 2005). A majority of symptoms may refer to the presence of 
inflammation, including fever, otalgia, otorhea, irritability, excessive crying, vomiting, 
diarrhoea, anorexia, URT symptoms, restlessness, poor feeding, ear tugging and emesis 
(Eneli, 1998; de Ru and Grote, 2004; Montgomery, 2005; Segal et al., 2005). Pain is 
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generally a definite association with inflammation. The TMs of AOM patients are generally 
hyperaemic, bulging, cloudy, opague, thickened, immobile, and red to pale yellow with 
greyish effusion (Eneli, 1998; AAP and AAFP, Clinical Practice Guidelines; Subcommittee on 
Management of Acute Otitis Media, 2004; Segal et al., 2005). Otitis media with effusion 
cannot be diagnosed symptomatically and is detected using pneumoscopy, supplemented 
with tympanometry or acoustic reflectometry. Behavioural symptoms such as hearing loss 
and tinnitus might be present, with discomfort and little pain (Eneli, 1998; Segal et al., 2005). 
The TM is non-perforated, bulged and full, with a decrease in mobility (Cripps et al., 2005; 
Montgomery, 2005).   
 
 
1.6. Management in an era of antibiotic resistance 
 
1.6.1. Treatment 
In the past AOM was easy to treat, but due to increasing antibiotic resistance OM has 
become difficult to manage (Pichichero, 2000a). Given the high prevalence of drug-resistant 
S. pneumoniae (DRSP) and β-lactamase-producing pathogens, the effectiveness in 
treatment is very important. Treatment strategies include medication for pain, antibiotic 
medication with or without steroids, myringotomy with or without insertion of ventilation tubes, 
adenoidectomy, and spontaneous resolution based on age, health, medical history and 
extent of disease (Paap, 1996; AAP and AAFP, Clinical Practice Guidelines; Subcommittee 
on Management of Acute Otitis Media, 2004; Rovers et al., 2004). The AAP, the AAFP, and 
the American Academy of Otolaryngology-Head and Neck Surgery have developed 
guidelines for the management of OME and AOM to combat the increase in the high 
occurrence of antibiotic-resistant pathogens (AAP and AAFP, Clinical Practice Guidelines; 
Subcommittee on Management of Acute Otitis Media, 2004; AAFP, American Academy of 
Otolaryngology-Head and Neck Surgery, AAP; Subcommittee on Otitis Media with effusion, 
2004). 
 
The first and very critical component is the management of pain within 24 to 36 hours 
after diagnosis. Oral treatment includes the use of acetaminophen (15 mg/kg per dose every 
4 to 6 hours) and ibuprofen (10 mg/kg per dose every 6 hours) as adequate analgesia (AAP 
and AAFP, Clinical Practice Guidelines; Subcommittee on Management of Acute Otitis 
Media, 2004). 
 
Various studies reported cases of AOM managed by spontaneous resolution 
(withholding antibiotics), which resulted in 85% eradication in some cases (Bamberger and 
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Jackson, 2001). Resolution of AOM is generally 60% at one month, 80% at two months and 
90% at three months (Eneli, 1998). By decreasing the use of antibiotics with 50%, a 50% 
decrease in antibiotic-resistant bacteria was observed (Seppälä et al., 1997; Spiro et al., 
2005). Spontaneous resolution of AOM occurred in 90%, 70% and 20% of cases caused by 
M. catarrhalis, NTHI and S. pneumoniae, respectively (Bamberger and Jackson, 2001; 
Fendrick et al., 2001; McCracken, 2002). The low eradication percentage for S. pneumoniae 
may be of major concern because S. pneumoniae, the predominant agent causing AOM, is 
associated with complications such as meningitis and pneumoniae and often requires 
hospitalisation. During the last five years, 20-30% of S. pneumoniae strains developed 
resistance to penicillin (Bamberger and Jackson, 2001; Fendrick et al., 2001).  
 
According to the AAP and AAFP Clinical Practice Guidelines (2004) spontaneous 
eradication should only be considered for healthy children six months to two years of age, 
with an uncomplicated or an uncertain diagnosis of AOM. Complications include anatomical 
abnormalities such as cleft palate, genetic conditions such as Down syndrome, 
immunodeficiencies, and cochlear implants. Children older than two years of age may use 
spontaneous eradication even if diagnosis is uncertain, or certain but not severe. Children 
younger than three to six months have to use antibiotics even if diagnosis is uncertain. 
Spontaneous resolution has to be observed for a period of 48 to 72 hours (AAP and AAFP 
Clinical Practice Guidelines; Subcommittee on Management of Acute Otitis Media, 2004). 
 
Resolution occurs over a period of time, while antibiotics are used for eradication of 
pathogens from the site of infection over a shorter period of time and to avoid possible local 
complications (Fendricks et al., 2001; AAP and AAFP Clinical Practice Guidelines; 
Subcommittee on Management of Acute Otitis Media, 2004). Therefore, withholding 
antibiotics may not be the prudent choice in all cases. More research has to be done to 
evaluate this method and its possible link to resistance (Fendricks et al., 2001). To use an 
antibiotic, a significantly better outcome has to be achieved with the drug than achieved by 
spontaneous eradication (Segal et al., 2005). 
 
Antibiotic treatment is based on eradication of pathogens and penetration of sufficient 
levels of the antibiotic into the middle ear (Dagan and Leibovitz, 2002). Various factors have 
to be considered when choosing an appropriate antibiotic. These include compliance and 
susceptibility. Antibiotic resistance patterns also have to be determined. Taste and 
palatability, dosing interval, proven clinical efficacy, history of drug allergies, costs, and 
previous response to different antibiotic regimens must also be taken into account (Eneli, 
1998). Currently, no single drug eradicates all pathogens involved in AOM (Segal et al., 
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2005). Resistance patterns vary in different communities and geographical locations and 
influence antibiotic prescription (Eneli, 1998). It is important to determine the minimum 
inhibitory concentration (MIC) against the causative pathogen (Dagan and Leibovitz, 2002; 
Kaieda et al., 2005). Most antibiotics are β-lactams, acting in a time-dependent killing 
mechanism. The major determinant of efficacy is the time the drug concentration at site of 
infection exceeds the MIC for pathogens. An effective dose regimen in middle ear fluid 
concentration exceeds the MIC values for a pathogen by at least 40-50% of the dosing 
concentration (Segal et al., 2005).  
 
High-dose amoxicillin (80-90 mg/kg per day) for 10 days is used as first-line therapy 
in cases with a high prevalence of penicillin-resistant pneumococci, yielding middle ear fluid 
levels of amoxicillin that exceeds the MIC of many resistant strains of S. pneumoniae 
(Bamberger and Jackson, 2001; AAP and AAFP, Clinical Practice Guidelines; Subcommittee 
on Management of Acute Otitis Media, 2004; Segal et al., 2005). Amoxicillin has the greatest 
in vitro inhibition against S. pneumoniae, an excellent pharmacokinetic profile, and is 
relatively inexpensive. However, amoxicillin is not effective against β-lactamase-producing 
strains M. catarrhalis (50-100%) and H. influenzae (40-60%) (Eneli, 1998; AAP and AAFP, 
Clinical Practice Guidelines; Subcommittee on Management of Acute Otitis Media, 2004; 
Segal et al., 2005). If patients do not respond to therapy within 48 to 72 hours, the antibiotic 
treatment has to be changed.  
 
Second-line agents include amoxicillin/clavulanic acid, cefuroxime axetil, and 
intramuscular ceftriaxone. Amoxicillin/clavulanic acid or augmentin for 10 days (90 mg/kg per 
day of amoxicillin component, with 6.4 mg/kg per day of cluvanate divided into two dosages) 
is effective to eradicate β-lactamase-producing bacteria and is used in severe illnesses were 
moderate to severe otalgia or a fever of more than 39 °C are observed (Segal et al., 2005).  
Cephalosporin and cefuroxime axetil are only used if severe allergies occur, displaying the 
greatest in vitro activity against PRSP and also against β-lactamase-producing bacteria. 
Cephalosporins and cefuroxime axetil are known for poor palatability (McCracken, 2002; 
Montgomery, 2005; Segal et al., 2005). In cases of children vomiting or in a situation that 
precludes administration of oral antibiotics, ceftriaxone (50 mg/kg/day for 3 days) is used 
(Bamberger and Jackson, 2001; McCracken, 2002; AAP and AAFP, Clinical Practice 
Guidelines; Subcommittee on Management of Acute Otitis Media, 2004; Segal et al., 2005). 
Parenteral ceftriaxone (effective as a single-dose) is effective against all common pathogens, 
especially resistant streptococci, but is expensive and has a broad activity range. Parenteral 
ceftriaxone is only required for patients unable to use oral antibiotics (Eneli, 1998; 
Bamberger and Jackson, 2001). 
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Patients with non-type 1 allergic reaction to amoxicillin are prescribed cefdinir (14 
mg/kg/day once daily), cepodoxime or cefuroxime (30 mg/kg/day), while those with type 1 
hypersensitivity allergies are prescribed macrolides, including azithromycin (10 mg/kg/day on 
day 1, followed by 5 mg/kg/day for 4 days as a single dose daily), or clarithromycin (15 
mg/kg/day bid) as alternative therapy (McCracken, 2002; Montgomery, 2005; Segal et al., 
2005). Trimethoprim/sulfamethoxazole and erythromycin-sulfisoxazole are only used in 
cases of severe penicillin allergies, due to their high prevalent resistance (Bamberger and 
Jackson, 2001; McCracken, 2002; AAP and AAFP, Clinical Practice Guidelines; 
Subcommittee on Management of Acute Otitis Media, 2004; Segal et al., 2005). Third-line 
agents include clindamycin (Eneli, 1998). Clindamycin (30-40 mg/kg/day in 3 separate 
doses) is recommended in cases of penicillin resistance.  However, it is ineffective against 
Gram-negative bacteria and will not act against H. influenzae and M. catarrhalis (McCracken, 
2002; Montgomery, 2005; Segal et al., 2005).  
 
With the use of antibiotics, side effects have to be considered. 
Trimethoprim/sulfamethoxazole has been associated with Steven-Johnson syndrome and 
had an increased failure rate of 79% and 46% in S. pneumoniae and H. influenzae, 
respectively, suggesting increasing resistance. Augmentin may cause a rash and diarrhoea 
(Bamberger and Jackson, 2001; Segal et al., 2005). Infants and toddlers are recommended a 
10-day oral antibiotic treatment, while older patients are recommended a five to seven-day 
treatment. If symptoms deteriorate within two days, tympanocentesis is required. Younger 
patients have to be re-evaluated for clinical resolution in two to three weeks from initiation 
therapy (Bamberger and Jackson, 2001).  
 
Recently, new quinolones (gafifloxacin and levofloxacin) were studied as an 
alternative to treat acute otitis media. Gafifloxacin and levofloxacin are 100% efficient in the 
eradication for H. influenzae. Levofloxacin and gafifloxacin eradicated 84% and 94% of S. 
pneumoniae, respectively, after four to six days. The success rate of the treatment is 90-
94%. None of these two antibiotics have yet been licensed for use in paediatric AOM (Segal 
et al., 2005). Research is also conducted on the use of oxazolidinones, streptogramins and 
ketolides (Pichichero, 2000b). 
 
Otitis media with effusion generally develops after AOM. In 50% of cases, effusion 
directly follows an episode of infection (de Ru and Grote, 2004). According to de Ru and 
Grote (2004), OME should not be treated.  The authors argue that it is selflimiting, and more 
likely to be a well-balanced response, regulated by the host’s innate and aquired immune 
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system to protect the body. Research has indicated the presence of several factors of the 
immune system in middle ear effusions induced by the middle ear mucosa. Several cytokines 
are produced to control acute inflammation (de Ru and Grote, 2004). Bacterial metabolites, 
peptidoglycan-polysaccharide (PG-PS) and endotoxin may also induce the production of 
cytokines, tumor necrosis factor (TNF)-α and interleukin (IL)-1β (Schousboe et al., 2001; 
Kawano et al., 2002). The latter cytokines induce neutrofil infiltration, increasing capillary 
permeability, and promote development of subepithelial edema in the middle ear resulting in 
effusion (Lee et al., 2001). Tumor necrosis factor-α and IL-1β induce goblet cells, leading to 
increased secretion of mucin and OME. With additional stimulation of IL-8, mucin secretion 
from the goblet cells is prolonged and results in long-term progression of OM (Smirnova et 
al., 2002).  
 
In healthy children, first-line treatment for OME is spontanoues resolution by adjusting 
environmental factors responsible for causing obstruction of the eustachian tube. Guidelines 
for the management of OME, developed by the Guidelines and Protocols Advisory 
Committee (2004), are only recommended for healthy children over the age two months, 
without craniofacial abnormalities, immune deficiencies, AOM complications or other serious 
underlying diseases. Spontaneous resolution is recommended in children with no risks or 
complications. If OME does not resolve spontaneously, the history and risks of disease have 
to be examined (de Ru and Grote, 2004). Antibiotics may hasten resolution of OME in only 
14% of cases, making antibiotic treatment generally ineffective (Guidelines and Protocols 
Advisory Committee, 2004). Rosenfeld and Kay (2003) demonstrated spontaneous 
resolution in 20-56% of cases after three months. If effusions are still present after three 
months, surgery has to be considered (AAFP, American Academy of Otolaryngology-Head 
and Neck Surgery, AAP; Subcommittee on Otitis Media with effusion, 2004).  
 
1.6.2.  Antimicrobial resistance 
Antibiotic resistance can be inherent or acquired. Inherent resistance results from the 
normal genetic, structural, or pathologic state of the microorganisms, while the occurrence of 
spontaneous mutations or the acquired genetic material encoding a novel resistant 
mechanism develops in acquired resistance (Low, 2001). 
 
Antibiotic resistance of a microorganism may be caused by several factors, including 
the production of inactivating enzymes, mutations and post-translational or post-
transcriptional modification of the target site, reducing antibiotic affinity to the agent, 
overproduction of the target of agent, active efflux or reduced uptake of the antimicrobial 
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agent (Fluit et al., 2001). Repeated exposure of the bacteria to antibiotics and geographical 
variations may explain the increase in resistance (Pichichero, 2000a).  
 
Beta-lactams are the most extensively used antibiotics (Fluit et al., 2001). Beta-
lactams are structurally analogous to peptidyl-D-Ala-D-Ala termini of the peptidoglycan cell 
wall precursors, responsible for the inhibition of cell wall synthesis. Beta-lactams have the 
ability to interact with both PBPs and β-lactamase. PBPs are cytoplasmic-anchored enzymes 
responsible for terminal cell wall synthesis, forming a stable interaction-bond with its target 
peptidoglycan precursor. Beta-lactamase is chromosomally located or acquired plasmid-
encoded enzymes that hydrolyse some β-lactams by forming a labile interaction with the 
peptidoglycan precursor (Fluit et al., 2001; Low, 2001). Beta-lactamase enzymes are 
generally produced by H. influenzae and M. catarrhalis, making them the most important 
resistant mechanisms to β-lactams and cephalosporins (Sahm et al., 2000; Fluit et al., 2001). 
The stability of the β-lactam–β-lactamase interaction determines resistance in the target 
organism. Approximately 200 β-lactamases have been described, with most bacteria 
containing at least one of the 200 enzymes (Low, 2001). 
 
Streptococcal-resistance to antimicrobials may be a result of an active efflux 
mechanism, explaining a decreased accumulation of antibiotic within the active site of 
infection. Bacteria contain an array of cytoplasmic membrane transport systems essential for 
the uptake of nutrients and the excretion of toxic compounds. These transport systems may 
play a role in bacteria, by conferring resistance to antibiotics by extrusion of the drug. Some 
systems handle a wide range of structurally dissimilar compounds, known as multi-drug-
efflux-pumps (MDEPs). The majority of MDEPs use a proton motive force as the driving force 
for efflux. These pumps are divided into three families, viz. the major facilitator superfamily 
(MFS), the resistance-modulation-cell division family, and small multi-drug-resistant family. 
Substrates for the MFS pumps in S. aureus (norA) and S. pneumoniae (pmrA) include 
fluoroquinolons, and in S. pneumoniae (mefE) and S. pyogenes (mefA) the 14- and 15-
membered macrolides (erythromycin, clarithromycin, and azithromycin) (Low, 2001). 
Macrolide-resistance in S. pneumoniae may present two phenotypes: (1) the M phenotype, 
encoded by mefA, which causes an efflux, thus removing macrolides, and (2) the MLSB 
phenotype, encoded by erm(B) which produces erythromycin ribosomal methylase and 
blocks binding of an antimicrobial agent, resulting in resistance (Jacobs, 2004). 
 
Multi-drug-resistance (MDR) is often located on integrons. Integrons are genetic 
elements consisting of genetic determinants of a site-specific recombination system that 
captures mobile gene cassettes. The integrons contain integrase and an adjacent 
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recombination site. The cassettes may be integrated by integrase at the recombination site, 
and multiple gene cassettes may be present in one intergron. Intergrons are not mobile and 
are often associated with transposons, well known for their capacity to carry MDR genes. 
Multi-drug-resistant genes may cause resistance by decreasing the expression of porins and 
changes in a cell. The changes cause reduced uptake or expression of an efflux (Fluit et al., 
2001). 
 
To prevent resistance, an antibiotic is effective when local concentrations greater 
than the MIC penetrate into the site of infection (Agro, 1999; Jacobs, 2004). Marked 
geographical differences occur in antibiotic resistance among AOM pathogens and are 
essential to ensure adequate therapy (Jones et al., 2003). 
 
1.6.3. Complications 
Complications are rare in developed countries because of the effective use of 
administrated antibiotics and low mortality. Antibiotic-resistant pathogens may cause serious 
and fatal infections (Dagan and Leibovitz, 2002). Since the post-antibiotic era, there has 
been a major decrease in complications to less than 0.5% (Eneli, 1998). The vast decline 
favours the use of antibiotics.  
 
Complications occur in three anatomical areas: (1) the aural cavity, including the 
external, middle, and inner ear, (2) intratemporal, and (3) intracranium (Eneli, 1998). Mastoid 
dermatitis is a complication of the external ear, while conductive hearing loss, TM 
perforation, tympanosclerosis, facial nerve palsy, ossicular discomfort, and cholesteatona are 
middle ear complications. The inner ear is associated with neurosensory hearing loss and 
suppurative labyrinthitis (Eneli, 1998). Intracranium complications are central nervous 
system-associated, including petrosis, labyrinthitis, and mastoiditis, while meningitis, 
extradural- and brain abscess, lateral sinus thrombosis, empyema, and otitic hydrocephalus 
are intracranium-associated (Eneli, 1998). 
 
Mastoiditis and meningitis are the most common complications, followed by brain 
abscess (Eneli, 1998; Penido et al., 2005). An otogenic brain abscess is the most life-
threatening intracranial complication and is always located adjacent to the temporal bone, 
leading to osteitis and erosion of the bone (Penido et al., 2005). Meningitis arises from direct 
invasion via osteothrombophlebitis of small vessels or by labyrinth or endolymphatic 
channels, or related traumatic bone defects, as a result of simultaneous infection in the URT 
and middle ear (Eneli, 1998; Aimoni et al., 2005). Intracranial complications seek immediate 
treatment, which includes carniotomy, drainage of abscess, open mastoidectomy with 
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abscess drained through the mastoid, open mastoidectomy alone, and closed 
mastoidectomy (Penido et al., 2005). Meningitis is treated with intravenous antibiotics for 24 
to 48 hours after surgery, such as mastoidectomy and spheno-ethmoidectomy (Aimoni et al., 
2005). Mastoiditis presents an infra-autricular swelling with chronic otorhea and TM 
perforation. The disease is difficult to treat with oral antibiotics (Eneli, 1998; Bamberger and 
Jackson, 2001).  
 
Conductive hearing loss is the most regularly occurring middle ear complication. The 
degree and frequency of hearing loss (25 to 30 decibels) is associated with an increased 
mass of fluid in the middle ear, filling the air-filled space and decreasing ossicular motion for 
sound pressure. A decrease in sound transmission through the middle ear also results in 
hearing loss (Ravicz et al., 2004). Temporary hearing loss is common in OME, and in the 
long run may cause bone erosion and retracted pockets (de Ru and Grote, 2004). 
Conductive hearing loss may lead to behavioural problems and poor academic 
performances, affecting language and speech. The development of speech and language is 
important at age three and younger. The effect of OM on concentration, learning and 
academic achievement is usually not a long-term effect and hearing loss usually restores as 
OME resolves, unless chronic changes develop (Holm and Kunze, 1963; Eneli, 1998). A 
Swedish study by Augustsson and Engstand (2001) described no long-term effects of OM 
upon concentration, learning and academic achievement. However, a Finnish study 
concluded that many episodes of AOM during the first three years have long-term effects on 
learning and attention skills, at least up to nine years of age, in spite of active treatment 
(Loutonen et al., 1998). In New Zealand, SOM was associated with delayed hearing ability 
up to 15 years of age (Stewart and Silva, 1996). 
 
Surgical complications are commonly found in cases where tympanostomy tube 
insertion was performed. Two kinds of complications may be present after tube insertion: (1) 
early complication, occurring while tubes are still in place in the TM, and (2) late 
complications, occurring after extrusion of the tube. Early complications include persistent 
otorhea, tube blockage, early extrusion, hearing loss, and ossicular disruption, while late 
complications include persistent perforation after tube extrusion, scarring of the TM, atrophic 
monomeric TM, granuloma, tympanosclerosis, cholesteatoma, and migration of the tubes 
into the ear canal (Pitcher et al., 1997). The use of anaesthesia in surgical procedures is also 
a risk (Eneli, 1998).  
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1.7. Other alternatives 
 
1.7.1. Bacterial interference 
During the past decade, research has extensively focussed on new alternative treatments 
in the increasing era of antibiotic resistance. Several strategies have been tested for the 
treatment of AOM, especially focussed on the protection against OM (Tagg and Dierksen, 
2003; Brook, 2005). Bacterial interference (BI) plays an important role in maintaining the 
normal flora of the upper respiratory tract. Normal flora is maintained by the implantation of 
indigenous microflora of low virulence, capable of interference, colonization and subsequent 
infection, with more virulent pathogens. Mechanisms for BI involve colonisation of normal 
flora on epithelial cells preventing the adhesion of pathogens, changes in the bacterial 
environment, production of bactericidal substances, and competition for nutritional 
substances (Brook, 2003; Brook, 2005). Several studies provide evidence that normal 
microflora of the nasopharynx may support non-specific defence systems against infections 
such as OM (Fujimori et al., 1996; Brook and Gober, 2000; Tano et al., 2000; Tano et al., 
2002). The majority of interfering bacteria include aerobic α-haemolytic streptococci (AHS), 
mostly Streptococcus mitis and Streptococcus sanguis, and anaerobic streptococci such as 
Peptostreptococcus anaerobius and Prevotella melaninogenica (Bernstein et al., 1993; 
Bernstein et al., 1994; Brook, 2005). 
 
High numbers of AHS have been reported in the nasopharynx of healthy children 
compared to those prone to AOM, and are supported by research (Bernstein et al., 1993; 
Bernstein et al., 1994; Fujimori at al., 1996; Brook and Yocum, 1999; Tano et al., 1999; 
Brook and Gober, 2000; Walls et al., 2003). AOM prone children tend to have an increase in 
S. pneumoniae and NTHI (Bernstein et al., 1993; Tano et al., 2002). Alpha-haemolytic 
streptococci isolated from eustachian tube openings have a higher interfering activity against 
AOM pathogens than those from adenoid tissue (Brook and Yocum, 1999; Tano et al., 1999; 
Brook, 2005). Tano et al. (2002) developed a nasal spray containing AHS with good activity 
against OM pathogens. However, no difference was obtained in relation to the placebo 
group. Children with recurrent AOM had less AHS than in healthy children. These AHS had a 
lower inhibitory activity against S. pneumoniae, and NTHI to healthy children. This suggests 
that an isolate of AHS has to be selected with superior adherence to the epithelium of the 
nasopharynx. None of these children were treated with antibiotics prior to introduction of AHS 
(Tano et al., 2002). Roos et al. (2001) introduced a nasal spray containing five AHS (two S. 
sanguinis, two S. mitis and one S. oralis) in a double-blind, placebo-controlled study, to 
reduce recurrent AOM and the frequency of OME. Children were treated with antibiotics for 
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10 days before the use of either the streptococcal or placebo spray. In vitro inhibition against 
the AOM pathogens was achieved, suggesting the problem involved modification of the 
normal microflora in the absence of antibiotics (Tagg and Dierksen, 2003).  
 
The decrease in the number of AOM pathogens may be a result of the production of 
bacteriocins or bacteriocin-like substances (BLIS) that suppress some bacterial growth 
(Brook and Gober, 1998). Streptococcus salivarius, a non-pathogenic bacteria, isolated from 
the oral cavity of humans, is known to produce salivaricin A and B. Salivaricin A and B and 
its activity against S. pyogenes has been well documented (Dierksen and Tagg, 2000; Walls 
et al., 2003). In vitro inhibitory activity against Gram-negative pathogens such as M. 
catarrhalis and H. influenzae was also reported (Walls et al., 2003). 
 
De Gutierrez et al. (2001) studied the effect of Lactobacillus fermentum against S. 
pneumoniae by intranasal introduction. A decrease in the number of S. pneumoniae was 
obtained, together with an increase in the number of activated macrophages and lymphocyte 
population. An increase in anti-S. pneumoniae antibodies also suggested the involvement of 
the mucosal immune system as a protective barrier. Lactic acid bacteria are known to restore 
the ecological equilibrium of different mucosal areas (de Gutierrez et al., 2001).  
 
Administration of antibiotics disturbs the balance of natural microflora and facilitates 
colonization of pathogens (Brook and Foote, 1997; Faden et al., 1997; Brook and Gober, 
1998; Brook and Gober, 2005a). Normal oral microflora, such as AHS (mostly S. mitis and S. 
sanguinis), anaerobic streptococci (P. anaerobius) and P. melaninogenica, are generally 
susceptible to amoxicillin, while these microflora are relatively resistant to second- and third-
generation cephalosporin treatment (Brooke and Gober, 2005b). Brook and Foote (1997) 
studied the effect of amoxicillin and second-generation cephalosporin, cefprozil, on the 
interfering flora isolated from the adenoids. A decrease in AHS and an increase in the 
number of S. aureus and β-lactamase-producing bacteria were established. No change in 
AHS was found when treated with cefprozil. Another study compared the effect of 
amoxicillin/cluvulanate with cefprozil and third-generation cephalosporin, cefnidir. Both 
amoxicillin/cluvulanate and cephalosporins inhibited the pathogens causing AOM. The 
oropharyngeal bacteria were more depleted by amoxicillin/cluvulanate than after treatment 
with cephalosporins (Brook and Gober, 1998; Brook and Gober, 2005b). 
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Various strains of the normal nasopharyngeal flora produce bacteriocins or BLIS, and 
may be used as an alternative to antibiotics. A few advantages and disadvantages of an 
interfering organism are listed in Table 2. 
 
Table 2: Advantages and disadvantages of a BLIS-producing strain when used in 
replacement therapy (modified from Tagg and Dierksen, 2003). 
Advantages 
1. Narrow spectrum of activity 
2. Cost effective, long-term protection against specific infections 
3. Direct implantation, thus highly competitive 
3. Foster increased protection by natural transmission through close contact with host 
4. Genetic engineering to obtain a superior strain 
Disadvantages 
1. As a result of quantitative and qualitative stability of normal flora, invasion of any foreign 
microbe may be limited 
2. High intrinsic stability of indigenous flora may be a major obstacle in modification of the 
composition by introducing a specific effector strain 
3. Effector strain has to be strongly competitive; thus it must be administrated before 
microbial climax community is established or after exposure to antimicrobial agents to create 
an appropriate niche. Once antibiotic selective pressure is removed, resistant strains may 
disappear 
 
Several principle characteristics are required for interfering strains to be used in 
replacement therapy. These include: specific activity against pathogens, avoiding disruption 
of normal microflora, the ability to survive a selected habitat and not elsewhere, non-
pathogenic or weak opportunistic pathogens for host, susceptibility to low-risk antibiotics, 
easy to prepare for commercial distribution, easy to identify among resistant microflora, not 
causing cytotoxicity of immunological sensitisation in host, and persisting in host tissue to 
effect long-term protection (Tagg and Dierksen, 2003).  
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1.7.2. Vaccines 
Little research is done on the development of specific vaccines against OM. For an OM 
vaccine to be accepted, it has to be safe and efficient, induce an appropriate immune 
response to clear pathogens and decrease colonisation in the nasopharynx, without causing 
any immune-mediated damage to the middle ear (Cripps et al., 2005). Otitis media is a 
polymicrobial disease, which complicates the development of vaccines. To prevent OM, 
vaccines have to inhibit S. pneumoniae, NTHI, M. catarrhalis, RSV and parainfluenza. A 
number of lead protein antigens for all three bacterial pathogens have been identified (Cripps 
et al., 2005; Murthy et al., 2005).  
 
Pneumococcal vaccines do not have a significant impact on the prevalence of OM 
(Cripps et al., 2005). Pneumococcal vaccines include pneumococcal polysaccharide and 
pneumococcal conjugate vaccines, both effective against pneumococcal disease. S. 
pneumoniae are an encapsulated bacteria consisting of complex polysaccharides, 
pathogenic to humans.  Based on the antigenic properties of the capsules, the bacteria may 
be classified into various serological groups. About 90 serotypes have been identified 
(Reinert, 2004; Sokos, 2005). The current pneumococcal polysaccharide vaccine consists of 
23 capsular polysaccharide antigens representing 85-90% of serotypes responsible for 
invasive pneumococcal infection. Six of the 23 antigens cause drug-resistant diseases. 
Pneumococcal polysaccharide vaccines cause T-cell independent immune responses and 
can only activate mature B-cells (Reinert, 2004; Sokos, 2005). Pneumococcal conjugant 
vaccines are T-cell dependent antigens providing protection against only a limited number of 
serotypes (Reinert, 2004).  
 
The heptavalent pneumococcal conjugate vaccine (PvCV7) was designed based on 
serotypes predominant in the USA. The heptavalent pneumococcal conjugate vaccine was 
the first pneumococcal vaccine approved for use in children younger than 2 years of age 
(van Kempen et al. 2005). Although PvCV7 is effective in the eradication of pneumococcal 
disease, only a slight decrease in OM was observed. A study conducted in Finland evaluated 
the efficacy of the vaccine in children with AOM. A 34% and 57% reduction in respiratory and 
pneumococcal infections was demonstrated, respectively, with only a 6-7% reduction of 
AOM. A 33% increase in episodes caused by serotypes, not included in the vaccine, with an 
11% increase in OM infection caused by H. influenzae, was also observed (Eskola and Kilpi, 
1999; Eskola et al., 2001; Fireman et al., 2003). A shift in S. pneumoniae serogroups from 
the conjugate vaccine to non-vaccine serotypes was noted following vaccination (van 
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Kempen et al., 2005). In cases where high-dose amoxicillin therapy and pneumococcal 
conjugate vaccinations were used, H. influenzae has become the predominant pathogen. 
Fewer occurrences of penicillin-resistance S. pneumoniae AOM isolates and more beta-
lactamase-producing strains of H. influenzae were recorded (Casey and Pichichero, 2004). 
Other studies indicated that the immunisation of infants with PcCV7 resulted in a 20.1-24% 
less occurrence of ventilation tubes for recurrent AOM than unimmunised controls (Eskola et 
al., 2001; Fireman et al., 2003). In an Israeli study carried out with toddlers attending day 
care, a 20% decrease in AOM was observed when associated with antibiotics, with a 
decrease in antibiotic resistant S. pneumoniae (Dagan et al., 2001; Dagan et al., 2003). 
Serotype coverage greatly differs between countries, age and disease. The serotype also 
varies in virulence, depending on the ability to activate the alternative pathway to alter 
resistance to phagocytosis (Reinert, 2004). 
 
Little research has been done on the development of vaccines against NTHI and M. 
catarrhalis in OM (Murthy et al., 2005). Although a conjugate H. influenzae type b vaccine 
has been used, no effect on the prevalence of OM was recorded (Cripps et al., 2005). 
Vaccines for viruses do exist but do not seem to affect OM. The influenza vaccine had a 
slight effect on the prevention of OM, but it is not practical to include in a polymicrobial otitis 
vaccine because of its active constituents (Murthy et al., 2005). The impact of existing 
respiratory syncytial virus vaccines on OM has not been studied. Vaccines developed for 
parainfluenzae had no effect on the eradication of AOM (Cripps et al., 2005). 
 
The Centers Committee and Immunization Practices recommend universal influenza 
vaccine immunization for all children six months and two years of age (AAP and AAFP, 
Clinical Practice Guidelines; Subcommittee on Management of Acute Otitis Media, 2004).  
However, due to a lack in scientific data, the application of the influenza vaccine in AOM is 
limited (Reinert, 2004). 
 
 
2. The genus Enterococcus 
 
2.1. Introduction 
 
The genus Enterococcus belongs to a group of generally regarded as safe (GRAS) 
microorganisms, known as lactic acid bacteria (LAB) (Devriese and Pot, 1995). Enterococci 
are Gram-postitive, catalase- and oxidase-negative, non-sporeforming, facultative anaerobic 
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cocci (Holt, 1994; Moreno et al. 2005).  Enterococci are ubiquitous LAB, isolated from 
various sources including fermented meat, olives, vegetables and diary products. They form 
part of the natural microflora of the gastrointestinal tract (GIT) of animals and humans 
(Murray, 1990; Franz et al., 1999; Moreno et al., 2005). Some strains cause food spoilage 
and have been associated with diseases (Franz et al., 1999). Over the past two decades, 
enterococci have emerged as potential opportunistic pathogens in nosocomial disease, 
becoming a serious problem in human medicine as a result of their increase in antibiotic 
resistance, and the production of various virulence determinants (Franz et al., 1999; Franz 
and Holzapfel, 2004).  
 
 
2.2. Biochemical, physiological and phenotypic characterization 
 
Lactic acid bacteria are grouped into different genera based on various morphological, 
physiological and biochemical characteristics. Lactic acid bacteria can be divided into rods 
(Carnobacterium and Lactobacillus) and cocci (all other genera). One exception is the genus 
Weissella, which includes cocci and rods. The tetrad-forming genera are Aerococcus, 
Pediococcus and Tetragenococcus (Axelson, 2004). 
 
Enterococcus was first described as a diplococcus by Thiercelin and Jouhaud in 1899 
(Thiercelin and Jouhaud, 1903). In 1906 it was reclassified as Streptococcus faecalis based 
on the formation of short and long chains (Andrews and Horder, 1906). However, the genus 
Enterococcus was separated from Streptococcus based on 16S rRNA cataloguing, 
DNA:DNA and DNA:rRNA hydridisation, and serological studies with superoxide dismutase 
antisera (Schleifer and Kilpper-Bälz, 1984). Enterococci form a distinct cluster with 
Vagococcus, Tetragenococcus and Carnobacterium in the clostridial sub-branch (Devriese et 
al., 1993; Franz et al., 1999). The phenotypic description of the genus Enterococcus is 
vague, if not impossible (Devriese et al., 1993; Devriese and Pot, 1995). Identification relies 
on the use of a combination of phenotypic, genotypic, and phylogenetic information in a 
polyphasic taxonomic approach, as described by Vandamme et al. (1996). Currently, 28 
species are assigned to the genus, which is subdivided into at least seven recognised 
species based on 16 S rRNA gene sequences (Stiles and Holzapfel, 1997; Franz and 
Holzapfel, 2004). Species are differentiated mainly by carbohydrate fermentation patterns, 
arginine and hippurate hydrolysis, and the presence and/or type of menaquinones (Schleifer 
and Kilpper-Bälz, 1987). Most enterococci are positive to the Voges-Proskauer test and 
fermentation of ribose (Franz and Holzapfel, 2004). Enterococci are chemo-organotrophs 
with a strictly fermentative metabolism, using glycolysis to convert glucose quantitatively to 
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lactic acid (Franz and Holzapfel, 2004). The phylogenetic relationship has been determined 
by comparative sequence analysis of the 16S rRNA and is divided into seven groups (see 
Table 3).   
 
Table 3: Characteristic physiological properties and phylogenetic groups of enterococci.a, b  
Growth at Growth in the presence of 
Phylogenetic groups and 
species 10 ºC 45 ºC
pH 
9.6 
6.5% 
NaCl 
40% 
Bile 
0.04% 
Sodium 
azide 
Esculin 
hydrolysis 
Group D 
antigen 
E. faecium group         
E. azikeevi n.d n.d n.d n.d n.d n.d n.d n.d 
E. canis n.d n.d n.d n.d n.d n.d n.d n.d 
E. faecium + + + + + + + V 
E. durans + + + + + + + (+) 
E. hirae + + + + + + + V 
E. mundtii + + + + + + + + 
E. villorum n.d n.d. n.d. + + + + n.d. 
E. avium group         
E. avium V + + V v/+ n.d. + + 
E. malodoratus + - + + + n.d. + + 
E. pseudoavium + + + +/- V/+ n.d. + - 
E. raffinosus (+) + + + V/+ n.d. + n.d. 
E. gilvus + + n.d. + + n.d. + + 
E. gallinarium group         
E. gallinarium + + + + + + + + 
E. casseliflavus + + + V/+ + + + + 
E. flavescens V/- V/+ n.d. + + + + + 
E. dispar group         
E. dispar + - n.d. +/- + - + - 
E. asini (+) (+) n.d. - + n.d + + 
E. pallens + + n.d. + + n.d. + + 
E. saccharolyticus 
group 
        
E. saccharolyticus  + + n.d. (+) + n.d. + - 
E. sulfureus + - n.d. + + n.d. + - 
E. cecorum group         
E. cecorum - + (+) - (+) - + - 
E. comlumbae - n.d. n.d. - (+) - + - 
E. faecalis group         
E. faecalis + + + + + + + + 
E. haemoperoxidus + - n.d. + + + + + 
E. moraviensis + - n.d. + + + + + 
E. ratti + + n.d. + n.d. n.d. + (+) 
Other         
E. phoeniculicola n.d n.d n.d - - n.d. n.d. n.d. 
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Table 3: (continued)  
Growth at Growth in the presence of 
Phylogenetic groups and 
species 10 ºC 45 ºC
pH 
9.6 
6.5% 
NaCl 
40% 
Bile 
0.04% 
Sodium 
azide 
Esculin 
hydrolysis 
Group D 
antigen 
E.porcinus + + n.d. + n.d. n.d. + + 
E.solitarius + + n.d. + + n.d. + + 
a Franz and Holzapfel, 2004, b Moreno et al., 2005.  n.d. = not determined, (+) = weak 
positive, V = variable, +/- = differing reports in literature. 
 
Enterococcus spp. grow between 10 ºC and 45 ºC, in the presence of 6.5% NaCl, and 
between pH 4.4 and 9.6. All species belong to Lancefield antigen group D (Prescott et al., 
1999). Enterococcus sulfureus, Enterococcus palens, Enterococcus gilvus, Enterococcus 
mundtii and Enterococcus casseliflavus produce a yellow-pigment.  E. casseliflavus and 
Entoerococcus gallinarum are motile (Moreno et al., 2005). Genotypic methods used to 
differentiate enterococci and lactococci on genus level involves PCR with conserved 16S 
rRNA gene sequences (Deasy et al., 2000). Enterococci are differentiated by PCR 
amplification of a conserved internal fragment of D-alanine:D-alanine ligase genes, by 
restriction fragment length polymorphism of the 16S/23S intergenic spacer region, tRNA 
intergenic spacer PCR and RAPD-PCR (Tyrrell et al., 1997; Baele et al., 2000; Ozawa et al., 
2000; Franz and Holzapfel, 2004).   
 
 
2.3. Infections caused by enterococci 
 
Enterococci are the most common nosocomial pathogens in immunocompromised 
patients with structural abnormalities (Chenoweth and Schaberg, 1990; Murray, 1990; 
Moellering, 1992; Morrison et al., 1997). Enterococci are responsible for 12% of infections, 
and are the second greatest cause of hospital-acquired infections in the USA (Schaberg et 
al., 1991). These bacteria are typical opportunistic pathogens, and have been an important 
cause of bacteremia, infective endocarditis, urinary tract infections (UTI), infections of the 
central nervous system, intra-abdominal and pelvic infections and wound infections (Franz et 
al., 1999). Enterococcus faecalis and Enterococcus faecium are responsible for up to 90% 
and 10% of infections, respectively. Enterococcus avium, E. casseliflavus, Enterococcus 
durans, E. gallinarum, Enterococcus hirae, Enterococcus malodoratus, E. mundtii, 
Enterococcus pseudoavium, Enterococcus raffinosus and Enterococcus solitarius are only 
occasionally associated with infections (Mundy et al., 2000). Enterococci consist of virulent 
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factors and are resistant to antimicrobial agents that make them effective opportunistic 
pathogens (Moreno et al., 2005).  
 
 
2.4. Antibiotic resistance 
 
Enterococci from clinical, food and faecal sources are resistant to a broad range of 
antibiotics (Leclercq et al., 1992; Moellering, 1992). Enterococci are either intrinsically 
resistant or they possess acquired resistance determinants. Intrinsic resistant genes are 
located on the chromosome, while acquired resistant genes are located on plasmids or 
transposons (Clewell, 1990; Murray, 1990). Constitutive intrinsic resistance was described 
for cephalosporins, β-lactams, sulphonomides, low levels of clindamycins and 
aminoglycosides. Acquired resistance includes resistance to ampicillin, macrolides, 
trimethoprim/sulfomethoxole, quinolones, streptogramins, chloramphenicol, erythromycin, 
high levels of clindamycins and aminoglycosides, tetracycline, high levels of β-lactams, 
fluoroquinolons and glycopeptides, such as vancomycin (Murray, 1990; Leclercq, 1997; 
Morrison et al., 1997; Moreno et al., 2005). 
 
Infections with multiple-antibiotic resistant Enterococcus strains are normally treated with 
clinically relevant antibiotics such as ampicillin, gentamycin and vancomycin (Franz and 
Holzapfel, 2004). As result of the extensive use of vancomycin, high levels of vancomycin-
resistant enterococci (VRE) have emerged (Endz et al., 1999). VRE possess vanA, vanB, 
vanD, and vanE type resistance genes, with vanA and vanB considered to be of clinical 
importance (Moreno et al., 2005).  
 
Many cases of resistance are located in mobile genetic elements, such as conjugative 
transposons and resistant plasmids typical for enterococcal species (Noble et al., 1992). The 
spread of antibiotic resistance, via these elements to other genera, such as pathogenic 
Staphylococcus, may be of major concern. Vancomycin-resistant transposons of 
enterococcal strains, involved in nosocomial infections, have received a great deal of 
attention (Noble et al., 1992). Tn916 was the first enterococcal transposon described 
conferring resistance to tetracycline. Tn916 is expressed in both Gram-positive and Gram-
negative bacteria, and is used in genetic studies to inactivate genes in recipient strains 
(Franke and Clewell, 1981; Gasson, 1990). Conjugation is the transfer of DNA from a donor 
cell to the recipient by direct cell-to-cell contact. In LAB, donor-recipient pairs are formed by 
the production of sex pheromones, or substances produced by the recipient that stimulates 
cell aggregation (Clewell et al., 2002). Examples of conjugative plasmids with a broad host 
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range are pAMβ1 (Clewell et al., 1974) and pIP501 (Horodniceanu et al., 1976), encoding 
erythromycin-resistance and chloramphenicol-erythromycin resistance, respectively. These 
plasmids are regularly conjugative to other genera of LAB (Gibson et al., 1979; Gonzalez and 
Kunka, 1983). 
 
The classical regimen for treating systemic enterococcal infections is a synergic 
combination of a cell-wall-active antibiotic (penicillin or ampicillin) and aminoglycoside, which 
is ineffective in the presence of resistance to one or both components (Witte, 1999; Moreno 
et al., 2005). To use enterococci as potential starter cultures, it is necessary to check for the 
absence of transferable antibiotic resistance, as it is strain specific (Moreno et al., 2005).  
 
 
2.5. Virulence factors 
 
 Virulence of enterococci cannot be explained by antibiotic resistance alone. To cause 
infection, enterococci have to consist of various virulent determinants enhancing 
colonisation, invasion and translocation of the strain to host tissue and epithelial cells 
(Johnson, 1994; Moreno et al., 2005).  Virulent traits of enterococci include adherence to 
host tissue by a variety of adhesions, e.g. the enterococcal surface protein (Esp), 
aggregation substance (AS), enterococcal endocarditis antigens (EfaAfm or EfaAfs from E. 
faecium and E. faecalis, respectively), or adhesion to collagen (Ace). Enterococcal virulence 
is also based on invasion and abscess formation, resistance to and modulation of specific 
and unspecific host defence mechanisms, and by the production and secretion of toxins such 
as the plasmid-encoded cytolysin, and secretion of hyaluronidase and gelatinase, which may 
result in pathological changes (Witte, 1999; Franz and Holzapfel, 2004; Moreno et al., 2005). 
 
2.5.1. Aggregation substance (AS)  
An aggregation substance is a pheromone-inducible surface-bound glycoprotein 
produced by E. faecalis and is encoded on a sex pheromone-responsive plasmid. The AS 
mediates mating aggregate formation during conjugation, which is the binding of donor cells 
to plasmid-free recipients, thereby facilitating plasmid transfer. The AS is essential for high-
efficiency conjugation of sex pheromone plasmids (Mundy et al., 2000; Semedo et al., 2003; 
Moreno et al., 2005). The AS has several other functions, including adherence to a variety of 
eukaryotic tissue surfaces, such as pig tubular cells, influences phagocytosis and the 
subsequent fate of an organism, and contribute to pathogenesis of enterococcal infections by 
a number of mechanisms (Mundy et al., 2000; Sübmuth et al., 2000; Semedo et al., 2003; 
Moreno et al., 2005).  It is speculated that macrophages act as a vehicle of enterococci from 
 33
the intestine to the lymph system and bloodstream, thus facilitating transport (Wells et al., 
1990). The AS may work synergistically with cytolysin in endocarditis (Mundy et al., 2000). 
The AS is also associated with adhesion (adhesins) to eukaryotic cells, promoting 
colonization, invasion of eukaryotic cells, and adhesion to extracellular matrix protein to 
promote translocation, and increase the survival in immune cells by evading the host immune 
system (Franz and Holzapfel, 2004).  
 
2.5.2.  Sex pheromones  
Sex pheromones are small, linear, peptides of 7-8 amino acids, excreted to promote 
acquisition of plasmid DNA and cause pathological changes such as acute inflammation. 
When pheromones bind to receptors on the cell surface of strains containing plasmid DNA, a 
signal is transducted and leads to induction of the AS gene. Expressed peptide mediates cell 
clump formation by binding to a complementary receptor, allowing a highly efficient transfer 
of the pheromone plasmid on which the AS gene is encoded. Sex pheromones are 
associated with surface proteins of unknown function. Sex pheromones may also serve as 
chemo-attractive substances for human neutrophils and induce inflammation and superoxide 
production (Franz and Holzapfel, 2004). 
 
2.5.3. Cytolysin (Cyl)   
Cytolysin is an eukaryotic toxin and lyses the immune cells to invade the immune 
response (Franz and Holzapfel, 2004). Cytolysin was the first-studied virulence factor, and 
may be encoded either on a highly transmissible pheromone-responsive conjugative 
plasmid, or integrated into bacterial chromosome or pathogenicity islands (Mundy et al., 
2000; Semedo et al., 2003; Moreno et al., 2005). Cytolysin is a unique novel post-
translationally-modified bacterial protein that is distantly related to lantibiotic bacteriocins, 
contributing to the severity of disease, such as bacteremia and systemic disease (Booth et 
al., 1996). The toxin causes a β-hemolytic reaction on red blood cells and has an activity 
against a large variety of Gram-positive bacteria (Mundy et al., 2000; Semedo et al., 2003). 
Cytolysin is also responsible for direct tissue damage by a reduction in renal function and 
complete destruction of the renal architecture (Chow et al., 1993; Booth et al., 1996). In 
some cases the toxin is responsible for organotoxic activity, where combined effects of 
antimicrobial and anti-inflammatory therapy are set off and the organ is completely destroyed 
(Mundy et al., 2000). Cytolysin is generally isolated from E. faecalis, E. durans and E. 
faecium, with 60% of E. faecalis strains isolated from disease outbreaks (Mundy et al., 2000; 
Semedo et al., 2003). E. faecalis isolated from endocarditis and bacteremia has the ability to 
adhere to Girarti heart cell lines (Archimbaud et al., 2002; Moreno et al., 2005).  
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2.5.4.  Enterococcus surface protein from E. faecalis (Espfs) and E. faecium (Espfm)  
Enterococcus surface proteins are large, chromosomally gene-encoded adhesions, 
consisting of an interesting structure mostly produced by E. faecalis (Moreno et al., 2005). 
The central part consists of distinct repeated regions acting as a retractable arm with an 
extended globular N-terminal through the cell to the surface. During adverse conditions, such 
as immune deficiencies, the ability to retract surface proteins may facilitate immune evasion 
(Mundy et al., 2000). Esp is associated with the ability to form biofilms at abiotic surfaces 
such as stainless steel and infections involving catheters (Semedo et al., 2003). Biofilms 
generally induce antimicrobial and antibiotic resistance. Enterococcus surface proteins 
contribute to colonization and persistence of enterococci in urinary tract infections, 
associated with colonisation and spread among liver transplant patients, and is part of the 
pathogenicity island in E. faecalis (Shankar et al., 2001; Toledo-Arana et al., 2001; Eaton 
and Gasson, 2002; Shankar et al., 2002; Waar et al., 2002; Semedo et al., 2003). 
Enterococcus surface proteins exhibit microbial surface components recognizing adhesive 
matrix molecules (MSCRAMM) characteristics with a role in adhesion and evasion of 
immune response (Franz and Holzapfel, 2004; Moreno et al., 2005). 
 
2.5.5. Adhesin to collagen from E. faecalis (Ace) and E. faecium (Acm) 
The adhesins Ace and Acm are responsible for pathogenesis in enterococci. Adhesion to 
collagen is generally expressed during human infection, promoting translocation and evasion 
of the host immune system (Franz and Holzapfel, 2004). 
 
2.5.6. Enterococcus endocarditis antigen from E. faecalis (EfaAfs) and E. faecium 
(EfaAfm)  
The production of these antigens is important in the infection of human tissue, 
endocarditis (Franz and Holzapfel, 2004). It suggested that a carbohydrate antigen mediates 
the adherence of enterococci to cultured heart cells (Guzman et al., 1991a).  
 
2.5.7. Gelatinase (Gel) 
Gelatinase is an extracellular Zn-metalloprotease capable of hydrolysing various proteins 
such as collagen, casein, gelatine and other small biologically-active peptides, to evade the 
host innate response, resulting in an increase in pathogenicity (Mundy et al., 2000; Franz 
and Holzapfel, 2004; Moreno et al., 2005). The majority of Gel is produced by E. faecium and 
E. faecalis, but it is also found in E. avium, E. casseliflavus, E. durans and E. raffinosus 
(Semedo et al., 2003; Moreno et al., 2005). Cleavage of hydrolysed peptides by Gel signifies 
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the potential to modulate the host response to enterococcal infection (Dupont et al., 1998). 
Gelatinase is also important in translocation. The genes encoding for Gel are normally 
located on the chromosome (Semedo et al., 2003). 
 
2.5.8. Hyaluronidase 
Hyaluronidase is a cell-surface-associated enzyme responsible for cleavage of the 
mucopolysaccharide moiety of connective tissue or cartilage, and degrades hyaluronix acid, 
a major component in the extracellular matrix, for the translocation and pathogenesis of 
some Enterococcus species (Jett et al., 1994; Witte, 1999; Franz and Holzapfel, 2004). 
Strains producing hyaluronidase are generally isolated from abscesses and play a role in 
host tissue invasion (Jett et al., 1994). The enzyme also acts as a spreading factor for 
dissemination of some microorganisms (Witte, 1999). 
 
2.5.9. Lipoteichoic acid (LTA)  
Lipoteichoic acid, also known as a group D streptococcal antigen, is present in a variety 
of biological processes. Some properties ascribed to it include modulation of the host 
immune response and mediating the adherence of enterococci to host cells (Guzman et al., 
1989; Guzman et al., 1991a; Guzman et al., 1991b; Montravers et al., 1997). Lipoteichoic 
acid induces the production of interleukin-1β, interleukin-6 and TNF-α in vitro and may 
contribute to local tissue damage (Witte, 1999). 
 
2.5.10. Extracellular superoxide 
Strains isolated from bacteremia are known to produce superoxide. The vast majority of 
E. faecalis produce superoxide, but it varies among strains. The role of superoxide in 
pathogenesis is not well defined.  Strains capable of producing superoxide may be better 
adapted physiologically to utilise limited sources in the intestinal environment, leading to 
overgrowth of the organism. Production of superoxide may enhance niche control in 
proximity to the intestinal epithelium. The effect of membrane damage by oxygen radicals 
may then potentiate the ability of the organism to translocate across the weakened epithelial 
barrier (Huycke et al., 1996).  Superoxide enhances the in vivo survival of E. faecalis in 
mixed infections with Bacteriodes fragilis in a subcutaneous infection model (Mundy et al., 
2000).   
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3. Bacteriocins of genus Enterococcus 
 
3.1. Introduction 
 
Bacteriocins are small, cationic, amphiphilic (rather hydrophobic) biologically active 
proteinaceous compounds, exhibiting antimicrobial properties, usually against closely related 
bacterial species, including food-borne and spoilage organisms (Klaenhammer, 1993; De 
Vuyste and Vandamme, 1994; Ennahar et al., 2000). Enterococcus species produce 
bacteriocins, known as enterocins. Enterocins are microbial active peptides and have 
developed a great deal of interest as an approach to control food-borne diseases, to be used 
as starter cultures and biopreservative in various food products. In some cases enterococci 
are used as probiotics as a result of their protective effects in the GIT (De Vuyst and 
Vandamme, 1994; Franz et al., 1999).  
 
 
3.2. Classification 
 
Bacteriocins are classified into four major classes based on their structural, 
physiochemical and molecular characteristics, and bactericidal activity (Klaenhammer, 1993; 
Nes et al., 1996; Moll et al., 1999). Enterococci are known to produce class II bacteriocins. 
These antimicrobial peptides are small (<10 kDa), heat-stable, cationic, hydrophobic and 
membrane-active peptides (De Vuyst and Vandamme, 1994; Abee et al., 1995; Nes et al., 
1996; Rodriguez et al., 2003). Class II, the largest group, is further classified into three 
subgroups based on their primary structures. Class IIa or pediocin-like bacteriocins are 
characterised by the presence of an unique highly conserved hydrophilic N-terminal amino 
acid sequence, YGNGVXaaC (Tyr-Gly-Asn-Gly-Val- Xaa-Cys) consensus motif, containing a 
high content of nonpolar amino acid residues, small amino acids (e.g. glycine), with one or 
more disulphide bridges, and strong inhibitory activity towards Listeria. The hydrophobic 
and/or amphiphilic C-terminal is also moderately conserved with low similarity (Nes et al., 
1996; Eijsink et al., 1998; Ennahar et al., 2000). Class IIb bacteriocins consist of a two-
component system, where activity depends on two distinct peptides with no significant 
similarities. Class IIc bacteriocins are thiol-activated and sec-dependent secreted 
miscellaneous peptides requiring a reduced cysteine residue for activity (Abee et al., 1995; 
Ennahar et al., 2000; Héchard and Sahl, 2002). Class I bacteriocins or lantibiotics are small 
(<5 kDa), cationic, heat-resistant peptides, consisting of unusual and special amino acids, 
lanthionine and β-methyl-lantionine, with thioether rings and dehydrated residues. These 
membrane-active peptides are synthesised via post-translational modifications to inhibit 
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sensitive organisms (Klaenhammer, 1993; Moll et al., 1999). Class III bacteriocins are large, 
hydrophilic (>30 kDa), heat-labile peptides and may furthermore include enzymes mimicking 
their physiological activities (Klaenhammer, 1993; Moll et al., 1999). Class IV bacteriocins 
are complex peptides, where activity depends on the composition of the protein plus a lipid or 
carbohydrate moiety. Class IV bacteriocins are not generally accepted (Klaenhammer, 
1993). To date, no enterocin has been classified into classes IIb, III, and IV. Class II is the 
most abundant and extensively studied of bacteriocins (Franz and Holzapfel, 2004).  
 
 
3.3. Biosynthesis and genetic organisation 
 
Four genes are required for the production of antimicrobial activity of class II bacteriocins. 
These genes are similarly organised in an operon cluster and may be encoded on the 
chromosome, or a pheromone-responsive, conjugate plasmid, or a transposon (Gilmore et 
al., 1994; Martinez-Bueno et al., 1994; Tomita et al., 1996; Chen and Hoover, 2003). The 
four genes consist of: (1) a structural gene encoding for a prepeptide containing a conserved 
leader peptide cleaved at a double-glycine proteolytic processing site, (2) a cationic immunity 
gene protecting the producer against its own bacteriocin, and (3 and 4) genes encoding a 
membrane-associated ATP-dependent binding cassette (ABC) transporter and an accessory 
protein essential for externalisation of class II leader peptides. The majority of immunity 
genes are cytoplasm-associated, with a small part interacting with the cytoplasmic 
membrane. In some cases regulatory genes are produced (Håvarstein et al., 1995; Nes et 
al., 1996; Chen and Hoover, 2003). Figure 2 illustrates the genetic organization of enterocin 
CRL353 (Saavedra et al., 2004), enterocin SE-K4 (Doi et al., 2002), enterocin P (Cintas et 
al., 1997) and enterocin A (O’Keeffe et al., 1999). Enterocin CRL35 and mundticin KS share 
similar genetic clusters.  
Bacteriocins of LAB are ribosomally synthesised as N-terminal precursor proteins 
containing a leader sequence cleaved during maturation (Nissen-Meyer and Nes, 1997). The 
leader peptides consist of highly conserved sequences recognised by a proteolytic domain of 
a dedicated ABC-transporter superfamily, and are secreted via a signal-sequence-
independent pathway (Klaenhammer, 1993; Nes et al., 1996). Class IIa bacteriocins are 
ribosomally synthesised as a prepeptide with a N-terminal leader peptide of a double-glycine 
type processing site that is secreted out of the cell by transport machinery, except enterocin 
P (Cintas et al., 1997). Enterocin P is secreted via the general secretory pathway of a cell, 
formally described as class IIc (Ennahar et al., 2000; Cleveland et al., 2001). Recently, a 
sec-dependent class IIa bacteriocin has been discovered (Cintas et al., 1997). In class IIa 
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bacteriocins the N-terminal and C-terminal parts of the ABC-transporters are a priority. The 
C-terminal has a highly conserved ATP-binding domain, while the hydrophobic integral 
membrane N-terminal domain is responsible for the proteolytic cleavage of the C-terminal 
part of the double-glycine motif removing the leader. Binding of the prepeptide triggers ATP 
hydrolysis, resulting in subsequent conformational changes, which is then followed by 
translocation across the membrane (Nes et al., 1996; Ennahar et al., 2000). ABC-
transporters require ATP to transport the bacteriocin (Moll et al., 1999).  
Enterocin P 
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71 88 
Enterocin SE-K4 
A B U U U
90 76 
Enterocin CRL35 
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98674 58
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FIG. 2. Genetic organization of enterocin CRL35, enterocin SE-K4, enterocin P and enterocin A.  
Open reading frames (ORFs) encoding the following proteins are marked by arrows with the 
corresponding shading patterns: Prepeptide (A); immunity protein (B); ABC-transporter (C); accessory 
protein  (D); induction factor’s prepeptide (F); histidine protein kinase (K); response regulator (R); 
product with unidentified function (U) ; putative promoter (P) ; and transcriptional terminator (T). The 
number of amino acids residues within each protein is shown below the corresponding ORF. 
 
Biosynthesis of class IIa bacteriocins is regulated by a 3-component system, including: 
(1) a membrane-bound histidine protein kinase (HPK), (2) an induction factor (IF) and (3) a 
cytoplasmic response regulator (RR). For biosynthesis, a prebacteriocin and a bacteriocin-
like prepeptide of an induction factor are produced. The IF is a small, hydrophobic 
synthesised peptide acting as an external signal for gene transcription of bacteriocin genes. 
The bacteriocin and IF are released via the ABC-transporters and are sensed by the HPK. 
The histidine residue in the extracellular domain autophosphorylates and is transferred to a 
conserved aspartic acid of the RR receiver. The interaction causes intramolecular changes, 
triggering the RR to activate transcription of regulatory genes, including the structural, 
externalising and immunity genes (Chen and Hoover, 2003). 
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3.4. Mode of bacteriocin activity 
ctivity depends on the structure of a bacteriocin, and the composition and amount of 
cyto
A       B 
 
A
plasmic membrane (Héchard and Sahl, 2002). Bacteriocins produced by LAB interact 
with specific targets in the cytoplasmic membrane making it more permeable through the 
formation of complex pores, resulting in the leakage of inorganic phosphate and an ionic 
imbalance (Ennahar et al., 2000). The consequence of such disturbances is the dissipation 
of the proton motif force (PMF), including partial or total dissipation of either or both the 
transmembrane potential and/or the pH gradient.   
 
                
 
FIG. 3. Class II bacteriocin insertion and pore formation. A). The barrel-stave model. Peptides 
atta
lass Il bacteriocins have a broad spectrum of activity with post-translational 
mo
ch to the membrane via electrostatic- and hydrophobic interactions, causing aggregation and 
insertion into the bilayer so that the hydrophobic peptide regions align with the lipid core region and 
the hydrophilic regions form the interior region of the pore; B). The carpet-like model. Membrane 
disruption is caused when the peptide is orientated parallel to the surface of the lipid bilayer, forming 
an extensive layer or carpet. Hydrophilic and hydrophobic regions of the peptide are shown in red and 
blue, respectively (Brogden, 2005). 
 
C
difications before exported from cell. The activated bacteriocins interact with various 
membrane-bound target molecules to form large and non-specific pores, causing total 
dissipation of both the transmembrane potential and the pH gradient. Dissipation of the PMF 
mediates the efflux of ions, amino acids and ATP from cells and liposomes (Moll et al., 1999; 
Héchard and Sahl, 2002). Class IIa bacteriocins provoke a total dissipation of the pH 
gradient and only partially the transmembrane potential (Ennahar et al., 2000). Proton efflux 
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is responsible for strong cytotoxic effects, resulting in a decrease in intracellular pH, inhibiting 
many enzymatic processes (Moll et al., 1999). Pore formation in class IIa bacteriocins may 
be explained by mimicking of the ‘barrel stave’ model or the ‘carpet-like’ model (Fig. 3) 
(Brogden, 2005). The barrel-stave model pores are formed as a result of the peptides’ 
amphiphilic transmembrane helices, water solubility and membrane-binding ability (Fig. 3A). 
The initial step in pore formation is activated in two ways, namely: (1) electrostatic interaction 
between the positively charged amino acids and heads of the phospholipids in the bilayer, 
and (2) hydrophobic interactions between hydrophobic residues of the peptide and the lipid 
acyl chains. Pore formation mediates leakage of ions, blockage of amino acid uptake, and 
intracellular ATP depletion (Ennahar et al., 2000; Héchard and Sahl, 2002). ATP depletion 
may be a result of accelerated consumption of ATP to maintain and restore PMF and/or the 
inability to produce ATP as a result of inorganic phosphate efflux (Ennahar et al., 2000). 
Another model used is a ‘carpet-like’ model (Fig. 3B), explaining the peptide-induced pore 
formation, where a single peptide molecule collapses as a result of a strong phospholipid 
mobilising activity, resulting in local and transient permeability (Moll et al., 1999). 
 
Structural features, including the β-turns, α-helixes, YGNGV motifs, and disulphide 
bridges of a bacteriocin, play one or more roles in the recognition and activity of the 
bacteriocin. The β-sheet exerts antimicrobial activity, while the α-helix is responsible for 
target specificity (Moll et al., 1999). The YGNGV motif in the β-turn structure is responsible 
for the recognition step in the mechanisms of action. The YGNGV motif is easily exposed 
and recognised by a membrane receptor being positioned correctly. Another component 
responsible for recognition is the hydrophilic/amphiphilic N-termini of the β-sheet, together 
with its significant role in electrostatic membrane-bacteriocin interaction. Both the N-termini 
of the β-sheet and the YGNGV motif do not determine the specificity of activity. The central 
part of the α-helix regions are hydrophilic/slightly amphiphilic, and responsible for anchoring 
of a bacteriocin into the cytoplasmic membrane. The hydrophobic/amphiphilic C-terminal part 
plays an essential role in the insertion of a bacteriocin into the cytoplasmic membrane, the 
formation of a water-filled pore, and the major part in target-cell specificity of the bacteriocin. 
It is expected that class IIa bacteriocins with similar C-terminal sequences will display similar 
spectra of activity. Another important feature in activation is the disulphide bridges, 
determining the range of activity. The more bridges a bacteriocin has, the broader and 
greater the spectrum of activity will be (Moll et al., 1999; Ennahar et al., 2000; Richard et al., 
2006). 
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All class IIb bacteriocins depend on the activity of two distinct peptides for activity. These 
peptides dissipate the transmembrane potential, while only a few dissipate changes in pH 
gradient. Dissipation of the PMF is usually induced by interacting with a specific receptor 
molecule, resulting in the formation of an anionic- and cationic-specific pore in the 
membrane, causing permeability (Ennahar et al., 2000; Héchard and Sahl, 2002). Class IIc 
bacteriocins are a heterogeneous group of miscellaneous peptides, using various different 
modes of action, resulting in membrane permeability, and specific inhibition of septum 
formation and pheromone activity (Ennahar et al., 2000; Héchard and Sahl, 2002). Studies of 
various class II modes of action studies have been carried out, but results are still not fully 
understood. 
 
 
3.5. Bacteriocin production 
 
Enterococcal bacteriocins have gained interest because of their activity against food-
borne pathogens. Enterococci isolated from food and other environments have been shown 
to produce bacteriocins, usually referred to as enterocins. Enterocins are usually 
characterised as class II bacteriocins exhibiting activity towards listeriae, but a few 
exceptions do occur (Giraffa, 1995; Floriano et al., 1998; Franz et al., 1999). The anti-Listeria 
activity may be explained by the fact that enterococci and listeriae are phylogenetically 
closely related (Franz et al., 1999). Not all enterocins can be readily grouped into various 
bacteriocin classes. Enterocins are characterised into class I, class IIa, class IIb, class IIc 
and class III bacteriocins (see Table 4) (Franz et al., 1999; Franz and Holzapfel, 2004; 
Moreno et al., 2005). Enterocins have been extensively studied, especially those produced 
by E. faecalis and E. faecium. Enterocin AS-48, produced by E. faecalis S-48, is the first 
enterocin purified to homogeneity (Galvez et al., 1989; Martinez-Bueno et al., 1994). 
 
Table 4: Classification of enterocins 
Enterocins Producer strain Size 
(kDa) 
Source Reference 
Class I     
Cytolycin (CylLL) E. faecalis DS16 3.437  Gilmore et al. 
(1994) 
Cytolycin (CylLS) E. faecalis DS16 2.031  Gilmore et al. 
(1994) 
Class IIa     
Enterocin A E. faecium CTC492 4.833 Dry-fermented 
sausages 
Aymerich et al. 
(1996) 
Enterocin CRL 
35 
E. faecium CRL 35 4.290 Regional 
Argentinean 
(Tafi) cheese 
Farias et al. (1996) 
Enterocin SE-K4 E. faecalis K-4 4.918 Grass silage  in 
Thailand 
Eguchi et al. (2001) 
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Table 4: (continued) 
Enterocins Producer strain Size 
(kDa) 
Source Reference 
Bacteriocin 31 E. faecalis  Y1717 5.009 Clinical isolate Tomita et al. (1996) 
Bacteriocin N15 E. faecium N15 3.500 Japanese rice-
bran paste  
Losteinkit et al. 
(2001) 
Bacteriocin 
RC714 
E. faecium RC714 4.937 Human faecal 
sample 
Del Campo et al. 
(2001) 
Mundticin E. mundtii AT06 4.290 Minimally 
processed 
vegetables 
Bennik et al. (1998) 
Mundticin KS E. mundtii NFRI 7393 4.290 Grass silage in 
Thailand 
Kawamoto et al. 
(2002) 
Mundticin QU2 E. mundtii QU 2 4.290 Soybean  Zendo et al. (2005) 
Class IIb     
Enterocin L50A E. faecium L50 5.190 
Enterocin L50B E. faecium L50 5.178 
Spanish dry-
fermented 
sausages 
Cintas et al. (1998) 
 
Enterocin 1071A E. faecalis BEF 1071 4.286 Porcine faeces 
in Göttingen 
Balla et al. (2000); 
Franz et al. (2002) 
Enterocin 1071B E. faecalis BEF 1071 3.899 Porcine faeces 
in Göttingen 
Balla et al. (2000); 
Franz et al. (2002) 
Enterocin A5-
11A 
E. durans 5206  Mongolian airag Batdorj et al. (2006)
Enterocin A5-
11B 
E. durans 5218 Mongolian airag Batdorj et al. (2006)
Class IIc     
Enterocin AS-48 E. faecalis S-48 7.167 Porcine GIT Martinez-Bueno et 
al. (1994) 
Enterocin B E. faecium T136 5.465 Dry-fermented 
sausages 
Casaus et al. 
(1997) 
Enterocin P E. faecium P13 4.630 Dry-fermented 
sausages 
Cintas et al. (1997) 
Enterocin EJ97 E. faecalis EJ97 5.328 Municipal water Galvez et al. 
(1998); Sanchez-
Hidalgo et al. 
(2003) 
Enterocin Q E. faecium L50 3.952 Spanish dry-
fermented 
sausages 
Cintas et al. (2000) 
Enterocin RJ-11 E. faecalis RJ-11 5.049 Rice bran Yamamoto et al. 
(2003) 
Class III     
Enterolysin A E. faecalis LMG 2333 34.501 LMG Panel Nilsen et al. (2003) 
 
In and between the different classes of enterocins, differences and similarities do occur. 
For instance, enterocin B and enterocin 1071 A and B, share class IIa characteristics, but do 
not contain the unique YGNGVXaaC consensus motif (Casaus et al., 1997). Enterocins L50A 
and L50B are synthesised without a N-terminal leader sequence or signal peptide (Cintas et 
al., 1998). Enterocin AS-48 is a cyclic peptide with a broad spectrum of activity against 
Gram-positive and Gram-negative bacteria and is therefore considered as a peptide 
antibiotic (Galvez et al., 1989; Martinez-Bueno et al., 1994).  
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In general, class I bacteriocins have a fairly broad spectrum of activity, inhibiting bacteria 
in the genera Enterococcus, Lactobacillus, Lactococcus, Leuconostoc, Pediococcus, 
Streptococcus, and to a lesser extent Clostridium, Staphylococcus, and Bacillus (Franz and 
Holzapfel, 2004). Class II bacteriocins have a narrow spectra of activity, normally inhibiting 
members of the genera Enterococcus, Lactobacillus and Pediococcus, with, in some cases, 
activity against Clostridium, Bacillus and in class IIa Listeria (Chen and Hoover, 2003; Franz 
and Holzapfel, 2004). Antiviral activity has been observed for enterocin CRL35 and ST4V, by 
activity against thymidine-kinase positive and deficient strains of herpes simplex types 1 and 
2 in Vero and BHK-21 cells, affecting intracellular viral multiplication, and inhibiting late 
stages of replication (Wachsman et al., 1999; Wachsman et al., 2003; Todorov et al., 2005). 
According to Wachsman et al. (2003), enterocin CRL35 did not inhibit the viruses in a direct 
manner, but affected protein synthesis (γ-protein synthesis), without altering virus uptake. 
Besides, enterocin CRL35 inhibited virus-induced cell fusion and virus spread without toxic 
effects to the host. The spread was affected by the accumulation of progeny viruses in the 
cell (Wachsman et al., 2003). 
 
 
3.6. Enterococci as starter cultures and probiotics 
 
Bacteriocin-producing enterococci may be exploited as commercial starter cultures and 
have been used for decades as a probiotic in the promotion of human and animal health 
(Lewenstein et al., 1979; Bellomo et al., 1980; Underdahl, 1983; Giraffa et al., 1997). 
 
One of the best-studied enterococcal probiotics is E. faecium SF68.  E. faecium SF68 is 
commensal in the intestine, has a short lag phase and generation time, with moderate 
resistance to antibiotics and low pH. E. faecium SF68 is insensitive to bile salts, which makes 
it effective for treatment (Lewenstein et al., 1979; Bellomo et al., 1980). The probiotic is used 
as an alternative for antibiotic treatment of diarrhoea and shortens the period by one to three 
days. SF68 is effective for both children and adults, by decreasing the duration of diarrhoeal 
symptoms and stool normalisation time in patients. E. faecium SF68 is inhibitory against 
strains of Escherichia coli, Shigella, Salmonella species, and Enterobacter species. SF68 
has also been used in animals to increase lactase concentrations in the small intestine, 
stimulating LAB growth and repressing the growth of intruding pathogens (Lewenstein et al., 
1979; Bellomo et al., 1980; Moreno et al., 2005). E. faecium SF68, used in dry dog food, 
enhanced specific immune functions, such as cell-mediated and humoral immune functions 
(Benyacoub et al., 2003). In fermented milk products, E. faecium SF68 causes a 
hypocholesterolemic effect on individuals (Agerback et al., 1995). 
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Causidofi is a probiotic consisting of two Streptococcus thermophilus strains and one 
strain of E. faecium. The probiotic is claimed to be hypocholesterolaemic in the short-term 
(Agerholm-Larsen et al., 2000). No signs of long-term reduction of LDL-cholesterol are 
demonstrated, but studies indicate uncertainty of this effect in clinical relevance (Richelsen et 
al., 1996; Lund et al., 2002).  
 
Bacterial bile salt hydrolase (BSH) activity is linked to the reduction of cholesterol. 
Various Gram-positive bacteria, including Enterococcus species, have BSH activity (Franz 
and Holzapfel, 2004).  Marteau et al. (1995) suggest that BHS activity is common among 
enterococci, with 81% occurrence in E. faecalis, 50% in E. faecium, and 44% in E. durans. 
 
More enterococcal strains with potential probiotic properties are E. faecium CRL 183 and 
E. faecium PR88, with decreasing cholesterol levels in vitro in combination of Lactobacillus 
jugurti and alleviation of symptoms of irritable bowl syndrome in humans, respectively (Allen 
et al., 1996; Rossi et al., 1999).   Walthers ECOFLOR is an E. faecium-containing probiotic, 
with anticarcinogenic effects, efficient against diarrhoea, active against L. monocytogenes, 
with possible reduction of LDL-cholesterol levels, and is sensitive to vancomycin and L (+)-
lactic acid production (Moreno et al., 2005).  
 
The use of enterococci as starter or co-cultures has increased considerably. Enterococci 
have the ability to withstand pasteurising temperatures, and to adapt to different substrates 
and growth conditions. This makes them good candidates to be found in food products 
manufactured from raw materials (milk or meat) and heat-treated food products. Enterococci 
contribute to the organoleptic properties of fermented food products and by producing 
enterocins, and are therefore important in food technology (Herranz et al., 2001; Franz and 
Holzapfel, 2004). Various studies support the ability of enterococcal strains to inhibit spoilage 
organisms Listeria and Clostridia, as well as Gram-negative Escherichia coli and Vibrio 
cholera (Galvez et al., 1989; Simonetta et al., 1997; Moreno et al., 2005).  Enterococci, 
mainly E. faecalis, E. faecium and E. durans, are used as starter cultures in cheese and, in 
some cases, in meat products. The strains are included in various European cheeses, such 
as Cheddar, Feta, water-buffalo Mozzarella, Venaco, Cebreiro, Hispanico, and many more. 
Enterococcal cheese-starter cultures consist of various abilities, such as acidifying activity 
(important in any fermentation), proteolytic activity (breakdown of milk casein in ripening of 
cheeses), lipolytic activity (breakdown of substrates in solution, and texture), esterase activity 
(breakdown of substrates in solution, and texture), and citrate metabolism (formation of 
products and metabolites other than lactic acid). Some metabolic end products play a role in 
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aromatic properties such as diacetyl, acetaldehyde, acetoin, texture (CO2), flavour, and 
colour (Franz and Holzapfel, 2004; Moreno et al., 2005).  
 
The increasing emergence of antibiotic resistance in enterococci, the presence of virulent 
determinants, and its association with human disease, makes the use of enterococci as 
probiotic still a controversial issue. To use enterococci as a probiotic, the antibiotic resistance 
and virulence determinants have to be determined (Moreno et al., 2005).   
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ABSTRACT 
 
Bacteriocin ST4SA (bacST4SA), an antimicrobial peptide produced by Enterococcus mundtii 
ST4SA isolated from soya beans, inhibits the growth of Bacillus cereus, Clostridium 
tyrobutyricum, Enterococcus faecalis, Enterococcus faecium, Lactobacillus sakei, 
Propionibacterium spp., Streptococcus caprinus, Pediococcus sp. and Listeria 
monocytogenes.  No change in bacST4SA activity was recorded after 2 h of incubation at pH 
2.0 to 12.0, and after 90 min at 100 °C.  Fifty percent of activity was lost after 20 min at 121 
°C.  BacST4SA was inactivated by proteolytic enzymes and Triton X-114, but not when 
treated with α-amylase, Tween 20, Tween 80, Triton X-100, SDS, urea and EDTA. Maximum 
activity (51 200 AU/ml) was recorded in MRS broth after 14 h at 30°C. According to electron 
spray mass spectrometry, bacST4SA is 3.950 kDa in size. The double-glycine processing 
site, YGNGV consensus sequence in the N-terminal, disulphide bridge in the hydrophilic 
domain, and activity against Listeria spp. is characteristic of a class IIa bacteriocin. The 
genes encoding peptide ST4SA are located on a 50-kb plasmid. MunA encodes a 58-amino 
acid pre-peptide of bacST4SA, munB a 674-amino acid membrane-bound peptide involved in 
bacteriocin transport, and munC a 98-amino acid immunity protein. BacST4SA shares 
complete homology with mundticin KS, mundticin AT06, bacteriocin QU 2, and enterocin 
CRL35 produced by E. mundtii. The leader peptide of bacST4SA differs from enterocin 
CRL35 by two amino acids. 
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Bacteriocins of lactic acid bacteria (LAB) are ribosomally synthesized (1-4) and inhibit 
bacteria genetically closely related to the producer strain (2). These peptides are classified 
into four classes, with most bacteriocins grouped in classes I and II (1, 3, 5, 6). Class I 
peptides, known as lantibiotics (< 5 kDa), are post-translationally modified and contains 
lanthionine and β-methyl-lanthionine (1). Class II bacteriocins are small (< 10 kDa), heat-
stable, cationic, hydrophobic and membrane-active peptides (2, 3, 7, 8). Bacteriocins with the 
highly conserved N-terminal amino acid sequence YGNGVXaaC (Tyr-Gly-Asn-Gly-Val- Xaa-
Cys), nonpolar amino acids, one or more disulphide bridges, and activity against Listeria spp. 
are grouped in class IIa (3, 9, 10). Bacteriocins that function in pairs, usually as two distinct 
peptides, are grouped in class IIb (8, 10). Thiol-activated bacteriocins that rely on a sec-
dependent secretion mechanism are grouped in class IIc (7, 10, 11).  
Bacteriocins produced by Enterococcus spp. belong to class I, class IIa, class IIb, 
class IIc or class III (5, 6).  Most of these bacteriocins are produced by Enterococcus faecium 
and Enterococcus faecalis (12). Enterocin A (13), bacteriocin N15 (14) and bacteriocin 
RC714 (15) produced by E. faecium, and enterocin SE-K4 (16) and bacteriocin 31 (17) 
produced by E. faecalis are classified as class IIa bacteriocins. Enterocins 1071A and 1071B 
produced by E. faecalis (18, 19), and enterocins L50A and L50B (20) produced by E. 
faecium are grouped in class IIb. Enterocin AS-48 (21), enterocin EJ97 (22), and enterocin 
RJ-11 (23) produced by E. faecalis, and enterocin P (24), enterocin B (25) and enterocin Q 
(26) produced by E. faecium are grouped in class IIc. 
Thus far, four bacteriocins of class IIa have been described for E. mundtii, viz. 
mundticin KS (27), mundticin ATO6 (28), bacteriocin QU 2 (29) and enterocin CRL35 (30). 
Mundticin KS, mundticin ATO6 and bacteriocin QU 2 have identical leader and mature 
peptides. Although the mature peptide of enterocin CRL35 is identical to the mature peptides 
of the mentioned three bacteriocins, the leader peptide differs by two amino acid residues 
(27-30). Wachsman et al. (31) reported activity against herpes viruses for enterocin CRL35. 
This has not been reported for any of the other bacteriocins produced by E. mundtii. 
A strain isolated from soya beans and identified as E. mundtii produces a bacteriocin 
with a broad spectrum of activity. The genes encoding bacteriocin ST4SA (bacST4SA), the 
immunity protein and proteins involved in secretion of the peptide (ATP-dependent transport 
proteins) have been sequenced. 
 
 
MATERIALS AND METHODS 
 
Isolation of lactic acid bacteria and screening for antimicrobial activity. Soya 
beans were homogenized in sterile physiological water, serially diluted and plated onto MRS 
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Agar (Biolab, Biolab Diagnostics, Midrand, SA), supplemented with 50 mg/l Natamycin 
(Delvocid®, Gist-brocades, B.V., Delft, The Netherlands) to inhibit fungal growth. Plates were 
incubated at 30 °C for 2 days and those with 50 to 100 colonies screened for antimicrobial 
activity according to the method described by Todorov and Dicks (32). Selected plates were 
overlaid with a second layer of MRS Agar supplemented with Natamycin (50 mg/l) and 
incubated at 30 °C for 48 h in the presence of a gas-generating kit (Oxoid, New Hampshire, 
England). Plates with 10 to 50 colonies were overlaid with a third layer of 10 ml semi-solid 
BHI medium, 1.0% (w/v) agar (Merck, Darmstadt, Germany), seeded with Lactobacillus sakei 
LMG 13558 (ca. 106 cfu/ml). Plates were incubated at 37 °C for 24 h. The test was repeated 
with target cells listed in Table 1. Colonies surrounded with the largest inhibition zones were 
selected, inoculated into MRS broth (Biolab), and re-streaked to obtain pure cultures. 
Antimicrobial activity was confirmed using the agar-spot method described by Ivanova et al. 
(33). Strains were stored at -80 °C in growth medium supplemented with 80% (v/v) glycerol.  
 
Identification of strain ST4SA. Identification was by physiological and biochemical 
tests (34, 35, 36). Testing for pigment production and mobility were performed as described 
by Facklam and Collins (37) and Ball and Sellers (38), respectively. Carbohydrate 
fermentation reactions were recorded by using API 50 CHL and API 20 Strep test strips 
(Biomérieux, Marcy-I’Etiole, France). Identification was confirmed by PCR with genus- (Ent1, 
5′-TACTGACAAACCATTCATGATG-3′; Ent2, 5′-AACTTCGTCACCAACGCGAAC-3′) and 
species-specific [1101A, 5’-AACGAGCG(A/C) (A/G)ACCC-3’; 1407R, 5’-
GACGGGCGGTGTGT(A/G) C-3’] primers used in previous studies (29, 39). Cell morphology 
was studied by atomic force microscopy, as described by Todorov et al. (40). 
 
Bacteriocin bioassay. Antimicrobial activity of strain ST4SA was confirmed by the 
agar-spot test and well-diffusion methods (33). To prevent the inhibitory effect of lactic acid, 
the pH of the supernatant was adjusted to 6.0 with sterile 1 N NaOH. Activity was expressed 
in arbitrary units (AU) per ml. One AU was defined as the reciprocal of the highest dilution 
showing a clear zone of growth inhibition (33). Indicator strains are listed in Table 1.  
 
Growth and bacteriocin production at different conditions. An 18 h-old culture of 
strain ST4SA was inoculated (2%, v/v, OD600=2.0) into 100 ml MRS broth (Biolab), BHI broth 
(Merck), M17 broth (Merck), soymilk (10%, w/v, soy flour), LAPTg broth (41) supplemented 
with peptone from casein, 8% (w/v) molasses and 10% (w/v) molasses, respectively. 
Duplicate flasks were inoculated and incubated for 29 h at 30 °C and 37 °C, without agitation. 
Samples were taken every hour and examined for bacterial growth (OD600), changes in 
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culture pH, and activity against Lactobacillus casei LHS. The agar-spot test method (33) was 
used and activity expressed in arbitrary units (AU) per ml, as described before. 
In a separate experiment, the effect of initial medium pH on production of bacST4SA 
was studied. MRS broth (300 ml volumes) were adjusted to pH 4.5, 5.0, 5.5, 6.0, and 6.5, 
respectively, with 6 M HCl or 6 M NaOH and then autoclaved. Each flask was inoculated with 
2% (v/v) of an 18 h-old culture of strain ST4SA and incubated at 30 °C for 20 h, without 
agitation. Changes in pH and bacST4SA production (AU/ml) were determined as described 
before. 
 
Sensitivity of bacST4SA to temperature, pH, detergents, and enzymes. Strain 
ST4SA was grown in MRS broth (Biolab) at 30 ºC for 24 h, the cells were harvested (8000 x 
g, 10 min, 4 ºC) and the cell-free supernatant adjusted to pH 6.0 with 1 N NaOH. One ml 
samples of cell-free supernatant were exposed to 30, 60 and 100 °C, respectively, and 
residual bacteriocin activity tested after 10, 30 and 90 min, as described before. Activity was 
also tested after 20 min at 121 °C. 
   In a separate experiment, the effect of pH on bacST4SA activity was determined by 
adjusting cell-free supernatants to pH 2.0 to 12.0 (at increments of 1 pH unit) with sterile 1 N 
NaOH or 1 N HCl. After 2 h of incubation at room temperature, the samples were re-adjusted 
to pH 6.5 with sterile 1 N NaOH or 1 N HCl and tested for activity. 
   The effect of detergents on bacST4SA was determined by adding 1% (w/v) SDS, 
Tween 80, Tween 20, urea, Triton X-114 and Triton X-100, respectively, to a bacteriocin-
containing cell-free supernatant. EDTA was added to a final concentration of 0.1 mM, 2.0 
mM and 5.0 mM, respectively. Untreated bacteriocin-containing cell-free supernatant 
suspended in sterile distilled water served as control. All samples were incubated at 37 °C for 
5 h and then tested for antimicrobial activity by using the agar-spot test method (33). 
Resistance of bacST4SA to proteolytic enzymes was determined by incubating active cell-
free supernatants for 2h at 37 °C in the presence of 1.0 mg.ml-1 and 0.1 mg.ml-1 protease, 
Proteinase K, trypsin (Roche, Indianopolis, IN, USA), pronase and pepsin (Boehringer 
Mannheim GmbH, Germany), respectively. The effect of 0.1 and 1.0 mg.ml-1 α-amylase 
(Sigma Diagnostics, St. Louis, MO, USA) on bacST4SA was tested after 2 h at 37 °C. 
Antimicrobial activity was determined as described before. L. casei LHS was used as 
indicator strain. 
 
Molecular size of bacST4SA.  Strain ST4SA was grown in MRS broth (Biolab) for 20 
h at 30 °C. Cells were harvested (8000 x g, 10 min, 4 °C) and bacST4SA precipitated from 
the cell-free supernatant with 70% saturated ammonium sulphate (42). The precipitate was 
resuspended in one-tenth volume 25 mM ammonium acetate (pH 6.5), desalted by using a 
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1000 Da cutt-off dialysis membrane (Spectrum Inc., CA, USA) and separated by tricine-SDS-
PAGE, as described by Schägger and Von Jagow (43). A low molecular weight marker with 
sizes ranging from 2.5 to 45.0 kDa (Amersham International, UK) was used. The gels were 
fixed and one half stained with Coomassie Blue R250 (Saarchem, Krugerdorp, South Africa). 
The position of the active peptide band in the gel was determined by overlaying an unstained 
gel with L. casei LHS (106 cfu/ml), embedded in BHI agar (Merck). 
 
Isolation and purification of bacST4SA. Strain ST4SA was inoculated in MRS 
broth (Biolab), incubated for 18 h at 30 °C and then inoculated 2% (v/v) into freshly prepared 
MRS broth (Biolab). After 20 h of static incubation at 30 °C, the cells were harvested (8000 x 
g, 10 min, 4 °C) and bacST4SA precipitated from the cell-free supernatant with 80% 
saturated ammonium sulphate (42). The precipitate was resuspended in one-tenth-volume 
25 mM ammonium acetate (pH 6.5), desalted against distilled water by using a 1000 Da cutt-
off dialysis membrane (Spectrum) and loaded on a SepPak C18 column (Water Millipore, 
MA, USA). The column was washed with 20% (v/v) iso-propanol in 25 mM ammonium 
acetate (pH 6.5) and peptides eluted with 40% (v/v) iso-propanol in 25 mM ammonium 
acetate (pH 6.5). Fractions were collected, dried under vacuum (Speed-Vac, Savant), 
dissolved in 50 mM phosphate buffer (pH 6.5) and tested for antimicrobial activity as before.  
Active fractions were further purified by separation in a SeperdexTM 75 10/30 column 
(Amersham Pharmacia Biotech, Sweden) on an ÄKTApurifier (Amersham). Peptides were 
eluted from the column with 50 mM phosphate buffer and 400 mM NaCl (pH 6.5), and 
detected at 254 and 280 nm. Fractions containing active peptide were collected, dried under 
vacuum and stored at -20 °C. Activity was tested by using the agar-spot test method, as 
described before. 
 
Mass spectrometry. Active fractions collected from the ÄKTApurifier were subjected 
to electro-spray mass spectrometry (ES-MS). A VG Bio-Q quadrupole with a mass range of 
4000 Da (Bio-Tech, Manchester, UK) in the positive mode was used. The protein was 
dissolved in H2O/CH3CN (50/50, v/v) and 1.0% acetic acid at a concentration of 
approximately 5 pmol/μl (by volume). Ten μl-aliquots were introduced into the ion source at a 
flow rate of 4 μl/min. Scanning was performed from m/z = 500 to 1.500 in 10 s, with the 
resolution adjusted so that the peak at m/z = 998 from horse heart myoglobin was 1.5–2 wide 
on the base. Calibration was performed by using the multiply charged ions produced by 
separate injections with horse heart myoglobin (16950.4 Da), as described by Jaquinod et al. 
(44). 
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Analysis of the bacST4SA operon. Total genomic DNA was extracted according to 
the method described by Dellaglio et al. (45). Plasmid DNA was isolated according to Burger 
and Dicks (46), followed by CsCl density gradient centrifugation (47). DNA was separated on 
a 0.6% (w/v) agarose gel, according to Ausubel et al. (47). Genomic and plasmid DNA were 
used as templates. The structural gene encoding bacST4SA was amplified using DNA 
primers designed from the sequence of bacteriocin QU 2 (29). Two sets of primers were 
designed for amplification of the ATP-dependent transporter gene and one set for the 
amplification of the immunity gene, all based on sequences of the mundticin KS operon 
(GenBank Accession number AB066267). Primers and their base pair sequences are listed 
in Table 2. 
Amplification of the ATP-dependent transporter and immunity genes was performed 
with Taq DNA polymerase in the following settings: denaturation at 94 °C for 3 min, followed 
by 30 cycles of denaturation at 94 °C for 30 s, annealing at 53 °C for 30 s, and 
polymerization at 72 ° for 7 min. Amplified fragments were separated on a 1% (w/v) agarose 
gel as before. A 50-bp DNA fragment (Amersham Bioscience, UK Limited, UK) was used as 
marker. Amplified products were purified using the QIAquick® PCR purification kit (Qiagen, 
Valencia, California, USA). Purified fragments were cloned into pGEM®-T Easy Vector 
(pGEM®-T Easy Systems, Promega, Madison, USA). Plasmid isolations were performed on 
selected transformants, using the QIAquick® PCR purification kit (Qiagen). Fragments were 
purified as described before and sequenced using the BigDyeTM Terminator Cycle 
(Biosystems, Warrington, England) on an ABI Genetic Analyser 3130XL sequencer (Applied 
Biosystem, SA Pty Ltd.). 
 
Correlation of DNA and amino acid sequences. The BLAST program of the 
National Centre for Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov/BLAST/), 
and DNAMAN software for Windows® (Lynnon Biosoft, Vaureuil, Quebec, Canada) were 
used to obtain amino acid-, DNA sequences, and hydrophobicity profiles. The membrane 
spanning of the ATP-dependent transporter peptide of bacST4SA was predicted using the 
SOSUI transmembrane prediction program (48). 
 
Location of the bacST4SA gene cluster. Plasmid DNA was isolated from strain 
ST4SA as described before. A transposon with an R6Ky origin of replication and a 
kanamycin resistance gene was inserted into the plasmid DNA, using the EZ::TNTM <R6Kyori 
/ KAN-2> Insertion Kit (Epicenter®, Madison, Wisconsin). The transposed plasmid DNA was 
transformed to Escherichia coli EC100D (recA-, pit+) and plated onto LB Agar (Merck), 
supplemented with kanamycin (50 µg/ml). After 12 h of incubation at 37 °C, 24 colonies were 
randomly selected and plasmid DNA isolated as described before. Plasmids were digested 
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with EcoRI and EcoRV (Roche). Plasmid DNA with the transposon was amplified using the 
primers listed in Table 2 and primers described by Zendo et al. (29). The amplified DNA 
products were separated as described previously. 
 
 
RESULTS 
 
Identification of strain ST4SA. Strain ST4SA is a Gram-positive, non-motile, 
catalase-negative coccus (Fig. 1). Growth was recorded at 10 and 45 °C, pH 4.4 and 9.6, 
and in the presence of 6.5% (w/v) NaCl. L-lactic acid is produced from D-glucose. Sugar 
fermentation reactions corresponded to that described for the genus Enterococcus (49). 
Identification at genus-level was confirmed by amplification of a 112-bp PCR-fragment (Fig. 
2). Identification as E. mundtii was confirmed by a 306-bp fragment amplified with species-
specific primers (Fig. 3). 
 
Spectrum of activity. BacST4SA inhibited the growth of B. cereus, C. tyrobutyricum, 
E. faecalis, E. faecium, L. sakei, Pediococcus sp., Propionibacterium spp., S. caprinus and L. 
monocytogenes (Table 1). No activity was observed against Clostridium sporogenes, other 
Lactobacillus spp., Leuconostoc mesenteriodes subsp. cremoris, Pediococcus pentosaceus, 
Propionibacterium acidipropioni and Streptococcus thermophilus (Table 1). 
 
Growth and bacST4SA production at different conditions. Maximum activity of 
bacST4SA (51 200 AU/ml) was recorded after 14 h of growth in MRS broth at 30 °C (Fig. 4).  
During 29 h of growth, the culture pH decreased to 4.60 and the optical density (OD600) 
increased from 0.03 to approximately 2.5 (Fig. 4). Low levels (1 600 AU/ml) of bacST4SA 
were recorded in M17 broth and soymilk. BacST4SA activity of 3 600 AU/ml was recorded in 
molasses and 12 800 AU/ml in LAPTg broth supplemented with peptone from casein (not 
shown). 
No change in culture pH was recorded when strains were grown in MRS adjusted to 
pH 4.5. However, the culture pH decreased to 4.8 when cells were grown in MRS with an 
initial pH of 5.0 and 6.0. BacST4SA levels of 3 200 AU/ml were recorded in MRS broth with 
an initial pH of 4.5 and 5.0. Production increased to 6 400, 25 600 and 51 200 AU/ml in MRS 
broth with an initial pH of 5.5, 6.0 and 6.5, respectively (not shown).  
 
Effect of temperature, pH, detergents and enzymes on bacteriocin activity. 
Complete inactivation of antibacterial activity was observed after treatment of bacST4SA-
containing cell-free supernatant with proteolytic enzymes (not shown). No change in activity 
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was recorded when treated with α-amylase, after 2 h of incubation at pH 2.0 to 12.0, and 
after 90 min of treatment at 30, 60 and 100 °C, respectively. However, bacST4SA activity 
decreased by approximately 50% after 20 min at 121 °C. BacST4SA remained stable when 
treated with Triton X-100, SDS, Tween 20, Tween 80, urea (1%, v/v, final concentration), and 
EDTA (1.0, 2.0 and 5.0 mM). No activity was recorded after treatment with 1% (v/v) Triton X-
114. 
 
Purification and molecular size of bacST4SA. Separation by tricine-SDS-PAGE 
yielded an active peptide band between 2.35 and 3.4 kDa (Fig. 5).  Eighty percent of 
bacST4SA was recovered with ammonium sulphate precipitation. Active fractions collected 
from the ÄKTApurifier corresponded to a peak that eluted at 43 - 47 min (Fig. 6A). Re-
injection of the pooled fractions yielded an active peptide peak that eluted at 45 - 50 min (Fig. 
6B). Separation by ES-MS yielded a distinctive peak corresponding to 3 950 Da (Fig. 7). 
 
Analysis of the bacST4SA operon. Primers designed from the structural gene of 
bacteriocin QU 2 yielded a 380 bp fragment, designated as munA (Fig. 8A). DNA fragments 
of 914 and 974 bp were amplified with primers designed from the ATP-dependent transporter 
genes described for mundticin KS and were named munB (Fig. 8B). An immunity gene of 
767 bp (munC) was amplified with primers designed from the immunity gene of mundticin KS 
(Fig. 8B). 
Correlation of the sequences on the BLAST protein database revealed that munA 
encodes a 58-amino acid prepeptide, which contains a 15-amino acid leader peptide with a 
double-glycine processing site (Fig. 9A). The YGNGV consensus motif and a disulphide 
bridge linking cys9 and cys14 were detected (Fig. 9A). Alignment of the amino acid sequences 
revealed complete homology between the leader and mature peptides of bacST4SA and 
mundticin KS (27), mundticin AT06 (28) and bacteriocin QU 2 (29). BacST4SA is completely 
homologous to the mature peptide enterocin CRL35 (30). However, the leader peptide of 
bacST4SA differs from the leader peptide of enterocin CRL35 by two amino acids, at 
positions -6 (A to S) and -10 (S to A). The leader and mature peptides of bacST4SA are 
amphiphilic, consisting of hydrophobic and polar, hydrophilic residues (Fig. 9A).  
The immunity gene encoding the 98-amino acid protein (Fig. 9B) is completely 
homologous to the immunity protein of enterocin CRL35 and 96.9% homologous to the 
immunity protein of mundticin KS, with differences at positions 30, 47, and 89 (Fig. 9B). 
The 674-amino acid ATP-dependent transporter protein of bacST4SA is 98.9% 
homologous to mundticin KS and 99.3% to enterocin CRL35 (Fig. 10). Differences occurred 
at amino acid positions 107, 353, 494, 616, 642, 654, and 665 for mundticin KS, and at 
positions 108, 386, 579, 585, and 639 for enterocin CRL35 (Fig. 10). The ATP-dependent 
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transporter gene consists of three domains responsible for bacST4SA translocation (Fig. 10). 
The peptidase C39B domain (amino acid 1 to 25) contains a bacteriocin-processing site (Fig. 
10). Amino acid 137 - 415 represents the ABC-membrane transporter domain with several 
transmembrane helixes (Fig. 10). Amino acids 461 - 674 are part of the ABC-DLP family (Fig. 
10). Analysis of the ABC-transporter domain, using the SOSUI database, revealed five 
primary transmembrane helixes and one secondary transmembrane helix (Table 3). The 
membrane helixes have a number of hydrophobic residues and polar residues, and a few 
uncharged and charged residues (Table 3).  
The N-terminal region of the bacST4SA mature peptide is hydrophilic to amphiphilic, 
while the central and C-terminal regions are hydrophobic to amphiphilic (Fig. 11). 
 
Location of bacST4SA gene cluster. Two plasmids of approximately 50 and 100 kb 
were isolated from strain ST4SA (Fig. 12A). From the 24 clones selected for plasmid 
isolation, one contained the recombinant plasmid. Amplification of the 50-kb plasmid with 
primers designed to detect the structural-, ATP-dependent transporter- and immunity genes 
of bacST4SA yielded 380 bp, 914 and 974 bp, and 767 bp fragments, respectively (Fig. 
12B). The restriction enzyme banding patterns of plasmid containing the EZ::TN 
<R6Kγori/KAN-2> transposon and native plasmid were similar (Fig. 12C). 
 
 
DISCUSSION 
 
Strain ST4SA is identified as E. mundtii, based on phenotypic and genetic 
characteristics. The morphology is typical of that described for the genus Enterococcus. The 
strain is non-motile, which distinguishes it from the yellow-pigmented species Enterococcus 
casseliflavus (49). 
BacST4SA inhibited the growth of B. cereus, C. tyrobutyricum, E. faecalis, E. 
faecium, L. sakei, Pediococcus sp., Propionibacterium spp., S. caprinus and L. 
monocytogenes. The spectrum of activity of bacST4SA differs from that reported for 
enterocin A, mundticin KS and bacteriocin QU 2 by being active against Bacillus cereus, but 
not Lactobacillus plantarum (13, 27, 29). Concluded from the spectrum of activity, bacST4SA 
is closer related to enterocin P. However, enterocin P inhibits Lactobacillus fermentum and 
Lactobacillus curvatus (24), whilst bacST4SA does not. BacST4SA and mundticin KS inhibits 
E. faecium, whilst bacteriocin QU 2 does not (27, 29). 
The stability of bacST4SA at acidic and alkaline pH (pH 2 to 12) and at high 
temperatures (completely stable for 90 min at 100 °C and 50% reduction of activity after 15 
min at 121 °C) distinguishes the peptide from other enterocins in class IIa. Enterocin P (24), 
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enterocin RC714 (15) and bacteriocin N15 (14) lost activity after autoclaving (15 min, 121 
°C). Enterocin SE-K4 and mundticin KS remained active after incubation at pH 3 - 11, but 
lost 50% activity after 60 min at 100 °C (16, 27). Mundticin AT06 and enterocin CRL35 lost 
activity after 15 min at 100 °C (28, 30). Enterocin CRL35 is unstable at pH 3 and below (30). 
Bacteriocin QU 2 remains active between pH 2 and 11, but looses most of its activity at pH 
12. Bacteriocin QU 2 is heat resistant, depending on pH (29). The peptide remained active 
after 10 min at 100 °C when suspended at pH 3 and 5, but lost most of its activity under 
these conditions at pH 7 and 10 (29). 
Treatment of bacST4SA against a variety of proteolytic enzymes resulted in a 
complete loss in activity, confirming its proteinaceous nature. Similar results were reported 
for mundticin AT06 (28), mundticin KS (27), bacteriocin QU 2 (29), bacteriocin N15 (14), 
enterocin P (24) and bacteriocin RC714 (15). Resistance to α-amylase suggests that 
bacST4SA is not glycosylated and that it does not depend on a carbohydrate moiety for 
activity. 
No changes in bacST4SA activity were recorded when treated with Triton X-100, 
SDS, Tween 80, Tween 20 and EDTA. However, treatment with Triton X-114 resulted in a 
complete loss of activity. Triton X-114 is used to isolate soluble proteins from lipids and 
carbohydrates (47). Loss in activity suggests that bacST4SA has been dissolved in the Triton 
X-114 fraction. The effect of urea and EDTA on mundticin AT06 (28), mundticin KS (27), 
bacteriocin QU 2 (29) and enterocin CRL35 (30) is unknown. It is, however, unlikely that 
mundticin KS, mundticin AT06 and bacteriocin QU 2 are affected by SDS, since active 
peptide bands were obtained after tricine-SDS gel electrophoresis (27-29). Tween 20 and 
Tween 80 had no effect on bacST4SA production. However, Zendo et al. (29) reported an 
increase in activity of bacteriocin QU 2 when treated with Tween 80. This surfactant 
increases the activity of bacteriocins by reducing adsorption to the producer strain, glass 
surfaces and polypropylene (50-52).  
Low levels of bacST4SA activity were recorded when the strain was cultured in M17 
broth, BHI broth, molasses and soymilk, despite relative good cell growth. This suggests that 
specific nutrients are required for optimal bacteriocin production. Maximum production of 
bacST4SA (51 200 AU/ml) was recorded after 14 h of growth in MRS broth (Fig. 4). Low 
levels of bacST4SA were detected after 4 h of growth, suggesting that the peptide is a 
primary metabolite. Similar results have been reported for other class IIa enterocins.  
Maximum activity was recorded for enterocin P and bacteriocin N15 during late exponential 
phase, followed by a decrease during stationary growth (24, 14). Maximum activity of 
bacteriocin SE-K4 was recorded at 43 and 45 °C (16), while maximum activity of mundticin 
KS was recorded during early stationary growth at 15 to 40 °C, but not at 45 °C (27). 
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The culture pH of strain ST4SA decreased from 6.0 to 4.9 during growth in MRS 
broth.  BacST4SA production in the same medium, adjusted to pH 4.5 and 5.0 was relatively 
slow. However, optimal production was recorded at pH 5.5 and higher. This suggests that 
bacST4SA accumulates during the first phase of growth before the pH decreases to 5.0. 
Production of bacteriocin QU 2 continued during stationary growth when cells were 
inoculated in medium with a pH of 5.0 or 6.0 (29). Maximum activity (204 800 AU/ml) was 
recorded in medium adjusted to pH 6.0 (29). Production of bacteriocin QU 2 declined 
drastically during stationary growth when cells were inoculated in medium of pH 7.0 (29). 
BacST4SA has an estimated molecular mass of 3.950 kDa and is smaller than 
mundticin KS (4.290 kDa), mundticin AT06 (4.287 kDa) and bacteriocin QU 2 (4.287 kDa), 
but larger than enterocin CRL35 (3.500 kDa) (27-30). The differences recorded in molecular 
sizes might be due to buffers used during purification and mass spray spectrometry. 
BacST4SA has a theoretical molecular mass of 4271.73 Da.   
The bacST4SA operon consists of three genes, viz. munA encoding a soluble 58-
amino acid pre-peptide (Fig. 9A), munB encoding a 674-amino acid ATP-dependent 
transporter peptide (Fig. 10) located in the cell membrane, and munC encoding a soluble 98-
amino acid immunity peptide (Fig. 9B). 
The YGNGV consensus motif is considered to be part of a recognition sequence for a 
speculated membrane-bound protein receptor (53). BacST4SA is translated as a pre-peptide 
consisting of double-glycine amino acids at position -1 and -2, unique to class IIa 
bacteriocins (10). The double-glycine leaders generally serve as a signal peptide for a sec-
independent ABC-transporter (10). BacST4SA also contains one disulphide bridge, linking 
cys9 and cys14, not post-translationally modified. In class IIa bacteriocins, cysteine amino acid 
molecules form cross-linked, covalently disulphide bridges to maintain intramolecular rigidity 
(10, 54). The high number of non-polar amino acids renders a high degree of conformational 
freedom to bacST4SA (55). Polar, hydrophilic amino acid residues form binding sites with 
charged molecules (54). The bacST4SA ATP-dependent transporter peptide consists of 6 
bundles of hydrophobic transmembrane helices (Table 3). These helices are stabilized by a 
combination of amphiphilic side chains and polar side chain interactions (48). Similar 
conformations were recorded for enterocin P, consisting of hydrophobic transmembrane 
segments supported by highly hydrophobic transmembrane segments at the C-terminal, 
possibly responsible for insertion of the peptide into the cytoplasm membrane (24). The ATP-
dependent transporter also contained a peptidase C39B domain, responsible for cleavage of 
the double-glycine leader peptide from the precursors of class IIa bacteriocins, mediating 
secretion of the peptide and transport across the cytoplasmic membrane (56). The ATP-DPL 
domain is involved in lipid, peptide and drug export (57). 
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The mature bacteriocin (bacST4SA) is completely homologous to mundticin KS (27), 
mundticin AT06 (28), bacteriocin QU 2 (29) and enterocin CRL35 (30). The genes encoding 
these bacteriocins are located on plasmids and horizontal gene transfer may have occurred. 
The broad spectrum of activity recorded for bacST4SA, compared to mundticin KS, 
mundticin AT06, bacteriocin QU 2 and enterocin CRL35 remains unknown. 
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TABLE 1. Antimicrobial activity of bacST4SA in pH-neutralized cell-free supernatant 
Target strain 
Temperature 
(°C) 
Growth medium, 
incubation 
Antimicrobial 
activitya
Bacillus cereus LMG 13569 37 BHI, aerobic ++ 
Clostridium sporogenes LMG 13570 37 RCM, anaerobic - 
Clostridium tyrobutyricum LMG 13571 30 RCM, anaerobic ++ 
Enterococcus faecalis 20, 21, E77, E80, E90, 
E92, FA2, LMG 13566 
37 MRS, aerobic ++ 
Enterococcus faecium HKLHS 30 MRS, aerobic ++ 
Lactobacillus acidophilus LMG 13550 37 MRS, anearobic - 
Lactobacillus bulgaricus LMG 13551 37 MRS, anaerobic - 
Lactobacillus casei LMG 13552 37 MRS, anaerobic - 
Lactobacillus carvatus LMG 13553 30 MRS, anaerobic - 
Lactobacillus fermentum LMG 13554 37 MRS, anaerobic - 
Lactobacillus helveticus LMG 13555 42 MRS, anaerobic - 
Lactobacillus plantarum LMG 13556 37 MRS, anaerobic  - 
Lactobacillus reuteri LMG 13557 37 MRS, anaerobic - 
Lactobacillus sakei  LMG 13558 30 MRS, anaerobic ++ 
Leuconostoc mesenteroides subsp. cremoris 
LMG 13562 
30 MRS, anaerobic - 
Listeria innocua LMG 13568 30 BHI, aerobic - 
Listeria monocytogenes 30 BHI, aerobic ++ 
Pediococcus sp. 30 MRS, anaerobic ++ 
Pediococcus pentosaceus LMG 13560 30 MRS, anearobic - 
Propionibacterium acidipropionici LMG 13572 32 GYE, anaerobic - 
Propionibacterium sp. LMG 13574 32 GYE, anaerobic  ++ 
Streptococcus caprinus TS1, TS2 37 BHI, aerobic ++ 
Streptococcus thermophilus LMG 13565 42 MRS, anaerobic - 
a = no activity; + = activity zones of at least 5 mm in diameter; ++ = activity zones of at least 6 
mm in diameter. LMG = Laboratorium voor Microbiologie, University of Ghent, Belgium. The 
other strains were from own culture collection. GYE = glucose yeast extract, prepared 
according to Cintas et al. (58). The other growth media were from Biolab, Biolab Diagnostics, 
Midrand, South Africa. 
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TABLE 2. DNA primers used in this study 
Gene DNA primer Description 
Fragment size 
(bp) 
ABC-transporterN-terminal ABC1-F TGATGGATTTCAGTGGAAGT 
 ABC1-R ATCTCTTCTCCGTTTAATCG 
914 
    
ABC-transporterC-terminal ABC2-F GTCATTGTTGTGGGGATTAT 
 ABC2-R TCTAGATACGTATCAAGTCC 
974 
    
Immunity gene munC-F TTCCTGATGAACAAGAACTC 
 munC-R GTCCCCACAACCAATAACTA 
767 
 
 
 
 
 
 
 
 
 
 
TABLE 3. Amino acid sequence of a membrane ABC transporter protein consisting of 
six transmembrane helices 
N-terminal 
position 
Transmembrane region C-terminal Type Length 
147 LVILSSLIITIIGLSSYYFRILI 169 Primary 23 
179 FLNLFMISISYIIGIFITSIFEI 201 Primary 23 
214 VGRSILFKYLEHIFILPASFFS 235 Secondary 22 
254 EALASFTISIFLDLSSVIVVGII 276 Primary 23 
282 KQLFLITLSSIPFYILIILGSN 303 Primary 22 
370 NLKILVSLLTSAFVLWFGSYYVI 392 Primary 23 
Bold = polar residues; non-bold = hydrophobic residues; underline = negatively charged 
residues; italics = positively charged residues  
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FIG. 1. Morphology of strain ST4SA, visualized by atomic force microscopy. 
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FIG. 2. DNA banding patterns obtained for strain ST4SA after amplification with 
genus-specific primers. Lane 1: 50-bp molecular marker from Amersham (Bioscience, UK 
Limited, Buckinghamshire, UK), lanes 2 to 5: Strain ST4SA, lane 6: negative control (no 
DNA), lane 7: positive control (E. faecium LMG 8149). LMG: Laboratorium voor 
Mikrobiologie, University of Ghent, Ghent, Belgium.  
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FIG. 3. DNA banding patterns obtained for strain ST4SA after amplification with 
species-specific primers. Lane 1: 50-bp molecular marker from Amersham (Bioscience, UK 
Limited, Buckinghamshire, UK), lane 2: strain ST4SA. 
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FIG. 4. Growth of strain ST4SA in MRS broth. (●) = Optical density recorded at 
600nm, (■) = pH of culture, and ( ▌) = activity of bacST4SA, expressed as AU/ml. 
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FIG. 5. Separation of bacST4SA by tricine-SDS PAGE. A: molecular weight marker 
from Amersham (Bioscience, UK Limited, Buckinghamshire, UK), B: bacST4SA, overlaid with 
L. casei LHS (ca. 106 cfu ml-1) imbedded in MRS agar. The arrow indicates growth inhibition 
by bacST4SA. 
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A 
B 
 
 
 
FIG. 6. Separation of bacST4SA with the ÄKTApurifier using a SuperdexTM 75 
HR/10/30 column. A: First separation, B: second separation (fractions from separation A re-
injected). Active peaks are indicated between dotted lines. 
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FIG. 7. Molecular mass of bacST4SA, recorded by electro-spray ionization-mass 
spectrometry. 
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FIG. 8. DNA banding patterns obtained after amplification of the bacST4SA gene 
locus. A: Lane 1, 50-bp molecular marker from Amersham (Bioscience, UK Limited, 
Buckinghamshire, UK); lane 2, PCR amplified bacST4SA structural gene fragment (munA). 
B: Lanes 1 - 3, PCR amplified ABC-transporterN-terminal-, ABC-transporterC-terminal, and immunity 
gene (munC) fragments, respectively; lane 4, 50-bp molecular marker from Amersham. 
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A 
 →    Structural gene sequence        
                                                                                                                     ↓ 
                                  Leader peptide    
GTTTTGAAGAAATTAACAGCAAAAGAAATGTCACAAGTAGTAGGTGGAAAATACTACGGT 
  V    L     K     K     L     T      A     K     E     M    S     Q     V     V     G     G     K     Y    Y     G      
 
                                                     Mature peptide  
AATGGAGTCTCATGTAATAAAAAAGGGTGCAGTGTTGATTGGGGAAAAGCTATTGGCAT 
   N    G     V     S     C     N    K     K     G     C     S     V     D     W    G      K     A     I     G      I            
 
 
TATTGGAAATAATTCTGCTGCGAATTTAGCTACTGGTGGAGCAGCTGGTTGGAAAAGTTA    
     I      G    N     N     S     A     A     N     L     A     T     G     G     A      A     G    W     K     S     *   
 
A 
 
 
B 
→   Immunity gene sequence 
 
ATGAGTAATTTAAAGTGGTTTTCTGGTGGAGACGATCGACGTAAAAAAGCAGAAGTGATT 
  M     S     N    L     K     W    F     S    G      G     D     D     R     R     K     K     A      E     V     I       
 
ATTACTGAATTATTAGATGATTTAGAGATAGATCTTGGAAATTAGAGATAGAGATTAGAGA 
   I     T     E     L     L     D     D     L     E      I      D    L     G     N    E      S    L      R    K     V      
 
TAGATCTTGGAAATGAATCTCTTCGAAAAGTATTAGGCTCCTATCTTGAAAAGTTGAAAA 
L     G     S     Y     L     E     K     L     K     N     E    G     T     S     V     P     L      V     L     S      
 
ATGAAGGAACTTCAGTTCCATTAGTTTTAAGTCGTATGAATATAGAGATATCTAATGCAAT 
R     M    N      I     E      I     S     N     A     I      K     K     D    G    V     S     L     N    E      N    Q      
 
AAAAAAAGACGGTGTATCGTTAAATGAAAATCAATCTAAAAAATTAAAAG 
     S     K     K      L     K    E     L      I      S      I     S    N     I      R     Y    G     Y 
 
 
 Fig. 9. Analysis of the bacST4SA gene locus. A: Amino acid sequence of the 
bacST4SA structural gene. Bold = polar residues; normal font = hydrophobic residues; 
underlined = negatively charged residues; italics = positively charged residues; ↓ = double-
glycine processing site.  B: The bacST4SA immunity gene. Bold = amino acid differences 
compared with mundticin KS. 
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→   ABC transporter gene sequence 
 
  1       ATGCAGATGATTTTAAATAATTTTCATTCATGGATTTCAGTGGAAGTTTTAAGAGACTTA 
           M  Q  M  I  L  N  N  F  H  S  W  I  S  V  E  V  L  R  D  L      
 
 
 61       CTGAAACCGATTCTGAAGGTACCTGTGCATTAGGTATAGTTAACGGATTTGCTAAATTAG 
 20        T  E  T  D  S  E  G  T  C  A  L  G  I  V  N  G  F  A  K  L   
 
 
121       TAGGTATAGTTAACGGATTTGCTAAATTAGGAATAAATTGTGAAGCCTATAAAGCTAATA 
 40       L  G  I  V  N  G  F  A  K  L  G  I  N  C  E  A  Y  K  A  N    
 
 
181       GTGATGTATGGAAAGAAAATGAGTTCAATTATCCCGTAATTGCTAATATAGTAACGAATA 
 60       S  D  V  W  K  E  N  E  F  N  Y  P  V  I  A  N  I  V  T  N    
 
 
241       ATCAATTTCTTCATTATTGTATTGTATATGGTGTGAAAAAAGAGAAATTGTTAATAGCTG 
 80       N  Q  F  L  H  Y  C  I  V  Y  G  V  K  K  E  K  L  L  I  A    
 
 
301       ACCCTGCGATTGGAAAATACAAAGAATCAATAGAAAAGTTCAACAACAAATGGACTGGTG 
100       D  P  A  I  G  K  Y  K  E  S  I  E  K  F  N  N  K  W  T  G    
 
 
361       TTATTTTAGTTGCTGAAAAGACTCCTGATTTCCAACCCATAAATAATACAAAAAAAAGTT 
120       V  I  L  V  A  E  K  T  P  D  F  Q  P  I  N  N  T  K  K  S    
 
 
421       TTTTTTCTTCAATAAGTTTATTAAAAGATCAATATAAAAAAATTTTATTGGTGATATTAT 
140       F  F  S  S  I  S  L  L  K  D  Q  Y  K  K  I  L  L  V  I  L    
 
 
481       CTTCATTAATAATAACAATTATAGGAATACTATCAAGTTACTATTTTAGAATTTTAATAG 
160       S  S  L  I  I  T  I  I  G  I  L  S  S  Y  Y  F  R  I  L  I    
 
 
541       ATTGGTTACTTCCTGAAAAAGACTTTTTAAATCTATTTATGATATCAATTAGCTATATCA 
180       D  W  L  L  P  E  K  D  F  L  N  L  F  M  I  S  I  S  Y  I    
 
 
601       TAGGCATTTTTATAACAAGTATATTTGAAATTACCAGAAGATATAATTTAGAAAAGCTAG 
200       I  G  I  F  I  T  S  I  F  E  I  T  R  R  Y  N  L  E  K  L    
 
 
661       GACAAGATGTAGGTAGAAGCATTTTATTTAAATATTTAGAACATATTTTCATTTTACCAG 
220       G  Q  D  V  G  R  S  I  L  F  K  Y  L  E  H  I  F  I  L  P    
 
 
721       CTTCCTTTTTTTCTAAAAGAAAAACTGGAGATATTGTCTCTAGATTTTCTGATGCTAATA 
240       A  S  F  F  S  K  R  K  T  G  D  I  V  S  R  F  S  D  A  N    
 
 
781       AAATTATAGAAGCTTTAGCTAGCTTTACTATATCTATTTTTTTAGATTTAAGTTCAGTCA 
260       K  I  I  E  A  L  A  S  F  T  I  S  I  F  L  D  L  S  S  V    
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841       TTGTTGTGGGGATTATATTGATCAATATTAATAAACAATTATTTTTAATAACGTTAAGTT 
280       I  V  V  G  I  I  L  I  N  I  N  K  Q  L  F  L  I  T  L  S    
 
 
901       CTATTCCATTTTATATACTAATTATATTAGGATCAAATAAAAAAATGAGTCGATTAAACG 
300       S  I  P  F  Y  I  L  I  I  L  G  S  N  K  K  M  S  R  L  N    
 
 
961       GAGAAGAGATGCAAACAAATTCAATAGTTGATTCTAATTTTATTGAAGGATTAAACGGAA 
320       G  E  E  M  Q  T  N  S  I  V  D  S  N  F  I  E  G  L  N  G    
 
 
1021      TATATACTATAAAAGCACTTTGTAGTGAGAATAAGATTGTAAATCAAATATATAGAAGTT 
340       I  Y  T  I  K  A  L  C  S  E  N  K  I  V  N  Q  I  Y  R  S    
 
 
1081      TAAATAAATTTTTTGATGTATCACTAAAGAGAAATATGTATGATTCTATAATTCAAAATT 
360       L  N  K  F  F  D  V  S  L  K  R  N  M  Y  D  S  I  I  Q  N    
 
 
1141      TAAAAATTTTGGTTTCTCTTTTAACCTCGGCTTTTGTATTATGGCTTGGTTCGTATTATG 
380       L  K  I  L  V  S  L  L  T  S  A  F  V  L  W  F  G  S  Y  Y    
 
 
1201      TTATCAATGGAGAAATTACAATAGGAGAACTAATAACTTTCAATTCATTATCTATATTTT 
400       V  I  N  G  E  I  T  I  G  E  L  I  T  F  N  S  L  S  I  F    
 
 
1261      TTTCTACACCTCTACAAAATATAATAAATCTACAAGAAAAATTCCAAAAAGCACAAGTTG 
420       F  S  T  P  L  Q  N  I  I  N  L  Q  E  K  F  Q  K  A  Q  V    
 
 
1321      CAAATAATCGGCTTAACGATGTATTTTCTATAAATAATGAAAATAAAGACAAGTTTATTC 
440       A  N  N  R  L  N  D  V  F  S  I  N  N  E  N  K  D  K  F  I    
 
 
1381      ATTTGGCTAAATTAACTGAAAAAGCAACGATTACATTTGAAAATGTATATTTTAGTTATT 
460       H  L  A  K  L  T  E  K  A  T  I  T  F  E  N  V  Y  F  S  Y    
 
 
1441      CTACTAAATATCCTAATGTGTTAGATAATATGAGTTTTTCTCTACCTGTGAGTAAAAATA 
480       S  T  K  Y  P  N  V  L  D  N  M  S  F  S  L  P  V  S  K  N    
 
 
1501      TAGGAATAAAAGGTGATAGTGGTGCTGGGAAATCAACTTTAGCACAACTTCTAGCTGGAT 
500       I  G  I  K  G  D  S  G  A  G  K  S  T  L  A  Q  L  L  A  G    
 
 
1561      TTTACTCTCCAGATAATGGAAGAATTTGTATAAATGAGCAAAATATTGAAAATATTAATA 
520       F  Y  S  P  D  N  G  R  I  C  I  N  E  Q  N  I  E  N  I  N    
 
 
1621      GAAAAGATTTACGTAAGTTGATTACCTATGTGCCTCAAGAATCTTTTATTATGAGTGGAA 
540       R  K  D  L  R  K  L  I  T  Y  V  P  Q  E  S  F  I  M  S  G    
 
 
1681      CTATTAAAGACAATTTATTTTTAGGTTTAGAAAGTATTCCTGATGAACAAGAACTCGAAA 
560       T  I  K  D  N  L  F  L  G  L  E  S  I  P  D  E  Q  E  L  E    
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1741      AAGTACTGAAAGATACTTGTTTATGGAGTTATATTACTGCGATTCCTCTAGGACTTGATA 
580       K  V  L  K  D  T  C  L  W  S  Y  I  T  A  L  P  L  G  L  D    
 
 
 
1801      CGTATCTAGAAGAAAATGGTGCGAATTTATCAGGTGGTCAAAAGCAAAGAATTGCTTTAG 
600       T  Y  L  E  E  N  G  A  N  L  S  G  G  Q  K  Q  R  I  A  L    
 
 
1861      CAAGAGTTTTATTATTAGGAAGTAAAATTTTATTATTAGATGAAGCTACGAGTGCTCTAG 
620       A  R  V  L  L  L  G  S  K  I  L  L  L  D  E  A  T  S  A  L    
 
 
1921      ATTCTAAAACTGAAATGCTGATTTTAGAAAAATTATTAAAGTACCCTAATAAGTCAATCA 
640       D  S  K  T  E  M  L  I  L  E  K  L  L  K  Y  P  N  K  S  I    
 
 
1981      TTATGATATCTCATAATGATAAATTAATAGACAAGTGTGACTTAATCATTGATTTAGACG 
660       I  M  I  S  H  N  D  K  L  I  D  K  C  D  L  I  I  D  L  D    
 
 
2041      AAAGGGATTCATAA 
680       E  R  D  S  *     
 
 
Fig. 10. Analysis of the bacST4SA ATP-dependent transporter gene consisting of a 
peptidase C39B domain (underlined), an ABC membrane-linked transporter domain (bold) 
and an ABC-DLP domain (italic). Double underline = amino acid differences compared to 
mundticin KS; dotted line = amino acid differences compared to enterocin CRL35. 
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Fig. 11. Hydrophobicity profile of the bacST4SA mature peptide. 
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FIG. 12. Location of the bacST4SA locus on the 50-kb plasmid. A: Plasmid profile of 
strain ST4SA and recombinant plasmid DNA. Lane 1: lambdaecoRi/HindIII marker (Bioscience, 
UK Limited, Buckinghamshire, UK), lane 2: plasmids of strain ST4SA, lane 3: recombinant 
plasmid profile. B: PCR banding patterns of recombinant plasmid DNA using primers for 
location of the bacST4SA operon. Lane 1: 50-bp molecular marker from Amersham, lanes 2–
5: PCR amplified structural gene, ABC-transporterN-terminal, ABC-transporterC-terminal, and 
immunity gene fragments, respectively, lane 6: lambdaecoRi/HindIII marker from Amersham. C: 
Restriction analysis of bacST4SA plasmid DNA (pDNA) and recombinant plasmid DNA 
(pDNAr). Lane 1: lambdaEcoRi/HindIII marker from Amersham, lane 2-3: pDNA and pDNAr 
digested with EcoRI, lanes 4–5: pDNA and pDNAr digested with EcoRV. 
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ABSTRACT 
 
Bacteriocin ST4SA (bacST4SA) is a class IIa antimicrobial peptide, produced by 
Enterococcus mundtii ST4SA that has been isolated from soya beans. BacST4SA inhibits 
the growth of Acinetobacter baumannii, Enterococcus faecalis, Enterococcus faecium, 
Staphylococcus aureus, Streptococcus pneumoniae, and unidentified Gram-positive middle 
ear isolates A, BW, DW, F, G, and H.  BacST4SA was active against Pseudomonas 
aeruginosa G, BG, I, J, B and E, although some resistance was observed. The peptide 
adsorbed maximally (94%) to S. pneumoniae 40, P. aeruginosa 25 and E. faecium HKLHS. 
Low concentrations of bacST4SA (51 200 AU/ml) caused DNA- and enzyme-leakage to 
target cells, whilst higher bacST4SA concentrations (1 638 400 AU/ml) caused cell lyses. 
Structural damage to cells of E. faecium HKLHS treated with bacST4SA was observed by 
atomic force microscopy. BacST4SA is bactericidal towards E. faecium HKLHS and 
bacteriostatic towards S. pneumoniae 40 and middle ear isolates F, BW and H. The peptide 
is stable between -20°C and 25°C. No decrease in antimicrobial activity was observed when 
tested on solid medium with human blood as a base. Maximal bacST4SA production (102 
400 AU/ml) was recorded in MRS broth supplemented with tryptone, yeast extract, or a 
combination of tryptone and yeast extract; K2HPO4 (10.0 or 20.0 g/l); DL-6,8-thioctic acid; L-
ascorbic acid; or thiamine. BacST4SA revealed a similar level of activity when compared with 
tetracycline (30µg), but revealed much higher activity compared to nasal sprays, 
aminoglycosides, cephalosporins, fluoroquinolones, lincosamides, macrolides, 
nitroimidazole, penicillin, quinolones, sulfonamides, chloramphenicol, furanzolidone, fusidic 
acid, rifampicin, trimethoprim, trimethoprim-sulfamethoxazole and vancomycin when tested 
in vitro. 
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Otitis media is one of the most common diseases diagnosed in children under the 
age of two (1). Pathogens associated with the disease are β-lactamase-producing 
Haemophilus influenzae, Moraxella catarrhalis, multi-drug resistant (MDR) Streptococcus 
pneumoniae, group A streptococci, Staphylococcus aureus, Streptococcus pyogenes and 
Gram-negative rods, such as Pseudomonas aeruginosa (1, 2). Infection is treated with 
amoxicillin (1-3). Higher dosages of amoxicillin, amoxicillin-clavulanate (augmentin), 
cefuroxime axetil and intramuscular ceftriaxone are used to control β-lactamase–producing 
pathogens and MDR pneumococci (1, 3). Although broad-range antibiotics are effective 
against a variety of Gram-positive and Gram-negative bacteria, they also affect commensial 
microflora and should not be used on a routine basis (4-6). When used in cases of recurrent 
acute otitis media, changes in selecting antibiotic resistant strains increase (3, 7-10).  
In more recent papers, ribosomal synthesized peptides, known as bacteriocins, have 
been considered as an alternative to antibiotics (4, 6, 11-13). Bacteriocins are classified in 
four classes. Class I are small (<5 kDa), cationic, heat-resistant peptides, consisting of 
unusual amino acids, lanthionine and β-methyl-lantionine (14). Class II are small (<10 kDa), 
heat-stable, cationic and hydrophobic peptides (15-18). Class IIa or pediocin-like bacteriocins 
are characterised by the presence of an unique highly conserved N-terminal amino acid 
sequence, YGNGVXaaC (Tyr-Gly-Asn-Gly-Val- Xaa-Cys) consensus motif, nonpolar and 
small amino acids, with one or more disulphide bridges, and inhibitory to Listeria spp.(16, 19, 
20). Two-peptide bacteriocins with separate functioning are grouped in class IIb (18, 20). 
Class IIc bacteriocins are thiol-activated and sec-dependent secreted miscellaneous 
peptides that requires a reduced cysteine residue to be active (17, 20, 21). Class III 
bacteriocins are large, hydrophilic (>30 kDa), heat-labile peptides (14, 22).  Complex 
peptides associated with lipids or carbohydrates are grouped in class IV (14). Bacteriocins 
are commonly used as food preservatives (4, 23, 24). Some of these peptides have a 
relatively narrow spectrum of activity and inhibits closely related species by interacting with 
specific receptors on the target cell (6, 25). In medicine, it may be used as an antibiotic 
compliment, working synergistically with other antibiotic peptides, and as an antiviral agent 
(26-29). 
Bacteriocins of class IIa are generally active against Listeria spp. A few have a 
broader spectrum of activity and inhibit Enterococcus, Lactobacillus and Clostridium spp. (24, 
25, 30). The class IIa bacteriocins have a highly concerved N-terminal YGNGV consensus 
that binds to target cells through electrostatic interactions (20, 31). The amphiphilic or 
hydrophobic C-domain anchors to the hydrophobic core of the cytoplasmic membrane, 
causing leakage of intracellular compounds (20, 32). Class II bacteriocins normally inhibit 
target bacteria by dissipation of the proton motif force (PMF), including dissipation of the 
transmembrane potential and changes in cellular pH (20-22). 
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Bacteriocin production is frequently regulated by pH and growth temperature, as 
shown for bacteriocin ST311LD (33), enterocin 1146 (34), enterocin AS-48 (35), a 
bacteriocin produced by Enterococcus faecium RZS C5 (36), and enterocin P (37). In 
specific cases, higher levels of bacteriocin production have been recorded at optimal growth 
conditions (34, 38-42).  However, apart from studies on the effect of carbon and nitrogen 
sources on production of enterocin P (37), bacteriocin ST311LD (33), and a bacteriocin 
produced by E. faecium CRL 1385 (42), little is known about growth conditions required for 
optimal bacteriocin production. 
Bacteriocin ST4SA (bacST4SA) is a positively charged, hydrophobic, 43-amino acid 
class IIa peptide. The aim of this study was to determine the mode of activity of bacST4SA 
and evaluate the peptide as an alternative to antibiotics in the treatment of otitis media.  
 
 
MATERIALS AND METHODS 
 
Bacterial strains and growth conditions. Enterococcus mundtii ST4SA was 
cultured in MRS broth (Biolab, Biolab Diagnostics, Midrand, SA). The target organisms, their 
growth media and growth conditions are listed in Table 1. 
 
Production and partial purification of bacST4SA. Ten ml of an 18-h-old culture of 
E. mundtii ST4SA was inoculated into 500 ml MRS broth (Biolab) and incubated at 30 °C for 
20 h, without agitation. The cells were harvested (8000 x g, 10 min, 4 °C), the pH of the cell-
free supernatant adjusted to 6.5 using 1 N NaOH, and treated for 10 min at 80 ºC. The 
peptide was precipitated from the cell-free supernatant with 80% saturated ammonium 
sulphate (43). The precipitate was resuspended in sterile distilled water (one-fifth of the 
original volume) and desalted against sterile distilled water for 18 h at 4 °C. A dialysis bag 
with a pore size of 1000 Da (Spectrum inc., CA, USA) was used. The pH of the dialysate 
(crude-extract) was adjusted to 6.5 with sterile 1 N NaOH and treated for 10 min at 80 °C. 
Three ml aliquots of the suspension was lyophilised and stored at -20 °C. Just before an 
experiment, the lyophilised crude-extract was resuspended in 0.1 ml sterile MilliQ water 
(Millipore, MA, USA) and treated for 10 min at 100 °C. Resuspended samples were stored at 
4 °C. Antimicrobial activity of bacST4SA was determined by using the agar-spot test method 
described by Ivanova et al. (44). Activity was expressed in arbitrary units (AU) per ml. One 
AU was defined as the reciprocal of the highest dilution showing a clear zone of growth 
inhibition (44).  
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Adsorption of bacST4SA. Adsorption of bacST4SA to S. pneumoniae 27, 29, 40 
and D, Enterococcus faecalis 20 and 21, P. aeruginosa E, J, I and 25, S. aureus 13, middle 
ear isolates BW, DW, F, H and G, and E. faecium HKLHS were studied as described by 
Todorov and Dicks (45). Target strains were grown to mid-log phase, harvested (10 000 x g, 
15 min, 4 °C), washed twice with sterile 5 mM phosphate buffer (pH 6.5), and re-suspended 
to the original volume in the same buffer. Cell suspensions (0.7 ml) were mixed with an equal 
volume of bacST4SA (819 200 AU/ml). Samples were incubated at 37 °C for 1 h, the cells 
harvested (10 000 x g, 15 min, 4 °C), and the activity of unbound bacST4SA determined as 
described before. Resuspended cell suspensions, mixed with an equal volume of MRS 
medium, without bacST4SA, were used as controls. All experiments were conducted in 
duplicate. Adsorption of bacST4SA to target cells was calculated according to the following 
formula:  
 
% Adsorption = 100 – [(bacteriocin activity after treatment/ original bacteriocin 
activity) x 100] 
 
Mode of action. Target strains (Table 2) were cultured overnight as described 
before. Cells were harvested (10 000 x g, 15 min, 4 °C) and washed twice with sterile 5 mM 
phosphate buffer (pH 6.5). Cell-free supernatant containing bacST4SA was added to washed 
target cells at a final concentration of 5 160 AU/ml and incubated at 37 °C for 1 h. Cells were 
harvested (10 000 x g, 15 min, 4 °C) and the supernatant filtered through a 0.2 µm 
nitrocellulose membrane (Minisart®, Sartotius). Changes in external levels were recorded 
with optical density readings at 260 nm. The controls were target cells suspended in 5 mM 
phosphate buffer and not treated with bacST4SA.  
In a separate experiment, extracellular levels of β-galactosidase were monitored: Ten 
ml cultures of target strains (12-h-old) were harvested (10 000 x g, 15 min, 4 °C), the cells 
washed with 0.03 M sodium phosphate buffer (pH 6.5) and re-suspended in 2 ml of the same 
buffer. To each cell suspension, 2 ml bacST4SA cell-free supernatant was added to a final 
concentration of 25 600 AU/ml. After 5 min at 25 °C, 0.2 ml 0.1 M ONPG (O-nitrophenyl-β-D-
galactopyranosidase) in 0.03 M sodium phosphate buffer (pH 6.8) was added and incubated 
at 37 °C for 10 min. The enzymatic reaction of β-galactosidase was stopped by adding 2.0 ml 
0.1 M sodium carbonate. Cells were harvested (10 000 x g, 15 min, 25 °C) and optical 
density readings recorded at 420 nm. Controls were cells prepared in the same way, but not 
treated with bacST4SA. All experiments were performed in duplicate. 
In another experiment, E. faecium HKLHS and S. pneumoniae 40 were cultured 
overnight in MRS and BHI media, respectively. E. faecium HKLHS was inoculated (2.0%, 
v/v) into 100 ml MRS broth (Biolab) and incubated at 30 °C. S. pneumoniae 40 was 
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inoculated (0.2%, v/v) into 100 ml BHI medium (Merck, Darmstadt, Germany) and incubated 
at 37 °C. Ten ml bacST4SA (1 638 400 AU/ml) was added to both cultures at mid-
exponential growth and incubated for a further 12 h. Optical density readings (600 nm) were 
recorded every hour. The same experiment was performed with unidentified strains BW, F 
and H isolated from patients with acute otitis media infections. 
The effect of bacST4SA on cell morphology was determined by atomic force 
microscopy, as described by Todorov et al. (46). BacST4SA (49 152 AU/ml, final 
concentration) was added to an 18-h-old cell suspension and incubated for 1 h at 30 °C. 
Cells were then harvested (5000 x g, 10 min, 4 °C) and washed five times with 10 ml sterile 
distilled water before subjected to microscopy. 
 
Effect of growth conditions and medium compounds on bacST4SA production 
and stability. E. mundtii ST4SA was grown in 10 ml MRS broth (Biolab) for 18 h at 30 °C. 
Cells were harvested (10 000 x g, 10 min, 4 °C) and the pellet resuspended in 10 ml sterile 
physiological salt. Four ml of this suspension was used to inoculate 200 ml of the following 
media: (i) MRS broth (47), without organic substrates, supplemented with 1.0 to 40.0 g/l 
tryptone, 20.0 g/l meat extract, 20.0 g/l yeast extract, 12.5 g/l tryptone plus 7.5 g/l yeast 
extract, 10.0 g/l meat extract plus 10.0 g/l yeast extract, and 12.5 g/l tryptone plus 7.5 g/l 
meat extract, respectively; (ii) MRS broth (47) with 20.0 g/l glucose; (iii) MRS broth (47) 
without glucose, supplemented with 20.0 g/l maltose, mannose, fructose, lactose and 
saccharose, respectively; (iv) MRS broth (47) with 2.0 g/l KH2PO4 and 2.0 - 50.0 g/l K2HPO4; 
respectively (the pH was corrected to 6.5 with 0.1 M HCl); (v) MRS broth (47) with 0.0 to 10.0 
g/l  tri-ammonium sulphate; (vi) MRS broth (47) with 0.0 to 0.5 g/l magnesium sulphate; (vii) 
MRS broth (47) with 0.0 to 0.5 g/l manganese sulphate; (viii) MRS broth (47) with 0.0 to 10.0 
g/l sodium acetate; and (ix) MRS broth (47) supplemented with 1.0 to 50.0 g/l glycerol. 
Antimicrobial activity was determined using the agar-spot test method as described before. 
MRS broth (47) was supplemented with filter-sterilized cyanocobalamin (Sigma, St. 
Louis, Mo.), L-ascorbic acid (BDH Chemicals, Ltd, Poole, UK), thiamine (Sigma), 
phylloquinone (Sigma) and DL-6,8-thioctic acid (Sigma) to a final concentration of 1.0 mg/l. 
Incubation was at 30 °C for 20 h. Antimicrobial activity was determined using the agar-spot 
test method as described before. MRS broth (47) served as control. 
 In another experiment, E. mundtii ST4SA was grown in 10 ml LAPTg broth (48) and 
incubated for 18 h at 30 ºC. The cells were harvested a resuspended as described before. 
Four ml of this suspension was used to inoculate 200 ml of the following media: (i) LAPTg 
broth (48), without organic nutrients, supplemented with 35.0 g/l peptone from casein, 35.0 
g/l yeast extract and 35.0 g/l tryptone, respectively; (ii) LAPTg broth (48) with 5.0 to 20.0 g/l 
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glucose; and (iii) LAPTg broth (48) without Tween 80. Activity levels were determined using 
the agar-spot test method. LAPTg broth (48) served as control. 
 BacST4SA was suspended in middle ear fluid and blood (819 200 AU/ml, final 
concentration) and changes in activity determined by using the spot-on-lawn method.  
Samples were tested after 1, 2, 6 and 12 h at 37 °C.  In a separate experiment, bacST4SA 
was suspended in sterile distilled water and incubated at -20 °C, 0 °C, 25 °C, 37 °C and 60 
°C, respectively, for 6 weeks.  Activity was recorded every seven days, as described before. 
 
Comparison of bacST4SA with antibiotics and ototic drop suspensions. E. 
faecium HKLHS and middle ear pathogens, S. pneumoniae 27 and P. aeruginosa J, were 
grown for 12 h in MRS broth (Biolab) and BHI broth (Merck), respectively. MRS pour-plates 
(Biolab) were prepared, containing 5% (v/v) E. faecium HKLHS (ca. 107 cfu/ml). BHI pour-
plates (Merck), contained 5% (v/v) S. pneumoniae 27 (ca. 108 cfu/ml) and P. aeruginosa J 
(ca. 108 cfu/ml), respectively.  An antibiotic disc (Table 4) and10 µl bacST4SA (1 638 400 
AU/ml) were dropped onto the surface of the inoculated pour-plates and incubated for 18 h at 
37 °C. Activity was compared by measuring the diameter of the inhibition zones. 
 
 
RESULTS 
 
 All data represents an average of three repeats. The optical density values recorded 
in each experiment did not vary by more than 5% and standard deviation values are not 
shown. In case of bacteriocin production (AU/ml), all three repeats produced the same result. 
 
Isolation of bacST4SA. The cell-free supernatant of an 18-h-old culture of strain 
ST4SA yielded bacST4SA levels of 25 600 AU/ml. The activity after ammonium sulphate 
precipitation increased to 819 200 AU/ml, but decreased to 204 800 AU/ml after dialysis. 
Lyophilisation, followed by resuspension into smaller volumes increased the activity to 1 638 
400 AU/ml, i.e. 64-fold higher than in the culture supernatant. 
 
Spectrum of antimicrobial activity. BacST4SA inhibited the growth of 
Acinetobacter baumannii 16, E. faecalis 20 and 21, E. faecium HKLHS, S. aureus 36, S. 
pneumoniae 27, 29 and 40, and unknown middle ear isolates A, BW, DW, F, G, and H (Table 
1). No activity was observed against A. baumannii 19, H. influenzae C, P. aeruginosa 8, 14, 
and 25, S. aureus 13, Staphylococcus carnosus LMG 13567 and S. pneumoniae A, D, and 
10 (Table 1). BacST4SA was active against P. aeruginosa G, BG, I, J, B and E, although 
resistance (opaque zones) was observed for some strains (Table 1).   
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Adsorption of bacST4SA to target strains. BacST4SA adsorbed at different levels 
to target strains.  Maximum adsorption (94%) was recorded to cells of S. pneumoniae 40, P. 
aeruginosa 25 and E. faecium HKLHS. A smaller quantity (75%) of the peptide adsorbed to 
S. pneumoniae 27, 29 and D, E. faecalis 20 and 21, P. aeruginosa I and J, S. aureus 13 and 
unidentified middle ear isolates BW, DW, F, H and G and only 50% adsorbed to P. 
aeruginosa E.  
 
Mode of action. Treatment of pathogens with bacST4SA (25 600 AU/ml) led to the 
leakage of cellular components (DNA, RNA, proteins, etc.) and β-galactosidase (Table 2).  
Cells treated with bacST4SA showed a clear difference in cell structure (Fig. 1).  The surface 
of E. faecium HKLHS treated with bacST4SA changed from smooth (Fig. 1A) to rough (Fig. 
1B) after 1 h in contact with bacST4SA. Leakage of intracellular compounds from damaged 
cells was clearly visible (Fig. 1C and D). 
Addition of bacST4SA to S. pneumoniae 40 (Fig. 2A), middle ear isolates F (Fig. 2B) 
and BW (Fig. 2C), and E. faecium HKLHS (Fig. 2E) led to a rapid decline in cell density.  
Isolate H was less sensitive to bacST4SA and started to recover after the first hour of 
treatment (Fig. 2D). This was, however, followed by a decrease in cell density after 2 h.  The 
growth of E. faecium HKLHS was completely inhibited (Fig. 2E).   
 
Effect of medium compounds and vitamins on bacST4SA production. The effect 
of medium compounds on bacST4SA production is shown in Table 3. Optimal production of 
bacST4SA (51 200 AU/ml) was recorded in MRS broth with glucose, saccharose or maltose 
as sole carbon source. Approximately half the activity (25 600 AU/ml) was recorded when 
cells were grown in the presence of mannose and lactose (Table 3).  Growth in MRS broth 
with 20.0 g/l meat extract, 15.0 g/l tryptone, a combination of 10.0 g/l meat extract and 10.0 
g/l yeast extract, 12.5 g/l tryptone and 7.5 g/l meat extract yielded 51 200 AU/ml. The activity 
doubled (102 400 AU/ml) when cells were grown in MRS broth supplemented with 20.0 g/l 
tryptone, 20.0 g/l yeast extract, a combination of 10.0 g/l yeast extract and 10.0 g/l tryptone, 
or a combination of 12.5 g/l tryptone and 7.5 g/l yeast extract as sole nitrogen source. 
Growth in MRS broth without nitrogen sources led to a 98% decrease in bacST4SA 
production. 
Relatively good growth of bacST4SA was observed in MRS broth with different 
concentrations of tri-ammonium citrate, magnesium sulphate, manganese sulphate and 
sodium acetate. Production of bacST4SA was affected by different concentrations. The 
absence or 0.5, 1.0, and 5.0 g/l tri-ammonium citrate resulted in a 75% reduction of 
bacST4SA production (Table 3). Growth in the presence of 10.0 g/l tri-ammonium citrate led 
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to a 50% decrease in bacST4SA production (Table 3).  Maximum bacST4SA production (51 
200.AU/ml) was recorded in the presence of 0.1 g/l magnesium sulphate. In the absence of 
magnesium sulphate, or at higher concentrations, a decrease in bacST4SA production was 
observed. However, 1.0 g/l magnesium sulphate led to a 98% decrease in bacST4SA 
production (Table 3). Similar results have been recorded for manganese sulphate, with 
optimal activity (51 200 AU/ml) obtained in the presence of 0.05 g/l. Increased concentrations 
of manganese sulphate (0.2 and 0.5 g/l) led to 87.5% reduction in bacST4SA production 
(Table 3). The optimal concentration of sodium acetate for bacST4SA production was 5.0 g/l. 
A higher concentration (10.0 g/l) decreased bacST4SA production by 50% (Table 3). Growth 
in MRS without sodium acetate or in the presence of 1.0 g/l decreased bacST4SA production 
by 87.5% (Table 3). Higher levels of K2HPO4 (10.0 and 20.0 g/l) yielded 102 400 AU/ml 
bacST4SA (Table 3). Growth in the presence of 50.0 g/l K2HPO4 decreased bacST4SA 
production by 87.5%. Replacement of K2HPO4 with KH2PO4 resulted in a 50% decrease in 
bacST4SA production (Table 3). 
No change in bacST4SA production was recorded when cells were grown in medium 
without glycerol and in the presence of 1.0 g/l. BacST4SA activity was inhibited when 
cultured in MRS broth enriched with glycerol higher than 1.0 g/l. Production of bacST4SA 
changed to 12 800 AU/ml when MRS broth was supplemented with 20.0 g/l and 50.0 g/l 
glycerol. 
A high level of bacST4SA (102 400 AU/ml) was produced when cells were grown in 
MRS broth enriched with L-ascorbic acid, thiamine and DL-6,8-thioctic acid. No change in 
activity was observed when cells were grown in the presence of cyanocobalamin. However, 
the addition of phylloquinone to MRS broth led to a decrease in bacST4SA activity (25 600 
AU/ml). 
Optimal bacST4SA production (12 600 AU/ml) was recorded in the presence of 
LAPTg broth supplemented with 5.0 g/l glucose. However, bacST4SA production decreased 
by 50% when cultured in the presence of 35.0 g/l peptone, 35.0 g/l tryptone, or 35.0 g/l yeast 
extract, glucose (15.0 or 20.0 g/l), or in the absence of Tween 80. 
 
Effect of growth conditions on bacST4SA stability. BacST4SA remained active 
after 12 h of incubation in the presence of blood and 6 h in the presence of middle ear fluid. 
A two-fold decrease in activity was recorded after 12 h in the presence of middle ear fluid 
(not shown). 
BacST4SA was stable at -20 °C for at least 6 weeks and 3 weeks at 4 °C, with a two-
fold decrease after 4 weeks (Fig. 3). Activity continued to be stable for up to week 6. At 25 
°C, bacST4SA activity decreased two-fold after one week and remained stable for the 
duration of the experiment (Fig. 3). At 37 °C bacST4SA remained stable for one week, 
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followed by a four-fold decrease. After the fourth week a two-fold decrease was observed, 
which remained stable for the duration of the experiment (Fig. 3). No activity was observed 
for bacST4SA incubated at 60 °C (Fig. 3). 
 
Comparison of bacST4SA crude-extract with other antimicrobial agents.  
BacST4SA inhibited the growth of E. faecium HKLHS and middle ear pathogens P. 
aeruginosa J and S. pneumoniae 27 (Table 4). After prolonged incubation, P. aeruginosa J 
developed resistance. Similar results were recorded for tetracycline (30 µg), CiproBay®HC 
otic drops, and Exocin.  However, lower levels of activity were recorded against P. 
aeruginosa J, E. faecium HKLHS and S. pneumoniae 27. 
Exocin was highly active against P. aeruginosa J and S. pneumoniae 27, with less 
activity against E. faecium HKLHS. Tetracycline (30 µg) inhibited S. pneumoniae 27 and E. 
faecium HKLHS, with less activity and some resistance against P. aeruginosa J. BacST4SA, 
Augmentin (30 µg) and compound sulphonamides (300 µg) revealed similar activity against 
P. aeruginosa J, although some resistance was observed, whereas nitrofurantoin (300 µg), 
cefepime (30 µg), amikacin (30 µg), Sofradex® and Tobrex® presented the same level of 
activity against P. aeruginosa J, with no resistance observed. Ciprofloxacin (5 µg) had the 
best activity against P. aeruginosa J.  However, resistance was recorded. 
S. pneumoniae 27 was inhibited by bacST4SA, Exocin, amoxicillin (10 µg), 
Augmentin (30 µg) and tetracycline (30 µg) and revealed the highest activity against this 
strain. The other antibiotics had little or no activity against S. pneumoniae 27. 
BacST4SA, CiproBay®HC otic, Exocin, Flomist, Vibrocil, amoxicillin (10 µg), 
Augmentin (30 µg), cefotaxime (30 µg), ceftriaxone (30 µg), chloramphenicol (10 µg), 
ciprofloxacin (5 µg), erythromycin (5 µg), furazolidone (50 µg), nitrofurantoin (300 µg), 
oflaxacin (5 µg), rifampicin (5 µg) and tetracycline (30 µg) were active against all three 
pathogens. However, Flomist, Vibrocil, cefotaxime (30 µg), ceftriaxone (30 µg), erythromycin 
(5 µg), furazolidone (50 µg), oflaxacin (5 µg), and rifampicin (5 µg) revealed very low activity. 
Amoxicillin (10 µg), Augmentin (30 µg) and nitrofurantoin (300 µg) had low activity against E. 
faecium HKLHS.  Slight antibiotic resistance to Augmentin (30 µg) was detected for P. 
aeruginosa J. Chloramphenicol (10 µg) revealed very low activity against S. pneumoniae 27 
with some resistance against P. aeruginosa J. Ciprofloxacin (5 µg) inhibited S. pneumoniae 
27 and E. faecium HKLHS.  Cefuroxime (30 µg), metronidazole (5 µg), oxacillin (1 µg), 
sulfafurazole (25 µg), sulfamethoxazole (25 µg), and trimethoprim (25 µg) did not inhibit the 
growth of E. faecium HKLHS and middle ear pathogens P. aeruginosa J and S. pneumoniae 
27. 
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DISCUSSION 
 
BacST4SA is active against E. faecalis 20 and 21, E. faecium HKLHS, S. aureus 36, 
S. pneumoniae 27, 29 and 40, and unidentified middle ear isolates A, BW, DW, F, G, and H, 
and Gram-negative bacteria A. baumannii 16 and P. aeruginosa J. By definition, bacteriocins 
are only inhibitory towards closely related species (6). The activity against Gram-negative 
bacteria is thus an unusual phenomenon and has been reported for only a few bacteriocins. 
Enterocin AS-48, a class IIc bacteriocin produced by E. faecalis S-48, is active against a 
variety of Gram-negative bacteria (49). Enterocin 012, produced by Enterococcus gallinarum, 
inhibits the growth P. aeruginosa and Escherichia coli (50), whilst enterocin MR99 of E. 
faecalis inhibits E. coli, but not P. aeruginosa (51). Activity against A. baumannii has not 
been reported for other bacteriocins produced by the genus Enterococcus.  However, a 
bacteriocin produced by Lactobacillus plantarum isolated from molasses, revealed activity 
against A. baumannii (52). BacST4SA is the only class IIa bacteriocin active against S. 
pneumoniae and other Gram-positive middle ear isolates. The class IIc enterocins, 50LA and 
50LB produced by Enterococcus faecium L50, are active against S. pneumoniae (53). Only 
certain strains of S. pneumoniae were inhibited by bacST4SA. It might be that bacST4SA 
activity is serotype specific. In general, it is difficult to compare the spectra of activity of 
different class IIa bacteriocins, since the target strains, level of purification and methods used 
in antibacterial assays differ. 
BacST4SA adsorbed to sensitive and resistant cells of Gram-positive and Gram-
negative bacteria. Adsorption ranged from 50% for P. aeruginosa E to 94% for S. 
pneumoniae 40, P. aeruginosa 25 and E. faecium HKLHS. No differences were detected in 
adsorption levels between sensitive and resistant strains. Similar findings have been 
reported by other authors.  Buhnericin LB, produced by Lactobacillus buchneri, adsorbed 
100% to L. plantarum, Pediococcus dextranicus, Oenococcus oeni and E. faecalis (54). 
However, the authors also reported 100% adsorption of the peptide to a resistant strain of 
Pediococcus cerevisiae LB (54). Similar results have been recorded by Manca de Nadra et 
al. (55). Pediocin N5p adsorbed at higher levels to sensitive strains O. oeni X2L, 
Lactobacillus hilgardii, O. oeni L10, and L. higardii 6D (55).  Adsorption levels below 50% 
were recorded for resistant bacteria.  The percentage adsorption might depend on the assay, 
number and type of receptors available on the cytoplasmic membrane, surface area and 
several environmental factors. 
BacST4SA is an amphiphilic and cationic peptide, which interacts with negatively 
charged cytoplasmic membranes of sensitive cells. In this study, low concentrations of 
bacST4SA (51 200 AU/ml) caused the formation of small pores and the leakage of small 
intracellular molecules, such as DNA and enzymes. Higher levels of bacST4SA resulted in 
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an immediate efflux of intracellular macromolecules, as observed by atomic force 
microscopy. The mode of activity is most probably dissipation of the proton motif force. 
Similar results were reported for enterocin CRL35 (56, 57), mundticin KS (58), mundticin 
AT06 (59) and enterocin P (60-62) produced by E. mundtii CRL 35 (formerly known as E. 
faecium CRL 35), E. mundtii NFRI 7393, E. mundtii AT06 and E. faecium P136. The effect of 
bacST4SA on E. faecium HKLHS was bactericidal, whereas bacST4SA was bacteriostatic 
towards S. pneumoniae 40 and middle ear isolates F, BW and H. 
The activity of bacST4SA remained unchanged when incubated in the presence of 
blood and middle ear fluid, suggesting that the peptide could be used in the control of middle 
ear infections. The peptide is also relatively stable over a broad pH range (pH 2 to 12) and at 
high and low temperatures (6 weeks at -20 °C, 3 weeks at 4 °C and one week at 37 °C). 
Similar findings were reported for other enterocins.  Enterocin EJ97, produced by E. faecalis 
EJ97, is stable for 6 months at -20 °C and -70 °C (63). Mundticin AT06 was stable at 4 °C for 
the 14 h tested (59). 
Growth in the presence of tryptone and yeast extract as sole nitrogen source, or a 
combination of tryptone and yeast extract yielded increased levels of bacST4SA (102 400 
AU/ml). Similar results were reported for plantaricin 423 produced by L. plantarum 423 (64) 
and bacteriocin ST311LD produced by E. faecium ST311LD (33). Substitution of glucose 
with saccharose or maltose had no effect on bacST4SA production. However, lactose and 
mannose decreased bacST4SA production by 50%. Similar results were reported for 
bacteriocin ST311LD in the presence of glucose and maltose (33). However, low levels (5.0 
or 10.0 g/l) of saccharose increased bacteriocin ST311LD production. The effect of glucose 
on production of enterocin 1146 (65), plantaricin UG1 (66) and plantaricin ST31 (41) has 
been reported. Maximal levels of bacteriocin activity were produced by E. faecium RZS C5 
cultured in MRS broth supplemented with lactose (5.0%, w/v), adjusted to pH 6.5, and 
incubated at 37 °C (67). 
Little is known about the effect mineral ions have on production of bacteriocins. 
Different bacST4SA activity levels were recorded in the presence of K2HPO4 or KH2PO4. The 
highest bacST4SA production (102 400 AU/ml) was obtained when cells were grown in the 
presence of 10.0 or 20.0 g/l K2HPO4. No difference in bacteriocin ST311LD production was 
recorded when cells were cultured in medium supplemented with 2.0 g/l K2HPO4 or 2.0 g/l 
KH2PO4. Increased levels of K2HPO4 resulted in increased bacteriocin ST311LD production 
(33). 
Different concentrations of tri-ammonium citrate, magnesium sulphate, manganese 
sulphate, and sodium acetate influenced the production of bacST4SA. Exclusion of these 
components in MRS broth decreased the level of bacST4SA production. Optimal bacST4SA 
production (51 200 AU/ml) was recorded in the presence of 2.0 g/l tri-ammonium citrate, 0.1 
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g/l magnesium sulphate, 0.05 g/l manganese sulphate, or 5.0 g/l sodium acetate.  MRS broth 
contains 2.0 g/l tri-ammonium citrate, 0.1 g/l magnesium sulphate, 0.05 g/l manganese 
sulphate, and 5.0 g/l sodium acetate (47). Higher or lower concentrations of these 
compounds led to decreased activity. Changes in the levels of manganese sulphate and 
magnesium sulphate did not influence the production of bacteriocin QU 2 (68). The effect of 
cations and anions on bacteriocin production may be strain specific (69). 
Optimal levels of bacST4SA production (51 200 AU/ml) were recorded in the 
presence of 1.0 g/l glycerol. Glycerol concentrations higher and lower than 1.0 g/l resulted in 
the inhibition of activity. Similar results were reported for bacteriocin ST311LD (33) and 
plantaricin ST31 (41). Glycerol concentrations higher than 1.0 g/l decreased bacteriocin 
production, probably due to changes in osmotic stress.  
Production of bacST4SA is stimulated in the presence of Tween 80. Similar results 
were obtained for bacteriocin QU 2 (68). Tween 80 had no effect on the production of 
enterocin EJ97 (63).  However, it decreased the production of enterocin MR99 (51). Tween 
80 may stimulate bacteriocin production by decreasing the absorption of the bacteriocin to 
the producer strain, glass and polypropylene surfaces (69-71). 
The use of cationic peptides as a new alternative for treatment of various diseases 
has become of major interest. BacST4SA is more active towards middle ear pathogens, 
compared to other antimicrobial agents.  This suggests that bacST4SA may be used as an 
alternative in the treatment of otitis media. Aminoglycosides, fluoroquinolons, quinolones, 
lincosamides, macrolides, rifampicin, glycopeptides, vancomycin, tetracycline, 
chloramphenicol and several other antibiotics cause intracellular damage and require specific 
target molecules as receptors to initiate growth inhibition (72). Penicillin and cephalosporin 
antibiotics inhibit peptidoglycan cross-linkages, thus preventing cell wall synthesis (72). 
Bacteriocins only require certain docking molecules to initiate growth inhibition (4). 
BacST4SA revealed similar, and in some cases better, activity when compared to 
other antimicrobial agents. However, for bacST4SA to be accepted in otitis media treatment 
a number of clinical tests will have to be done. Currently, the toxicity, route of administration 
and pharmacological profile of bacST4SA are being investigated.   
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TABLE 1. Antimicrobial activity of bacST4SA crude-extract 
Pathogen 
Temperature 
(°C) 
Growth medium, 
incubation 
Origin, collection 
Antimicrobial 
activity 
Acinetobacter baumannii      
16 37 BHI, aerobic Human middle ear + 
19 37 BHI, aerobic Human middle ear - 
Enterococcus faecalis     
20  37 BHI, aerobic Human middle ear +++ 
21 37 BHI, aerobic Human middle ear + 
Enterococcus faecium      
HKLHS 
30 MRS, aerobic  ++++ 
Haemophilus influenza     
C 37 CBA, aerobic  Human middle ear - 
Pseudomonas aeruginosa     
8, 14, 25 37 BHI, aerobic Human middle ear - 
G, BG 37 BHI, aerobic Human middle ear (+) 
I, J 37 Bld, aerobic Human middle ear (+++) 
B 37 BHI, aerobic Nasal cavity (+++) 
E 37 BHI, aerobic Nasal cavity (+) 
Staphylococcus aureus      
13 37 BHI, aerobic Human middle ear - 
36 37 BHI, aerobic Human middle ear +++ 
Staphylococcus carnosus      
LMG 13567 37 BHI, aerobic Human middle ear - 
Streptococcus pneumoniae     
A, D, 10 37 BHI/Bld, aerobic Human middle ear - 
29  BHI, aerobic Human middle ear +++ 
27, 40  BHI, aerobic Human middle ear ++++ 
Unidentified Gram-positive     
A, BW, DW, F, G, H  BHI, aerobic Human middle ear ++++ 
- = no zones, + = diameter between 1 and 11mm, ++ = diameter between 12 and 16mm, +++ 
= diameter between 17 and 21mm, ++++ = diameter of at least 22mm. LMG = Laboratory of 
Microbiology, University of Gent, Belgium. Bld = blood agar, CBA = chocolate blood agar.  
Results in parenthesis refer to activity with some resistance. 
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TABLE 2. Effect of bacST4SA cell-free supernatant on cell permeability 
Pathogens Cellular leakage (OD260) 
β-galactosidase-leakage 
(OD420) 
Streptococcus pneumoniae   
            27 1.670 No leakage 
            29 1.182 No leakage 
             40 0.801 No leakage 
   
Enterococcus faecalis   
            20 0.930 No leakage 
   
Staphylococcus aureus   
             36 0.892 No leakage 
   
Gram-positive middle ear 
isolates (unidentified) 
  
              BW 1.186 0.370 
              DW 1.153 0.293 
          F 1.428 0.318 
          H 1.559 0.235 
          G 0.751 0.373 
   
Enterococcus faecium HKLHS     1.395 No leakage 
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TABLE 3. Effect of MRS components and vitamins on bacST4SA production. 
Component Concentration (g/l) 
Bacteriocin activity 
(AU/ml) 
Bacteriocin activity* (%) 
Carbon Source    
Glucose (control) 20.0   51 200 100 
Saccharose 20.0   51 200 100 
Lactose 20.0   25 600 50 
Maltose 20.0   51 200 100 
Mannose 20.0   25 600 50 
Nitrogen source    
Tryptone 20.0 102 400 200 
Meat extract 20.0   51 200 100 
Yeast extract 20.0 102 400 200 
Tryptone 0.0        800 2.0 
Tryptone 0.5      3200 6.25 
Tryptone 1.0      6400 12.5 
Tryptone 2.0, 3.0   12 800 25 
Tryptone 4.0, 5.0, 10.0, 30.0, 40.0    25 600 50 
Tryptone 15.0    51 200 100 
Meat and yeast extract 10.0 + 10.0   51 200 100 
Tryptone and meat 
extract 
12.5 + 7.5   51 200 100 
Tryptone and yeast 
extract 
12.5 + 7.5 102 400 200 
Mineral salts    
tri-Ammonium Citrate 0.0, 0.5, 1.0, 5.0  12 800 25 
 2.0  51 200 100 
 10.0  25 600 50 
Magnesium sulphate 0.0     6400 12.5 
 0.1 51 200 100 
 0.2  12 800 25 
 0.5     3200 6.25 
 1.0      800 2.0 
Manganese sulphate 0.0, 0.1 12 800 25 
 0.05 51 200 100 
 0.2, 0.5    6400 12.5 
Sodium acetate 0.0, 1.0    6400 12.5 
 2.0 12 800 25 
 5.0 51 200 100 
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TABLE 3. (Continued) 
Component Concentration (g/l) 
Bacteriocin activity 
(AU/ml) 
Bacteriocin activity* (%) 
 10.0 25 600 50 
K2HPO4 2.0, 5.0   51 200 100 
 10.0, 20.0 102 400 200 
 50.0      6400 12.5 
KH2PO4 2.0   25 600   50 
Glycerol 0.0, 1.0   51 200 100 
 2.0, 5.0, 10.0   25 600 50 
 20.0, 50.0   12 800 25 
Vitamins                         
Cyanocobalamin 0.001   51 200 100 
DL-6,8-thioctic acid 0.001 102 400 200 
L-ascorbic acid 0.001 102 400 200 
Phylloquinone 0.001   25 600 50 
Thiamine 0.001  102 400 200 
MRS broth (control) 51 200 100 
*Compared to the highest activity (AU/ml), as recorded with the control (MRS, Biolab) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 127
TABLE 4. Comparison of bacST4SA crude extract with other alternative treatments 
Inhibition of bacterial growth 
Treatments E. faecium 
HKLHS 
P. aeruginosa J 
S. pneumoniae 
27 
Eye/Otic drops    
CiproBay®HC Otic 1 ++ +++ ++ 
Exocin (Oflaxacin, 0.3%) 2 ++ +++ +++ 
Sofradex® 3 + ++ - 
Tobrex® (Tobramycin) 1 + +++ - 
Nasal Spray    
Flomist 4, Vibrocil 5 + + + 
Antibiotics 6    
Amikacin (30 µg) - +++ - 
Amoxicillin (10 µg) + ++ +++ 
Augmentin (30 µg) + (+++) +++ 
Cefepime (30 µg) - +++ + 
Cefotaxime (30 µg), Ceftriaxone (30 µg), 
Furazolidone (50 µg), Rifampicin (5 µg) + + + 
Ceftazidime (30 µg), Streptomycin (25 µg), 
Tobramycin (10 µg),  - ++ - 
Cefuroxime (30 µg), Metronidazole (5 µg), 
Oxacillin (1 µg), Sulfafurazole (25 µg), 
Sulfamethoxazole (25 µg), Trimethoprim (25 
µg) - - - 
Chloramphenicol (10 µg) ++ (++) + 
Ciprofloxacin (5 µg) + (++++) + 
Clindamycin (2 µg) + - - 
Compound sulfonamides (300 µg) - (+++) - 
Erythromycin (5 µg) + + ++ 
Fusidic acid (10 µg) + - ++ 
Nalidixic acid (30 µg) - + (+) 
Nitrofurantoin (300 µg) + +++ ++ 
Ofloxacin (5 µg) + ++ + 
Tetracycline (30 µg) +++ (++) +++ 
Vancomycin (30 µg) + - + 
Bacteriocin crude extract    
BacST4SA (1 638 400 AU/ml) +++ (+++) +++ 
- = no zones, + = diameter 1 - 11mm, ++ = diameter 12 - 16mm, +++ = diameter 17 - 21mm, ++++ = diameter at 
least 22mm.  Results in brackets refer to resistance with little growth. Antimicrobial agents were supplied by Alcon 
Laboratories, South Africa (1), Allergan Pharmaceuticals South Africa (2), Aventis Pharma, South Africa (3), Cipla 
Medpro, South Africa (4), Novartis SA, South Africa (5) and Oxoid, New Hampshire, England (6). 
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                                   C                      
 
 
 
Fig. 1. Atomic force microscopy images of E. faecium HKLHS before (A) and after (B and C) 
treatment with bacST4SA (49 152 AU/ml).  Leakage of cell contents from damaged cells is 
clearly visible (C).  
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ig. 2. Effect of bacST4SA crude-extract (1 638 400 AU/ml) on (A) S. pneumoniae 40, (B) 
 ear isolate BW (D) middle ear isolate H and (E) E. faecium 
bols: 
bacST4SA 
F
middle ear isolate F, (C) middle
 = growth in the absence of bacST4SA, HKLHS.  Sym   = growth in the presence of 
bacST4SA. 
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Fig. 3. Effect of temperature on the stability of bacST4SA.  Symbols:  = -20°C,  = 4°C,  = 
25°C, х =  37°C, Â = 60°C. 
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DISCUSSION AND CONCLUSIONS 
 
Acute otitis media is a common infectious disease of infants and children, and 
treatment with antimicrobial agents is familiar (Segal et al., 2005). After treatment, a risk of 
selection of antibiotic-resistant bacteria in the oropharynx and serious alternations of the 
ecological balance of the normal microflora is possible, opening possibilities for the re-
establishment of pathogens in the middle ear (Lisby-Sutch et al., 1990; Brook and Foote, 
1997; Faden et al., 1997; Brook and Gober, 1998; Klein, 1999; Block et al., 2001; Faden, 
2001; Rovers et al., 2004; Brook and Gober, 2005). An extensive focus is the bacterial 
interference (BI) of natural nasopharyngeal flora with their ability to produce antibacterial 
substances inhibiting pathogens (Brook, 2005). Important bacteriocin-producers are alpha-
hemolytic streptococci, mostly Streptococcus mitis and Streptococcus sanguis, anaerobic 
streptococci (Peptostreptococcus anaerobius and Prevotella melaninogenica) and non-
haemolytic streptococci (Sanders et al., 1977; Berstein et al., 1993; Bernstein et al., 1994; 
Brook, 2005). A bacteriocin-like substance produced by Streptococcus salivarius, a non-
pathogenic strain isolated from the oral cavity of humans, inhibited the growth of 
Streptococcus pyogenes, and revealed in vitro inhibitory activity against Gram-negative 
pathogens such as Moraxella catarrhalis and Haemophilus influenzae (Dierksen and Tagg, 
2000; Walls et al., 2003).  
 
In this study, a lactic acid bacterium was isolated from soya beans and identified as 
an Enterococcus mundtii ST4SA. A heat stable, cationic and hydrophobic bacteriocin, 
bacST4SA, was produced, identified and characterized. The bacST4SA gene cluster is 
located on a 50-kb plasmid and consists of three open reading frames (ORFs). The first ORF 
(structural gene) encodes a 58-amino acid peptide that consists of a 15-amino acid leader- 
and a 43-amino acid mature peptide. The structural gene is homologous to mundticin AT06, 
mundticin KS and bacteriocin QU 2, produced by E. mundtii AT06 (Bennik et al., 1998), E. 
mundtii NFRI 7393 (Kawamoto et al., 2002) and E. mundtii QU 2 (Zendo et al., 2005), 
respectively. The leader peptide of bacST4SA differ from that of enterocin CRL35 of E. 
mundtii CRL 35 by two amino acids (Farias et al., 1996; Saavedra et al., 2004). The mature 
peptide is typical of all class IIa bacteriocins, by the presence of a conserved YGNGV 
consensus motif, a disulphide bridge linking cys9 and cys14, and a high number of non-polar 
amino acids (Nes et al., 1996; Eijsink et al., 1998; Ennahar et al., 2000). The molecular 
weight of the mature peptide was determined at 3950 Da. The second ORF encodes a 674-
amino acid ATP-dependent transporter protein and is located downstream from the structural 
gene. The ATP-dependent transporter consisted of a peptidase C39B-, an ABC-membrane 
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transporter- (revealing five primary transmembrane helixes and one secondary 
transmembrane helix) and an ABC-DLP family domain. The second ORF is 98.9% 
homologous to mundticin KS (Kawamoto et al., 2002) and 99.25% to enterocin CRL35 
(Saavedra et al., 2004). The third ORF encodes a 98-amino acid immunity protein and is 
located immediately downstream of the ATP-dependent transporter gene. The immunity 
gene is completely homologous to enterocin CRL35 (Saavedra et al., 2004) and 96.9% 
homologous to mundticin KS (Kawamoto et al., 2002). 
 
The proteinaceous nature of bacST4SA was confirmed by it’s sensitivity to proteolytic 
enzymes. BacST4SA is stable in acidic conditions (pH 2.0), at high temperatures (121 °C 
for 15 min), and in the presence of middle ear fluid and blood. Optimal bacST4SA 
production (51 200 AU/ml) was recorded after 14 h of growth in MRS broth, pH 6.5, and 
inhibits the growth of Bacillus cereus, Clostridium tyrobutyricum, Enterococcus faecalis, 
Enterococcus faecium, Lactobacillus sakei, Pediococcus sp., Propionibacterium spp., 
Streptococcus caprinus and the food-borne pathogen Listeria monocytogenes. A two-fold 
increase in bacST4SA was observed in MRS broth supplemented with tryptone, yeast 
extract, or a combination of tryptone and yeast extract, K2HPO4 (10.0 or 20.0 g/l), DL-6,8-
thoictic acid, L-ascorbic acid, and thiamine, respectively. A 64-fold increase in activity (1 
638 400 AU/ml) was revealed after 80% saturated ammonium sulphate precipitation, 
followed by dialysis and lyophilisation, and displayed antimicrobial activity against strains of 
middle ear isolated pathogens Acitenobacter baumannii, E. faecalis, E. faecium, S. aureus, 
S. pneumoniae, and unidentified middle ear isolates A, BW, DW, F, G, and H. BacST4SA 
inhibits the growth Gram-negative strains of P. aeruginosa, although some resistance was 
observed. In general, the inability of bacST4SA to inhibit Gram-negative bacteria may be 
due to the protective outer membrane of Gram-negative strains. The outer membrane 
excludes hydrophobic macromolecules and substances from entering Gram-negative cells, 
preventing bacST4SA to reach the target (Nikaido, 1996). Future research will be to 
overcome this penetration barrier, rendering Gram-negative pathogens, currently resistant 
to bacST4SA, sensitive to bacST4SA. Sensitization can be brought about by metal-
chelating organic acids, such as EDTA, removing stabilizing cations from the outer 
membrane, resulting in the loss of LPS, decreasing the protective function as penetration 
barrier (Stevens et al., 1991; Delves-Broughton, 1993; Schved et al., 1994; Cutter and 
Siragusa, 1995; Boziaris and Adams, 1999; Helander and Mattila-Sandholm, 2000).   
 
The mode of activity of bacST4SA was bactericidal towards E. faecium HKLHS and 
bacteriostatic towards S. pneumoniae 40, middle ear isolate F, BW and H. The primary site 
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of action is the cytoplasmic membrane, resulting in the formation of pores, dissipation of the 
proton motive force (PMF) and leakage of intracellular molecules and substances. 
Interactions with the cytoplasmic membrane are by adsorption of bacST4SA to specific 
receptors of sensitive target strains (Ananou et al., 2005; Zendo et al., 2005). The 
percentage adsorption of bacST4SA might depend on the amount and type of receptors 
available on the cytoplasmic membrane for adhesion, and may be influenced by several 
environmental factors (Ananou et al., 2005; Zendo et al., 2005). The effect of environmental 
factors on bacST4SA, such as pH and temperature, will have to be studied. In general, 
maximum adsorption occurs at neutral pH, with a decrease in adsorption as the culture pH 
decreases (Yang et al., 1992). Low pH increases bacteriocin activity by changing the 
oligomerization of the bacteriocin and the electric charge on the surface of the target 
organism (Abriouel et al., 2001a; Abriouel et al., 2001b; Ananou et al., 2005). The increase 
in activity may be due to an increase in the net charge of the bacteriocin molecule, 
facilitating interaction with the negatively charges of the cytoplasmic membrane of the 
bacteria and translocation through the cell wall (Abriouel et al., 2001a; Abriouel et al., 
2001b). The effect bacST4SA has on the dissipation of the pH gradient and transmembrane 
potential, thus PMF dissipation, will have to be studied. Target-cell binding, potency and 
specificity of bacST4SA may also be investigated using site-directed in vitro mutagenesis 
(Kazazic et al., 2002). 
 
BacST4SA revealed similar to higher activity towards pathogens, when compared 
with other antimicrobial alternatives. The application of bacST4SA in medicine is promising, 
since encouraging examples of other cationic peptides have been reported (Giacometti et 
al., 1999; Giacometti et al., 2000 ; Brumfitt et al., 2002 ; Ingham et al., 2003) and bacST4SA 
retained activity in the presence of middle ear fluid and blood. However, for bacST4SA to be 
used as a new alternative for the treatment of otitis media, clinical research needs to be 
conducted. Strategies to enhance the activity of bacST4SA will be considered and can be 
approached in three different ways. The first approach is the identification and development 
of short peptides that exert strong enhancement on the antimicrobial activity of bacST4SA, 
and the design of variants with improved characteristics. The second approach is the 
genetic engineering of bacST4SA, by cloning bacST4SA and other antimicrobial or 
antifungal peptides into a suitable expression vector, enhancing its activity against 
pathogens of the middle ear. Thirdly, the synergistic effect of antibiotics and sub-lethal 
concentrations of bacST4SA to enhance activity against pathogens and the role played by 
proton gradient extrusion pumps should be investigated.  
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Studies on pharmacological profiles, immunogenic and toxicity, and route of 
administration are important if bacST4SA is to be used in clinical medicine. Pharmacological 
profiles are divided into two components: 1) pharmacokinetics, including the dosing regimen, 
adsorption of bacST4SA to middle ear mucosa, and its distribution and elimination, which 
determine the time course of bacST4SA concentrations in serum, middle ear fluid, and in the 
mucosal tissues that surround the middle ear fluid; and 2) pharmacodynamics, involving the 
association between concentrations of bacST4SA at the site of infection and it’s antimicrobial 
effect (Dagan and Leibovitz; 2002). In vivo studies are needed to conclude whether 
bacST4SA remains active against middle ear pathogens.  The effect of bacST4SA on the 
ecological balance of normal oropharyngeal microflora should be studied. 
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